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Antigen Presentation in Autoimmune Disease 
 
 
The aim of my project was to examine the extent to which endogenous 
expression of a largely renal-specific antigen influences the repertoire in adulthood 
of autoreactive T cells specific to that antigen. 
The renal-specific antigen, human α3(IV)NC1, is the target of autoimmune 
attack in Goodpasture’s disease.  This protein was expressed and purified in 
recombinant (using bacterial and mammalian cell expression systems) and purified in 
native (extracted from human tissue) forms.  Transgenic mice were generated that 
express HLA-DR15 (associated with Goodpasture’s disease) as their sole MHC class 
II molecule, and for which α3(IV)NC1 can be endogenous or exogenous.  The CD4 
T cell responses of these mice were then tested following immunisation with 
α3(IV)NC1.  
In mice with endogenous expression of α3(IV)NC1 there were no consistent 
detectable proliferative T cell responses to any α3(IV)NC1 peptides in a set of 
overlapping peptides representative of the entire sequence.  In the mice lacking 
endogenous α3(IV)NC1 there were consistent responses to the peptide α3(IV)NC1 
136-150.  This contains part of the peptide recognised by the most abundant 
autoreactive T cells in patients with acute Goodpasture’s disease.  Therefore, the T 
cell responses seen in man to an endogenous (auto)antigen have similar fine 
specificity to those seen in mice responding to the same protein as a foreign antigen.  
This is surprising as one might expect self-tolerance in man to be most secure to such 
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dominantly presented and immunogenic (in HLA DR15 mice) self peptides.  
However, recent work suggests that the peptide most commonly presented in humans 
is normally destroyed during antigen processing, giving a possible explanation for 
the lack of tolerance. 
Future work should study why tolerance is ineffective to this particular peptide, 
whether tolerance can be reinforced, these questions could be addressed using a 
transgenic mouse model that develops Goodpasture-like pathology.  In addition, how 
processing is defective in Goodpasture’s disease could be explored by making 
antigen presenting hybridomas from patient samples or from the transgenic mouse 
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Chapter 1 – General Introduction 
 
The main aim of this project was to determine CD4 T cell immune responses to 
a known and well-characterised kidney autoantigen, the non-collagenous domain of 
the α3 chain of type IV collagen (α3(IV)NC1), in the presence and absence of 
tolerance to that antigen.  It was clear from previous work that T cells specific for 
this autoantigen occurred in healthy individuals as well as those with acute 
autoimmune disease (1-3), raising questions as to the nature of T cell tolerance to 
this tissue-restricted basement membrane protein.  α3(IV)NC1 is expressed in the 
human thymus (4), so some element of central tolerance would be expected, but 
clearly that tolerance was far from complete.  Other data indicating interleukin (IL)-
10 production from α3-specific T cells pointed to a role for peripheral tolerance and 
T cell regulation. This project was conceived to examine the completeness of 
tolerance to α3(IV)NC1 and its robustness in the face of immunisation with α3. 
 
1.1. – CD4 T cell responses and epitope specificity 
 
When a CD4 positive T cell is stimulated, it proliferates and releases IL-2 in 
order to both propagate clonal expansion and to attract other white blood cells from 
the lymphatic system to the site of T cell activation.  This is a part of the cellular 
immune response and plays a role in eliminating extracellular threats (5). 
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However, antigen alone does not stimulate CD4 T cells.  These cells will only 
respond to processed antigen presented on the surface of antigen presenting cells 
(APCs).  APCs can take up antigen by phagocytosis (macrophages and dendritic 
cells) or through receptor binding interactions (B cells).  This antigen can be then 
processed into fragments, bound to major histocompatibility complexes (MHC) class 
II binding grooves, and presented on the APC surface (6).  CD4 T cells respond to a 
specific combination of the MHC class II molecule and the peptide within the 
binding groove.  The CD4 T cell response is therefore focused on fragments of 
antigen known as epitopes (5).   
This is in marked contrast to the immune responses of B cells, another crucial 
element of the cellular immune response.  The B cell receptor (BCR) recognises 
specific conformations on proteins.  The receptor binds the whole antigen, so tertiary 
and quaternary structural features of the protein are very important for enabling B 
cell recognition (7, 8).  Once the antigen has been bound to the receptor, the 
receptor-antigen complex is endocytosed and enzymatically processed in lysosomes.  
The peptide fragments are mixed with MHC class II molecules and those that bind to 
a peptide-binding groove on the MHC class II are presented on the cell membrane 
(6).  
The antigen receptors on B cells are multiprotein complexes made up of 
variable antigen-binding chains – the heavy and light immunoglobulin chains.  The 
invariant part of each chain is associated with specific accessory proteins.  These 
have two major functions: to transport the receptor to the cell surface; and to initiate 
signalling when the receptors bind an extracellular antigen (9).  Each B cell only 
produces one binding domain.  When antigen binds to surface immunoglobulin, the 
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signalling pathways activate and turn on the genes for protein production with the 
result that the cell is activated.  The surface immunoglobulins have an identical 
antigen binding region to the secreted immunoglobulins produced by the activated 
cell, but are anchored to the cell membrane through the carboxy termini of the paired 
heavy chains (6). 
Studies in man using peripheral blood mononuclear cells (PBMCs) and 
studying T cell responses to tetanus toxoid (TTD) and diphtheria toxoid (DTD) have 
found that T cell responses in most individuals include certain common, so-called 
“universal epitopes”.  These epitopes are thought to be able to cause an immune 
response in cells with major responses to a different antigen, so contain features 
similar to multiple pathogens.  Work studying TTD and DTD as a whole antigen 
versus peptide fragments showed similar orders of magnitude in immune response 
(10), but also that 8-29% of the toxoid specific CD4 T cells responded to the TTD, 
while 28-51% responded to the DTD.  These percentages also support the concept of 
universal antigens as all bar three of the candidates taking part had had booster 
injections more than four years before the study.  Therefore, they were unlikely to be 
generating an immune response to either TTD or DTD prior to extraction of the 
PBMCs.  It is also unlikely that all the responsive cells were primed to the same 
antigen, suggesting that the responses were to antigenic peptides that were somehow 
comparable to the original priming antigenic fragment (10).   
1.1.1. – Subsets of CD4 positive T cell responses  
CD4 positive T cells have a number of different responses to antigen and these 
can be distinguished by the cytokines released by the activated T cell.  The 
catagorisation of these responses increases in complexity as more is discovered about 
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the range of responses exhibited by Th cells.  While acknowledging this complexity, 
there are two broad classes of Th cell response (Th1 and Th2) that remain useful in 
distinguishing between different outcomes for T cell activation.  Th1 responses are 
characterised by interferon-γ (IFNγ) and generally associated with destructive 
responses such as viral infections.  In contrast, Th2 responses are characterised by  
interleukin (IL)-4, IL-5, IL-6 and IL-10 and generally associated with humoral 
immune responses, although asthma is also characterised by the production of Th2 
cytokines.  An additional major class of Th cell is regulatory T cells (Tregs) (11) 
which aid peripheral tolerance and maintain immunological homeostasis.  
Additional, more recently described, subsets are Th9 and Th17 cells (12).  The nature 
of immune responses depends on the balance of the different Th subsets involved, 
which in turn depends on probably numerous factors.  These may include co-
stimulatory molecules, the site of antigen-presentation, peptide density and binding 
affinity (high density favours Th1, low density favours Th2), antigen dose and the 
host genetic background (5).  It is now known that the differentiation decision is 
mainly governed by cytokines in the surrounding microenvironment and the strength 
of the interaction between the T cell antigen receptor with antigen (13). 
Th1 responses promote cellular immunity against intracellular organisms (14) 
and cell-mediated inflammatory reactions, they are also predominant organ-specific 
immune disorders, acute allograft rejection, and multiple sclerosis, amongst other 
things.  The Th1 response is characterised by release of IFNγ.  These promote the 
production of IgG2a opsonising and complement-fixing antibodies, macrophage 
activation, antibody-dependent cell-mediated cytotoxicity and delayed-type 
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hypersensitivity.  The major cytokine produced by Th1 cells is IFNγ which causes 
macrophage activation, but also actively inhibits proliferation of Th2 cells (5). 
Th2 T cells produce different cytokines and initiate a different type of T cell 
response.  Th2 responses are characterised by secretion of IL-4, IL-5, IL-6 and IL-
10.  These cells provide optimal help for humoral immune responses, including IgG1 
and IgE isotype switching and mucosal immunity, stimulation of mast cell and 
eosinophil growth and synthesis, and IgA synthesis.  They are typified by the 
production of IL-4 and IL-5 with IL-6, IL-9, IL-10 and IL-13 also being produced.  
In comparison with Th1 responses, Th2 cells are associated with strong antibody and 
allergic responses.  Overall, Th2 responses are classified as protective as they negate 
Th1 responses but do result in immune responses.  In particular, asthma has been 
linked to Th2 T cell responses (15).  However, Th2 responses also promote long-
term recognition of antigen by initiating antibody responses and therefore the 
existence of memory B cells, increasing responses to a future threat.  The cytokines 
produced by Th2 cells (IL-4 and IL-5) activate mast cells, B cells and eosinophils, 
resulting in the production of antibodies including IgE.  In addition, Th2 cells 
produce IL-4 which actively inhibits the production of IFNγ by Th1 cells, limiting 
the Th1 response – a reciprocal relationship as Th1 negate Th2 responses, while Th2 
negate Th1 responses.  Some work on Th1 and Th2 cells has shown that once a cell 
is in either of these lineages, it is terminally differentiated (14, 16).  However,  it has 
also been shown that TGF-β in the presence of IL-4 reprograms differentiation of 
Th2 cells into a population of Th9 cells that secrete IL-9 and some IL-10.  IL-4 
effectively blocks production of TGF-β-induced Treg cells and results in Th9 cells 
which have no suppressor function and promote tissue inflammation (17). 
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Th17 cells produce IL-17A, IL-17F and IL-22 and have been found to have an 
important role in clearance of extracellular bacteria and fungi, especially at mucosal 
surfaces.  Differentiation into Th17 cells requires retinoid-related orphan receptor γt, 
a transcription factor induced by TGF-β in conjunction with the proinflammatory 
cytokines IL-6, IL-21 and IL-23.  These then result in Stat3 phosphorylation (18).  
As with Th1 cells, Th17 cells play a critical role in organ-specific autoimmunity 
(19).  
Treg cells have an essential role in maintaining immune homeostasis.  They 
regulate the effector T cells (Th1, Th2 and Th17 are all effector T cell responses) and 
prevent potentially pathogenic effects through a variety of mechanisms (20, 21).  
Treg cells are characterised by expression of the forkhead transcription factor, 
FoxP3, which plays a critical role in specifying and maintaining the functional 
programme of these cells.  The Treg cell population is also complex, but has to date 
been split into two categories: the so-called naturally occurring CD4+ CD25+ Treg 
that develop in the thymus (nTreg), and the TGF-β-induced Tregs (iTregs) produced 
in the periphery.  Both of these sets of cells are believed to have a role in maintaining 
peripheral tolerance and preventing autoimmunity, but distinct roles for each have 
yet to be fully dissected in vivo (22-24).  It has been shown that nTregs require T cell 
receptor ligation and cell-cell contact for effective immunosuppression (25), while 
iTregs secrete cytokines to achieve a similar result (26).  Overall, Tregs secrete IL-10 
which results in: the suppression of dendritic cells; suppression of Th1, Th2 and 
Th17 responses; suppression of allergen specific IgE but induction of IgG4; 
suppression of mast cells, basophils and eosinophils; and suppression of effector T 
cell migration to tissues.  In addition, Treg cells interact with resident tissue cells and 
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influence remodelling (17).      In contrast with Th1/Th2 differentiation, expression 
of IL-17A by Th17 cells and of FoxP3 by induced Treg cells have been shown to be 
less stable, increasing the flexibility of their differentiation options (14). 
1.1.2. – T cell receptor plasticity and molecular mimicry 
Classical immunology suggests that each T cell has a specific receptor (TCR) 
that recognises a specific epitope in conjunction with the MHC class II molecule.  It 
has since been found that there is more plasticity in TCR recognition than was 
originally thought.  Experiments using a transgenic mouse line with restricted TCR 
repertoire revealed that this mouse was able to generate an immune response to all 
antigenic fragments tested, compared with non-transgenic littermates.  This suggests 
that, despite a more limited TCR, there was no difference in the response specificity 
profile between transgenic and non-transgenic mice.  However, the results from 
transgenic mice showed a 3-8-fold decrease in the frequency of transgenic T cell 
responses.  These data demonstrate unexpected plasticity in the TCR repertoire (27).  
Subsequent work has suggested that there are limitations on the degree of plasticity. 
It has been shown that peptides altered by a single amino acid generated different 
immune responses compared with unaltered peptide and caused variation in the level 
of cytokine production (28).  In addition, work by Gebe et al. has demonstrated that 
T cells selected  on an MHC class II molecule carry the potential for activation on 
altered self-ligands when encountering antigens presented on a related MHC class II 
molecule.  In individuals heterozygous for the alleles tested (human leukocyte 
antigen, HLA-DRB1*0401 and DRB1*0404), the possibility of TCR cross-
recognition could lead to an aberrant immune response or autoimmunity (29). 
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The priming of T cells by one antigen, resulting in a sustained response to a 
different self-antigen is known as molecular mimicry.  Wucherpfennig et al. have 
shown that viral peptides can activate T cells specific for myelin basic protein (a 
candidate autoantigen in multiple sclerosis) (30).  Other work by Uemura et al. 
identified candidate epitopes for which mimicry was possible, in the T cell 
population specific for glutamic acid decarboxylase-65 (implicated in type 1 
diabetes)  (31).  Molecular mimicry is more specific than identification of universal 
epitopes as specific viral or bacterial antigens have links to a specific autoantigen, 
whereas universal epitopes, as the name suggests, are more general, bind to the 
majority of HLA molecules and can be found within multiple antigens (those 
described above, TTD and DTD). 
As are described in more detail below, T cell epitopes are dramatically 
different from B cell epitopes.  T cell epitopes are contained within fragments of an 
original antigen, usually 12-17 amino acids in length.  By comparison, B cell surface 
receptors recognise whole antigen so recognise conformations, specific structural 
features, as well as sequence. 
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Figure 1.1 – Schematic of the trimolecular complex 
This schematic illustrates the interaction between CD4 positive T cell, the 
MHC class II complex and the peptide bound within the binding groove, in 
conjunction with other cell surface markers required for T cell activation (adapted 
from Janeway et al. (6)).  The major interaction illustrated is between the MHC class 
II molecule, the antigen (Ag) and the TCR.  The additional interactions shown are 
between costimulatory molecules on the APC (right) and T cell (left) required to 




1.2. – Molecular basis of T cell epitope specificity 
 
When a CD4 T cell recognises a peptide in the MHC class II binding site, the 
binding formed is known as the trimolecular complex and consists of the TCR, the 
MHC class II molecule (or human leukocyte antigen, HLA) and the peptide fragment 
(figure 1.1.). The TCR binds in a specific orientation.  Each TCR consists of two 
disulphide-linked polypeptide chains: either α and β; or γ and δ.  The overall features 
of the structure show that the two chains fold into a structure resembling the Fab 
region of immunoglobulin (32).  Both receptors are associated with a set of five 
polypeptides, the CD3 complex, and together form the T cell receptor complex.  
Approximately 90-95% of T cells are αβ T cells, while the remaining 5-10% are γδ 
T cells (thymic T cells and a minor population of peripheral T cells) (5). 
1.2.1. – MHC class II binding 
Most antigens taken up and processed by antigen presenting cells, including B 
cells, can be processed into lots of fragments.  Not all of these fragments bind the 
MHC class II binding groove with high enough affinity to remain bound and be 
transported to the cell surface to be presented to passing T cells.  The fragments that 
do successfully bind and that are presented are potential T cell epitopes.  It has been 
shown that the length of peptide sequence bound by MHC class II molecules is less 
limited than peptides for MHC class I molecules.  Most appear to be around 12 
amino acids in length, but they can be longer (MHC class I peptides are 9 amino 
acids long).  These peptides lie within the peptide groove, and are held there by 
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interactions between the peptide backbone and side chains, and between shallow and 
deep pockets that lie along the length of the groove (33, 34).  The peptides within the 
binding groove are bound by their backbone and can overhang from either end of the 
class II binding groove.  This means that, theoretically, there is no upper limit for the 
length of peptide bound by the complex.  In practice, most of the longer peptides are 
trimmed by peptidases to between 12 and 17 amino acids (35, 36). 
Through X-ray crystallography, it seems that amino acid side chains from 
residues 1, 4, 6 and 9 of the peptide (corresponding to pockets 1, 4, 6 and 9 of the 
MHC class II binding groove) are the most important for disrupting the overall 
binding of the peptide within the groove (37, 38).  However, there is a possibility that 
the MHC class II binding groove may have an overhang at the N-terminal end of the 
peptide.  This was demonstrated by a study in which mice were immunised with 
either an immunogenic peptide, or a longer peptide containing the immunogenic 
peptide sequence.  In this study, the longer peptide was found to propagate more 
long-term immune responses and induce immunological memory, while the shorter 
peptide did not (39).  This may be due to the processing required for the peptide 
binding, or due to the increased flexibility underlying the peptide fragment binding 
the MHC class II molecule.  It could also be a result of  the longer peptide containing 
an overlapping epitope with higher affinity for MHC class II molecules than the 
short peptide.  
1.2.2. – Peptide presentation by MHC class II molecules 
The MHC class II molecule is very important in determining which peptides 
are presented and which remain in the lysosome for further destruction and 
subsequent recycling of the amino acids.  The pockets within the MHC class II  
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Figure 1.2. – Side chain interactions of the MHC class II binding groove. 
This schematic illustrates the binding of a peptide into the MHC class II 
binding groove and shows pockets with which amino acid side chain interactions 
reduce affinity for the binding domain (adapted from Milinski  et al. (40)).  As is 
shown, the pockets are located to accommodate side chains from amino acids 1, 4, 6 
and 9 on the peptide chain, while the ends of the binding groove remain open.  This 
potentially enables any length of peptide to bind although these are more usually 12-




binding groove are lined with polymorphic residues that can exert some 
discrimination and prevent binding of peptides with lower affinity.  The arrangement 
of polymorphic pockets within the binding groove is not as restrictive as the very 
definite binding groove found in MHC class I molecules, making it difficult to 
ascertain which specific peptides will bind with the highest affinity to a specific 
MHC class II molecule.  However, by comparing sequences of peptides with known 
binding ability, certain common features can be determined and permissive amino 
acids for a specific class II allele can be defined (41-43).  This then enables 
modelling to show how the amino acids of a specific peptide will interact with the 
MHC class II binding groove.  A schematic of the binding groove is illustrated in 
figure 1.2. 
MHC class II molecules without bound peptide are inherently unstable, but the 
mechanism by which the MHC class II molecule is stabilised by binding peptide is, 
as yet, unknown.  This cannot be limited to specific amino acid residues binding 
specific regions in the MHC class II binding groove, as this restriction would greatly 
reduce the variation in peptides that are capable of binding (6). 
Various methods for investigating epitope selection by MHC class II molecules 
have been developed. As has already been described (section 1.1.), whole antigen has 
to be processed by APCs and presented on their surfaces bound to MHC class II 
molecules. While an antigen may be processed into dozens of fragments, only a few 
bind with a high enough affinity to the MHC class II molecules to actually be 
presented.  In particular, work has concentrated on determining the peptide 
fragments that generate the greatest immune responses when bound within the MHC 
class II binding groove.  These are not necessarily peptides that are presented with 
15 
the greatest abundance on the cell surface, but are those that bind with the highest 
affinity to the MHC class II molecule (44-47).  The fragment resulting in the most 
potent immune responses is classified as the immunodominant peptide as defined by 
T cell responses (44). 
 
1.3. – Influence of MHC class II on selection of epitopes recognised by 
T cells 
 
Questions then arise regarding determination of the immunodominant peptide.  
It is now thought that the process is partly driven by the MHC class II molecule and 
by the MHC class II “blocking peptide”, class II-associated invariant-chain peptide 
or CLIP (44, 46).  To understand this, more needs to first be understood about the 
production of the MHC class II molecules.  These molecules are polygenic and 
polymorphic, meaning that there are multiple genes and multiple alleles at these loci.  
The genes and alleles may not be transcribed equally (for example DRB1 
transcription shows a 5-fold excess of mRNA compared to DRB4 (48)).  The genetic 
variation and differing protein expression ensures diversity on an APC surface and is 
in contrast to both the BCR and the TCR, as BCR and TCR are monotypic 
molecules.  The receptor is unique to the B or T cell, so variation is obtained by cell 
numbers rather than with variety of surface receptors presented on each cell (49, 50). 
When the MHC class II molecule is translated, it could potentially bind any 
available peptide fragment with sufficient binding affinity within its empty binding 
groove.  This could cause autoimmunity or an aberrant immune response.  To  
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Figure 1.3. – MHC class II production and antigen presentation 
MHC class II αβ heterodimers are assembled in the endoplasmic reticulum, 
with the Ii fragment in the binding groove.  The major route of antigen presentation 
by MHC class II molecules shows Ii chaperoning the MHC class II molecule directly 
(black arrow) into the MIIC where Ii is degraded and  antigenic fragments bind into 
the MHC class II binding groove in subdomains of the MIIC prior to transport to the 











prevent this, the MHC class II molecules are made with the invariant chain (Ii) 
peptide bound within the binding groove (section 1.3.).  This peptide, when the MHC 
class II molecules coincide with processed antigen within the lysosome, is then 
cleaved enabling antigen-derived fragments to bind instead (figure 1.3.).  Relatively 
recently, work was published describing how the affinity of a peptide for the MHC 
class II, when comparable with the affinity of the Ii peptide with the MHC class II, 
may play a role in determining immunodominance (52, 53).  Peptides of high affinity 
derived from the CLIP and Ii have been shown to compete successfully with those of 
low affinity but derived from antigen, for binding to newly synthesised MHC class II 
molecules and thereby favouring their presence in the periphery (37).  This supports 
the notion of dominant capture – a process by which the first, most available and 
high affinity binding region on the antigen would preferentially bind to the MHC 
class II molecules.  Since the peptide binding groove of MHC class II molecules is 
open-ended, there is no limit to the length of peptide that can bind.  If binding occurs 
early within the lysosome, the bound peptide would be protected by the groove, 
while the fragment outside the binding domain is cleaved by external proteases and 
resulting in a small subset of fragments being presented on the cell surface.  This 
therefore predicts that a single determinant or a small number of determinants would 
emerge as competitively favoured over other determinants derived from the antigenic 
fragment. 
In summary, peptides that bind MHC class II with some affinity can be 
presented on the APC surface.  A current hypothesis regarding influences affecting 
peptide presentation is determinant capture.  Current evidence supporting 
determinant capture includes the fact that there is no length restriction on the 
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peptides binding the MHC class II binding groove; that residues bound within the 
groove are then protected from further proteolysis; and that the immunogenic 
peptides are generated and bind the MHC class II molecule within the same 
compartment (33, 45, 54, 55). 
 
 
1.4. – Evidence for influences beyond MHC class II on T cell response 
to exogenous antigen 
 
Affinity for MHC class II molecules is important but affinity alone is not 
thought to be sufficient to ensure peptide presentation.  It has been postulated that 
influences in addition to peptide sequence may have a role in determining how an 
antigen is processed and the presentation of processed peptides.  These influences 
have been postulated to include processing differences, MHC structure and 
competitive binding, availability to bind MHC class II, and quaternary structure and 
disulphide bonds.  All of these are linked to peptide sequence but may add 
complexity to the processing mechanisms. 
1.4.1. – The effect of processing on MHC class II binding by peptides 
Work studying immune responses in mouse strains expressing the same class II 
molecule, but in which there were differential immune responses to immunogenic 
peptides suggested that the ability to respond to the specific peptide does lie within 
each strain (56).  It has been further hypothesised, using  HEL peptide immunisation 
with subdominant peptides, that low level immune responses can arise by three 
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mechanisms: a) competition by an immunodominant peptide in vivo resulting in the 
subdominant peptide failing to bind the MHC molecule; b) failure to generate the 
subdominant peptide during processing; and c) an inherently poor capacity of the T 
cell repertoire to respond to a particular peptide-MHC complex (57). 
1.4.2. – The effect of antigen structure on MHC class II binding by peptides 
Early work by Streicher and Berzofsky et al. proposed that antigen 
conformation determines processing requirements by studying four different forms 
of a specific epitope of myoglobin (amino acids 132-153) (58).  These forms 
included the native antigen, the specific peptide fragment and two conformationally 
altered forms of the protein.  By investigating the T cell recall responses to these 
proteins, the group found that unfolding the native conformation was a critical 
parameter determining processing and showed that the epitope within native 
myoglobin was the least accessible of the four tried.  They proposed that processing 
may be necessary to allow effective presentation of the epitopes.  Berzofsky’s group 
subsequently showed that there was evidence of MHC-specific hindering structures 
on products of processing (59).  This was hypothesised as result of examining the 
recall responses to equine myoglobin and an immunogenic myoglobin peptide in 
different strains of mice.  One strain generated an immune response to both whole 
antigen and the specific peptide, while the other strain of mouse only generated an 
immune response to the peptide.  Since the mouse strains used express different class 
II molecules, it was hypothesised that the product of natural processing of the whole 
myoglobin protein contained sequences flanking the immunogenic peptide, which 
interfered with peptide binding to the MHC class II molecule or subsequent TCR 
binding (59). 
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1.4.3. – The effect of three-dimensional structure and disulphide bonds on 
MHC class II binding 
More recently, it was hypothesised that three-dimensional structure potentially 
limits the access of endoproteolytic processing enzymes to cleavage sites and of 
MHC class II molecules to helper T cell epitopes.  Data from Dai et al. has shown 
that the immunodominant peptide from bacteriophage T4 Hsp10 is on the N-terminal 
flank of a mobile loop, which is sensitive to proteolysis.  Mutations to stabilise this 
loop dramatically reduced the immunogenicity of the flanking immunodominant 
epitope, although the protein retained good overall immunogenicity.  They also 
showed that antisera generated against the stabilised mutant T4 Hsp10 epitopes 
exhibited increased cross-reactivity.  Overall these data support the concept that 
unstable loops can promote the presentation of flanking epitopes and suggest that 
deletion of these loops may have implications in improving both the breadth and 
strength of an immune response (60).  
Experiments by Rouas et al. using human chorionic gonadotropin (hCG) α- 
and β-subunits showed that the α- subunit of the hCG could induce in vitro 
responses in α-subunit-specific T cell hybridomas, but to a reduced extent when the 
α- subunit was in conjunction with the β- subunit (8).  By comparison, hybridomas 
specific for the β- subunit could mount a similar immune response to both the β- 
subunit and to the combined α- and β- subunits.  Human follicle-stimulating 
hormone α- and β- subunits are identical and homologous to the hCG α- and β- 
subunits respectively.  Comparison of the immune responses induced by these 
proteins showed that the three dimensional structure of a molecule could play a 
critical role in the processing pathway.  However, in kinetic experiments, expression 
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of the hCG β- subunit appeared to be independent of the quaternary structure of the 
hCG molecule.  That being the case, the conformation alterations within the 
combined αβ molecule mainly influenced processing of the α-subunit rather than of 
the β-subunit (8). 
One feature that can influence the quaternary structure of an antigen is the 
presence of disulphide bonds.  Li et al. have shown that mutagenesis of cysteine 
residues may minimally disrupt the abundance and overall conformation of a protein, 
but that disruptions in the disulphide bonds influenced the MHC class II expression 
of dominant and subdominant  T cell epitopes.  These data suggest that disulphide 
bonds can regulate antigen processing both locally and at distant sites, influencing 
epitope selection within the MHC class II pathway (61). 
 
1.5. – Processing of antigens for presentation by T cells 
 
Antigens that bind APC receptors are internalised by receptor-mediated 
endocytosis and results in the antigen-receptor complex enclosed within endosomes.  
As the endosome progresses through the cell, the interior becomes increasingly 
acidic and it eventually fuses with lysosomes.  These lysosomes contain acid 
proteases (for example, cathepsins D and E) that are activated at low pH and digest 
the antigen into peptide fragments (5, 62, 63).  Later on in the process, vesicles 
containing MHC class II complexes fuse with the vesicles containing antigen-derived 
peptides.   
1.5.1. – The mechanics of processing 
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MHC class II antigen complex assembly and presentation starts with a 
translocation of the MHC class II protein into the endoplasmic reticulum (ER).  The 
ER is associated with relatively high concentrations of unfolded and partially folded 
peptides so the MHC class II molecules must be prevented from binding prematurely 
to other peptides, so in order to prevent aberrant peptide binding, the MHC class II 
binding groove is blocked by Ii.  This protein forms trimers and each subunit binds 
covalently to the MHC class II α:β heterodimers.  Ii binds to the MHC class II 
molecule in such a way that part of its polypeptide chain actually lies within the 
binding groove, preventing binding of peptides or partially folded proteins.  
Additionally, while the MHC class II complex is being formed, the component parts 
are associated with calnexin.  When the proteins that make up the MHC class II 
molecule are in place, as well as the Ii, the calnexin is removed and the MHC class 
II: Ii complex is released from the ER.  It has been shown that MHC class II 
molecules produced without Ii remain in the ER and are eventually destroyed in the 
same way as misfolded proteins (64-67). 
As described earlier, processing mechanisms also have an important role in 
determining antigen presentation.  The processing of antigen occurs within the 
lysosome and fragments are generated by enzymatic cleavage.  The major enzymes 
involved in these processing steps are cathepsins D and E, and asparaginyl 
endopeptidase (AEP) (68, 69).  The processing of TTD (55, 70) and of  the non-
collagenous domain of the Goodpasture antigen, the α3 chain of type IV collagen 
(α3(IV)NC1) (71) influences the processing of the complete protein.  Both proteins 
require “unlocking” in order to be processed fully and for peptides to be presented on 
the surfaces of APCs . 
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In particular, processing has a major influence on TTD presentation.  Several 
experiments have been undertaken using a specific region of TTD, the C fragment 
(TTCF).  This fragment is responsible for binding to neurons via gangliosides (72, 
73).  This is important for the development of characteristic prolonged muscle 
spasms seen during the disease.  It has been shown that processing of the TTCF 
fragment involves cleavage at asparagine residues 873, 1184 and 1219 by asparagine 
endopeptidase (68).  Subsequent work has shown (by mutating the aspargine 
residues) that the mutant protein without asparagine at these sites is highly resistant 
to processing and that the asparagine at 1219 is obligatory for optimal presentation of 
many T cell epitopes within this protein (69).  Cleavage at this point effectively 
“unlocks” the tetanus molecule for processing.   
1.5.2. – The mechanics of class II binding 
The Ii does also have a second important function: it directs the MHC class II 
molecules to a low pH endosomal compartment in order for peptide loading to occur.  
This compartment is known as the MIIC (MHC class II compartment) and occurs 
late in the endosomal pathway (74, 75).  The MHC class II complexed with Ii 
remains in this compartment for up to four hours, during which time the Ii is cleaved 
by acid proteases in a very specific sequence of events (76).  The initial cleavage 
events result in a truncated Ii and this ensures the molecule is retained in the 
proteolytic compartment (67).  Subsequent cleavage events remove the membrane-
associated fragment of Ii and leave a short fragment of the Ii (class II-associated 
invariant-chain peptide, or CLIP) in the peptide binding groove.  No other peptide 
can bind the MHC class II molecule while the CLIP fragment remains associated 
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with the binding groove.  CLIP must either dissociate or be displaced in order for 
peptide binding and translocation to the cell surface membrane to occur (67, 77). 
In vitro experiments have shown that removal of CLIP and peptide loading can 
be directly catalysed by the HLA molecule, DM, suggesting the HLA-DM also has a 
role in the removal of CLIP from MHC class II molecules in vivo (64).  Subsequent 
work has shown that HLA-DM and HLA-DR can be co-precipitated, implying 
association under steady state conditions in vivo (78).  The association is favoured 
under low pH conditions, supporting the hypothesis that this association occurs 
during MHC class II peptide loading in the MIIC.  It has been shown that the DR-
DM association is transient and the DM also associates with MHC class II: peptide 
complexes (64).  Additional work in vitro showed that HLA-DM has a degree of 
specificity for MHC class II molecules bound to CLIP, and is directly involved in 
peptide loading of the MHC class II molecules by preferentially binding CLIP and 
causing it to dissociate from the HLA molecule.  These findings suggest a role for 
HLA-DM in prolonging the survival of empty class II molecules within the MIIC, a 
function likely to be important in peptide loading and presentation (79).  More recent 
publications have concentrated on the nature of the HLA-DR/HLA-DM interaction, 
with Pashine et al. determining that the HLA-DM can alter the conformation of the 
MHC class II binding groove as well as edit the sequence of MHC class II-bound 
peptides (80).  Mutating the HLA-DR molecule such that the HLA-DM binding site 
is acidic can disrupt the HLA-DM MHC class II interaction and the editing process.  
This group have also postulated that the HLA-DM molecule actually makes the 
HLA-DR molecule less specific (80).  The most recent data describing the HLA-
DR/HLA-DM interface has shown, through mutational analysis, that the DR-DM 
25 
interaction in inhibited by glycosylation of the HLA-DM molecule, supporting the 
need for a close interaction between the two molecules.  The interface was described 
such that the presence of an acidic cluster of amino acids at the peptide N-terminus 
may be utilised as a possible dissociation mechanism (81).  Additional work has 
suggested that HLA-DM is effectively a chaperone protein, and the inability of 
HLA-DM null mice and cell lines to remove the Ii fragment from the MHC class II 
molecules on the cell surface supports this idea (66, 80). 
 
 
1.6. - Impact of MHC class II type on epitope processing and 
presentation 
 
In 1979, Corradin et al. used enzymatic processing of cytochrome c to generate 
peptide fragments and then tested recall responses by T cells isolated from mice 
immunised with whole cytochrome c, in an attempt to determine specific T cell 
epitopes (82).  This experimental design was then used to determine T cell epitopes 
in multiple sclerosis using myelin basic protein as the target antigen in a murine 
multiple sclerosis model, experimental autoimmune encephalomyelitis (83).  Similar 
work was published using recombinant peptides to study epitopes in myasthenia 
gravis (84, 85), rheumatoid arthritis (86) and type 1 diabetes (87). 
It was also noted that different mouse strains responded to different epitopes 
within the acetylcholine receptor, the target autoantigen in myasthenia gravis (88).  
This work concluded that epitopes specifically recognized by T lymphocytes of 
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patients with myasthenia gravis also represent specific T-cell epitopes in the 
autoreactivity to the acetylcholine receptor in mice (the autoreactive peptides 
described in humans were tested in inbred mice) and that immune responsiveness to 
these peptides is influenced by the genetic make-up of the responding mouse strains.  
This is corroborated by the knowledge that most autoimmune diseases are linked to 
specific HLA molecules in humans (89).  In particular, Pette et al. published work 
investigating immune responses to myelin basic protein (linked with multiple 
sclerosis) with presentation of the peptides restricted to HLA DR2 (90).  The work 
involving HLA-restriction in autoimmune model systems was assisted further with 
development of transgenic mice that expressed HLA molecules in lieu of the murine 
equivalents IAB and/ or IEB (91).  These transgenic animals could be used to 
determine specific T cell epitopes that, when presented to reactive T cells, resulted in 
autoimmune reactions.  Since then, transgenic mice have been used to identify 
possible T cell epitopes in many autoimmune diseases, including type I diabetes (92) 
and multiple sclerosis (93). 
 
1.7. – Genetics and predisposition to autoimmunity 
 
It is becoming more and more apparent that susceptibility to autoimmune 
diseases is influenced by complex genetic interactions in which multiple genes act in 
concert to contribute to a disease, yet have no or only modest effects independently.  
The major genetic factor predisposing towards autoimmunity is HLA type (94), but 
polymorphisms within a few common genes have been shown to contribute to 
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multiple autoimmune disorders (PTPN22 and IL-23 for example (95)).  While 
currently only a few genes with influence are known, advances in genetic research 
are likely to rapidly expand the number of genes and specific genetic factors with an 
effect on overall predisposition.  That being the case, it is currently unclear how 
common genetic variation compared with multiple rare variants will contribute to 
overall disease susceptibility (95).  Even with genes displaying a marked association 
with autoimmunity, the likely mechanisms by which the genes contribute to risk 
remain unknown.  These genes include intracellular signalling molecules, 
transcription factors, cytokines and cytokine receptors (including IL-2), and 
membrane receptors or relevant co-stimulatory molecules (95), while the 
autoimmune diseases include type 1 diabetes and Crohn’s disease (96-98).  This 
variety in gene loci suggests that signalling processes are very important in the 
overall development of autoimmunity, but that there are very disparate mechanisms 
that may subtly interact or work in complete independence. 
One gene conferring increased susceptibility to autoimmunity is PTPN22, an 
intracellular tyrosine phosphatase.  Single nucleotide polymorphisms (SNP) have 
functional correlates on the protein produced: a variant in which the arginine at 
amino acid position 620 is substituted with a tryptophan residue has been shown to 
change functional properties and confer a 2-fold increase in the likelihood of 
developing rheumatoid arthritis (99) or type 1 diabetes (100).  This risk increases to 
3-4-fold if the person is homozygous for the tryptophan-coding allele.  In terms of 
strength of association, the tryptophan allele of PTPN22 is second in importance 
only to the MHC genotype for these two diseases (95).  Other autoimmune diseases 
that have been linked to this genetic variant include Grave’s disease (101), 
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Hashimoto thyroiditis (102), and myasthenia gravis (103).  In addition, a murine line 
in which the mouse ortholog of PTPN22 (Lyp or PEP) is knocked out exhibits 
enhanced T cell activation combined with increased production of antibody (104). 
Polymorphisms within cytokine and cytokine receptor genes influence 
autoimmune disease.  The best described association between a cytokine receptor 
gene and autoimmunity is between Crohn’s disease and the glutamine 381 variant of 
the IL-23 receptor (105-107).  This association has also been shown in psoriasis and 
ankylosing spondylitis (108, 109).  The IL-23 receptor shares a subunit with the IL-
12 receptor, so autoimmune interactions and correlations between IL-23 are also 
inextricably linked to the IL-12 receptor.  However, the SNP associated with the IL-
23 receptor and Crohn’s disease is actually on the unshared IL-23 receptor subunit.  
Amino acid 381, normally an arginine residue, is substituted with a glutamine 
residue and this substitution results in a strong preventative influence upon the 
development of Crohn’s disease, although the functional significance of this change 
has not yet been elucidated (95).   
The additional association of both Crohn’s disease (106) and psoriasis (109) 
with the β subunit of the IL-12 cytokine itself adds to evidence that the balance in 
activity of IL-23 and IL-12 cytokine pathways is an important component of disease 
pathogenesis in these disorders.  This association has been supported by findings in 
animal models, and recent data about the role of both IL-12 and IL-23 in 
differentiation of Th17 cells have also supported the evidence published from animal 
models (110).  In particular, both IL-12 and IL-23 are upregulated in Crohn’s disease 
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and trial therapies involving blockade of these cytokine pathways are showing 
promise for effective treatment of both Crohn’s disease and psoriasis (96). 
Polymorphism within the major T cell proliferative cytokine IL-2 has been 
linked with predisposition to coeliac disease (111).  Polymorphisms within IL-2 have 
also been linked to type I diabetes, rheumatoid arthritis and Grave’s disease (97, 105, 
112), but less definitively.  In particular, there are links between polymorphism in the 
IL-2 gene as a risk factor in non-obese diabetic mice (98), but no obvious functional 
variants have been identified in the non-obese diabetic mouse gene sequence (97).  
However, there are positive correlations between human type I diabetes and 
functional variation in the human IL-2 gene sequence (105, 113, 114). 
The major genetic factor associated with predisposition to autoimmune disease 
is HLA type.  Although numerous examples of specific HLA type and autoimmunity 
are documented, the specific mechanisms remain undefined.  There are numerous 
known SNPs across the entire MHC class II loci, an area with massive genetic 
complexity, and it has been shown that genes outside the specific HLA genes, but 
within the MHC class II loci, may also influence autoimmunity (95).  Multiple 
sclerosis and HLA-DR2 (of which HLA-DR15 is a subtype) (90), rheumatoid 
arthritis and HLA-DR4 (115), and Goodpasture’s disease and HLA-DR15 (41, 116) 
are all examples of autoimmune diseases with known associations to a specific HLA 
genotype.   
The mechanisms by which these HLA genotypes influence and predispose 
towards autoimmunity are not understood, but are likely to relate to the the particular 
capacity of the HLA molecule to present particular peptides.  This association 
appears to correlate with features in the class II peptide binding groove (and by 
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inference the peptides best presented).  These HLA genotypes may also have a 
higher affinity for antigen fragments that are not the major naturally processed 
peptides and are immunologically subdominant or cryptic (1, 50, 117-119).  A 
current theory is that these subdominant peptides may not have been presented 
within the thymus during central tolerance.  This suggests that T cells are able to 
recognise immunologically subdominant peptide fragments from self within the 
MHC class II peptide groove and become activated by the autoantigen.  This could 
result in a proliferative response usually seen to exogenous antigen (120, 121).  This 
in turn promotes an immune response to the self-antigen that is perpetuated by the 
gradual destruction of the tissue containing it.  Since these peptides could be derived 
from slightly different processing mechanisms, effectively the T cells respond to 
different epitopes within the same protein (44, 45, 120, 122). In Goodpasture’s 
disease, HLA-DR7 and HLA-DR1 have been shown to protect against the disease.  
In particular, the presence of HLA-DR7 ensures that despite the presence of DR15, 
the disease does not develop.  The association between Goodpasture disease and 
HLA-DR15 is such that approximately 80% patients with Goodpasture’s disease 
express this MHC class II molecule. 
 
1.8. – Tolerance and the CD4 T cell response to self-antigen 
 
In autoimmune disease, the immune system responds to an endogenous 
antigen, to self.  A collection of mechanisms exists to prevent immune activation by 
self-antigen.  This system is known as tolerance and is usually considered to 
comprise central and peripheral mechanisms.  Central tolerance determines which T 
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cells are allowed to mature and to enter the periphery, while peripheral tolerance 
controls aberrant activation of the T cells once they are in the periphery. 
1.8.1 – Central tolerance 
How the body recognised self from non-self became a major point for 
discussion.  With the discovery of mechanisms underlying how the immune system 
presents exogenous antigen, Owen first introduced the concept of tolerance in the 
immune response, in 1945.  His experiments showed that monozygotic bovine twins 
had two types of erythocyte circulating within their blood, but that they did not 
mount an immune response to the circulating “foreign” cells (123).  Since then, the 
mechanisms underlying immunological tolerance have been studied in depth.  The 
Nobel prize for medicine in 1960 was jointly awarded to Sir Frank Macfarlane 
Burnet and Peter Medawar for their work investigating acquired immunological 
tolerance with particular relevance to transplantation (124-128).    
Of particular interest for this project was work by Lo and Sprent, in 1986 
(129), demonstrating the importance of the thymus in developing T cell tolerance.  In 
these experiments, mice were thymectomised then engrafted with a replacement 
thymus from a 14 day old foetus.  The donor thymus was either the same genotype as 
the original mouse, or from a different strain of mouse so of a different genotype.  
These mice were then irradiated to remove the circulating T cell population, and 
given bone marrow intravenously to provide stem cells.  After sufficient time had 
passed to enable the immune system to recover following the irradiation, the animals 
were primed with antigen (keyhole limpet haemocyanin, or KLH), and the 
proliferative responses of the T cell in the various strains were analysed.  These 
experiments showed that mice with an engrafted thymus had a greater immune 
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response to the antigen determinants favoured by the engrafted thymus genotype, so 
showed that the thymic environment is necessary for T cells to develop MHC class II 
recognition.  Additional experiments in which the foetal thymuses were incubated 
with deoxyguanosine prior to graft (deoxyguanosine destroys intrathymic cells of 
macrophage and dendritic lineage, so all APCs), showed that the bone-marrow 
derived cells were not necessary for the development of MHC class II recognition by 
T cells (129). 
Central tolerance has since been defined as the process of refining the T cell 
repertoire by testing for the T cells that recognise MHC-peptide complexes too 
weakly to be useful or too strongly to avoid autoimmunity.  Tolerance begins, as 
described by the experiment above, in the thymus.  Double-negative T cells (express 
neither CD4 nor CD8 on their surfaces) emerge from the bone marrow and migrate 
to the thymus where they begin to mature and express both CD4 and CD8, becoming 
double-positive T cells.  These then further mature into single positive T cells 
depending on their affinity for either MHC class I or MHC class II, and start being 
selected according to their ability to bind MHC-peptide complexes. 
1.8.2. – The role of the thymus in determining tolerance 
Antigen recognition is crucial for the development of the T cell repertoire.  The 
actual T cell selection is very much compartmentalised within the thymus.  The 
thymus consists of lobes, each of which is organised into outer cortical and inner 
medullary regions, each containing specialised cells.  Rapidly proliferating immature 
cells are associated with the outer cortex; as cells enter the inner cortex they are 
expressing both CD4 and CD8 and are probably being tested for their ability to bind 
MHC class II (130, 131).  The medulla contains the mature, CD4- or CD8-positive 
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lymphocytes, medullary epithelial cells, bone marrow-derived macrophages and 
dendritic cells.  It is not currently known whether the expression and concentration of 
MHC class II on antigen presenting cells and their isolation have an influence on the 
selection processes.  It is currently thought that thymic endothelial cells express 
MHC class II molecules on their surfaces, T cells that can bind the MHC class II 
molecules are kept, while those that do not recognise the MHC class II molecules are 
deleted (131).  This leaves a population of cells that recognise MHC class II.  
Thymic cells within the corticomedullary junction of the thymus and the thymic 
medulla have been shown to express MHC class II molecules containing self-derived 
peptides in their binding groove (131).  Under these conditions, all T cells binding 
with too high an avidity for the MHC class II: peptide complexes are more likely to 
be deleted since these are the cells likely to induce autoimmunity (negative 
selection).  This could leave a T cell population that is capable of recognising MHC 
class II: peptide complexes, but without a high enough avidity to cause aberrant 
autoimmune reactions. It could be assumed that these cells therefore only present 
peptides from processed endogenous antigen and not antigen from the circulation.  It 
has been shown that peptides derived from the Goodpasture antigen, the α3 chain of 
the non-collagenous domain of type IV collagen (α3(IV)NC1) (4) and peptides 
derived from insulin (132) are expressed in the thymus.  This suggests that there is 
potential opportunity for negative selection of these antigens, and therefore supports 
the idea of centralised tolerance to antigens with which the circulating T cells may 
come into contact while in the periphery.  T cells that are released into the periphery, 
the mature T cell pool, may recognise MHC class II molecules associated with a 
foreign peptide, or a peptide not expressed by the thymus, but some that respond to 
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self-antigen within the binding groove escape central deletion (133).  Peripheral 
tolerance controls them. 
Experiments with mice that express MHC class II molecules without peptide 
on their cortical epithelial cells show a normal level of positive selection for ability 
of their T cells to bind MHC class II, but impaired selection for ability to bind MHC 
class II: peptide complexes, supporting the hypothesis that these cells play a role in 
selecting T cells for ability to bind MHC class II molecules.  It has also been found 
that bone marrow-derived macrophages and dendritic cells are responsible for the 
removal of at least 50% of all T cells positive for MHC class II binding ability (130). 
1.8.3. – The role of autoantigen in tolerance 
Antigens targeted in autoimmune diseases have been shown to be presented 
within the thymus and are therefore hypothesised to induce central tolerance.  
Tolerance can prevent those autoimmune diseases in the majority of the population 
(diabetes, multiple sclerosis).  A possible explanation for the occurrence of 
autoimmunity lies in peptide presentation during T cell selection, so within the 
development of tolerance.  Although the thymic epithelial cells are presenting 
peptides from various endogenous antigens, the peptides have to be processed and 
exposed to MHC class II molecules in the same way as exogenous antigen.  This 
suggests that during the development of the T cell repertoire, that epitopes presented 
within the thymus are major naturally processed peptides.  It could therefore be 
hypothesised that during development of autoimmunity, the processing differs 
slightly so the peptides presented within the MHC class II binding grooves on APCs 
are different from those normally presented and to which the T cells were exposed in 
the thymus.  For tissue-specific antigens like α3(IV)NC1, this is not always thought 
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to be the case as these antigens may have some protection from immune responses 
through sequestering the whole antigen (134). 
While it is now accepted that central tolerance and T cell selection occurs in 
the thymus, there are questions arising regarding how the thymus could actually 
present all possible self-antigens.  The thymus cannot and does not present all 
possible antigens, but there is evidence to support expression of antigens such as 
insulin (diabetes) (132), proteolipid protein from the brain (experimental 
autoimmune encephalomyelitis, a mouse model of multiple sclerosis) (135), and 
fragments of type IV collagen (Goodpasture’s disease) (4).  This information 
suggests that cells within the thymus can take advantage of so-called promiscuous 
gene expression (136), so are a unique cell type capable of expressing a diverse 
range of tissue-specific antigens.  It has been shown that this ability is maintained 
through thymic T cell output and regulated by the nuclear protein autoimmune 
regulator (AIRE) (137-139).  It was hypothesised that this capability may enable 
presentation of the limited range of self-antigens that would otherwise be temporally 
or spacially secluded from the immune system.  However, upon testing, the actual 
presentation of the self-antigens within the thymus appeared more random and was 
not confined to sequestered self-antigens (136). 
1.8.4. – Peripheral tolerance 
Peripheral tolerance can be described as the mechanisms by which the 
circulating T cell population is prevented from reacting to self.  The mechanisms 
resulting in regulation of peripheral T cell activation can be diverse, including 
limiting access to tissues, induction of apoptosis for aberrantly activated T cells and 
directly regulating effector T cell responses by other T cells.   
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While some tissues and antigens are sequestered (immunologically privileged), 
some tissues are frequently exposed to the immune system.  Certainly, the antigens 
that are sequestered are unlikely to activate T cells, through inaccessibility to the 
immune system (134).  Privileged sites initiate mechanisms that cause activated T 
cells to either undergo apoptosis or encourage them to migrate away from the area.  
For example, immune privilege has been investigated in respect of T cell access to 
the retina.   D’Orazio et al. showed that local cytokine release (TGF--β, IL-10) 
impedes the entry of T cells in the retina (140), while Sonoda et al. showed that 
cytokines and Tregs prevent self-deleterious responses of T cells that reach the retina 
(141).  Tissues transplanted into immune privileged areas have increased chances of 
survival and reduced rejection, for example corneal allografts (142), while stem cells 
that have potential uses in transplantation have also been shown to exhibit some 
immune privilege (143). 
A balance of co-stimulatory signals affects immune homeostasis and self-
tolerance.  Naïve T cells require two signals to proliferate and differentiate.  The first 
is triggered by TCR recognition of the appropriate MHC class II: peptide complex, 
while the second signal is from CD80 and CD86 co-stimulatory molecules on the 
APC surface.  Depending on the co-receptor used, these signals can be interpreted in 
different ways.  Some examples of different interpretations through use of different 
co-receptors include CD28, a molecule constitutively expressed on T cell surfaces 
that enhances cell survival (144), CD40 ligand expression that prevents T cell anergy 
(145), while ligation of CTLA-4 (CD152) inhibits T cell responses (146). 
Both naturally occurring and antigen-induced Treg cells have a major influence 
on peripheral tolerance and maintaining immunological homeostasis by ensuring 
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overwhelming immune responses to antigen or autoantigen are unable to proceed.   
Overall, Treg cells suppress immune responses.  They suppress activation of 
dendritic cells, Th1, Th2, Th9 and Th17 cells, mast cells, basophils and eosinophils.  
They suppress effector T cell migration and IgE production in responses to allergens 
(17).  One mechanism by which suppression is induced is by rendering the 
circulating T cells anergic.   This means that although the T cells are able to be 
activated, they require higher levels of stimulation in order to differentiate into the 
appropriate effector T cells.  Treg cells can also result in deletion, either by inducing 
apoptosis, or by neglect, although nTregs use cell-cell contact (25) and iTregs use 
cytokine secretion (26) to achieve similar results.  In order to maintain a healthy 
circulating T cell population, the peripheral T cells need access to certain cytokines 
to keep them alive but inactive, in stasis.  In order for a cell to be deleted by neglect, 
the cell fails to receive costimulatory signals through CD28.  Tolerance in the 
context of lack of CD28 costimulation can result from Fas-independent peripheral 
deletion (147).   
Suppression of antigen-specific immune responses by IL-10, a known 
suppressive cytokine of T cell proliferation and cytokine production, is thought to be 
important in ensuring peripheral tolerance to allergens, autoantigens, transplantation 
antigens, and tumour antigens (148).  In mice, it has been shown that IL-10 
administration prior to allergen treatment induces antigen-specific T cell 
unresponsiveness and demonstrates the pivotal role of IL-10 in the establishment of 
peripheral T cell tolerance (149).  Inhibition of graft-versus-host disease by IL-10 
and allograft rejection in patients with severe combined immunodeficiency 
undergoing HLA-mismatched bone marrow transplantation provide additional 
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evidence for a key role of this cytokine in the induction and maintenance of 
peripheral tolerance (150).  The mechanism by which IL-10 suppresses T cells 
involves that direct blocking of inducible costimulator, CD2 and CD28 costimulatory 
signals in a rapid signal transduction cascade and occurs through direct use of the Src 
homology 2 domain-containing protein tyrosine phosphatase (151) by IL-10 (151, 
152).  This ensures that the T cells cannot become activated. 
Overall, peripheral tolerance maintains immunological reactivity in the 
periphery, while preventing aberrant responses that could result in an autoimmune 
reaction. 
 
1.9. - The scope of tolerance across peptides of an antigen 
 
The scope of tolerance across peptides from an antigen has been shown using 
mice that are transgenic for expression of hen egg lysozyme (HEL) (120).  In 
particular, work by Gapin et al. has shown that tolerance is not only induced to the 
immunodominant peptide of HEL, testing immune responses of HEL transgenic 
mice, but also to subdominant or cryptic peptides within HEL (153).  This work was 
further expanded to show that while dendritic cells mainly present the 
immunodominant peptide, B cells are capable of diversifying the T cell response by 
presenting a more heterogeneous set of peptide-MHC complexes, and that a peptide 
designated subdominant due to inefficient processing and reduced immunogenicity, 
was equally tolerogenic as the immunodominant peptide (154).  This work is 
corroborated by the experiments carried out by Peterson et al., who found that there 
is equal tolerance among epitopes of HEL expressed at different levels on APCs, and 
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that central tolerance to a limited number of peptide-MHC complexes occurs with 
high sensitivity (155).  This was also shown by Gammon and Sercarz, who showed 
that mice were tolerant to HEL despite the presence of HEL-reactive T cells.  They 
proposed that these HEL-reactive T cells escape tolerance because some minor 
determinants are only available in relatively low amounts after in vivo processing.  
As a result, these T cells are not normally activated but can be stimulated under 
special circumstances and circumvent tolerance (156). 
The current consensus is that tolerance to HEL can be initiated in transgenic 
mice, even with restricted distribution of the HEL throughout the animal, as 
determined by Ham et al.  They generated transgenic mice that expressed HEL under 
the control of the rhodopsin promoter and found that these mice were resistant to the 
expected ocular inflammation following immunisation with HEL.  They then found 
HEL mRNA in the thymi of transgenic animals and, following cross-breeding with a 
transgenic mouse that expresses HEL specific T cell receptors, found that there were 
reduced numbers of HEL-specific T cells in the circulation of these animals (157). 
1.9.1. – Tolerance across peptides in autoantigens 
Importantly, tolerance has also been shown in mouse models of experimental 
autoimmune disease.  Fairchild et al. showed that the main autoimmune response in 
experimental allergic encephalomyelitis (EAE) was directed towards the 
subdominant epitopes of myelin basic protein, rather than towards those peptides 
displaying immunodominance (121).  They found that a modified subdominant 
epitope was expressed on the APC surface for almost four hours, while the wild-type 
epitope bound very transiently and could not be measured on the APC surfaces.  
These data suggested that epitopes could escape tolerance mechanisms by binding 
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transiently without enabling autoreactive T cells to bind and be deleted during 
negative selection (121).  This work was corroborated by Joosten et al. who 
investigated specific T cell responses in the Lewis rat to autoimmune epitopes from 
different disease models including EAE (myelin basic protein), autoimmune arthritis 
(heat-shock protein 65) and myasthaenia gravis (acetylcholine receptor).  They found 
that autoimmune epitopes were intermediate to poor binders of the MHC class II 
molecule compared to other, known immunodominant peptides (158).  They also 
found that single amino acid substitutions at defined positions were sufficient to turn 
certain peptide into good binders, and postulated that these data could be relevant to 
the design of competitive binding peptides in the treatment of autoimmunity (158). 
More recent work by Kanagawa et al. found that specific MHC class II 
genotypes had increased numbers of autoreactive T cells.  This work showed that 
non-obese diabetic (NOD) mice that expressed I-Ag7 molecules on their cell surface 
contain a high number of autoreactive T cells compared to NOD mice with I-Ab.  It 
was subsequently found that the autoreactive T cells have a high level of reactivity to 
APCs not pulsed with antigen, so the T cell repertoire is skewed towards 
autoimmunity, possibly due to weak binding properties of the I-Ag7 (159).  The 
situation with these NOD mice is somewhat akin to that with mice bearing I-Au.  If 
these I-Au mice are immunised with an EAE epitope, EAE develops despite a very 
weak binding interaction between the peptide and the I-Au molecule (159). 
Additional work on EAE models has shown that encephalitogenic T cells that 
escape tolerance either recognise short-lived peptide/ MHC complexes, or express 
TCRs with unique specificities for stable complexes.  It was hypothesised that a 
decrease in the level of expression of myelin basic protein epitopes on cells that 
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mediate tolerance would enable more T cells to escape tolerance.  This decrease 
would therefore result in a greater percentage of the repertoire consisting of T cells 
that would require a lower level of antigenic exposure for activation, and may have 
implications for the development of autoimmunity, or multiple sclerosis in particular.  
This work also implies that genetic or environmental influences that decrease the 
efficiency of induction of tolerance may change the repertoire of self-reactive T cells 
to include a greater number of T cells with the potential to be triggered by lower 
concentrations of self-antigens.  This suggests that both subdominant and 
immunodominant peptides may be targets in the initiation of autoimmune disease 
(160).  
Additional work has suggested that immunisation of HEL transgenic animals 
with exogenous HEL in conjunction with CpG oligonucleotides can break tolerance 
to HEL, as measured by high titres of anti-HEL antibodies, but does not induce 
autoimmune disease.  The animals used, even with long term immunisation 
schedules, did not develop T cell responses to endogenous antigen or tissue damage, 
despite the presence of HEL-specific antibodies.  This suggests that B cell tolerance 
is broken by this system, rather than central T cell tolerance, but work is ongoing to 
clarify this point (161). 
Another explanation for lack of tolerance to specific epitopes from 
autoantigens is that of destructive processing.  This theory suggests that some 
potential T cell epitopes may contain protease cleavages sites and are therefore 
destroyed during normal processing mechanisms (55).  With self-proteins, this may 
have more serious consequences if other factors can modulate the epitope crypticity.  
There is also evidence to suggest that antigens could be subjected to processing in 
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such a way that premature lysosomal proteolysis is prevented, resulting in 
modulation of peptide binding and the potential for enhanced MHC class II- peptide 
complex formation (67).  One such example is a peptide from myelin basic protein 
(MBP 85-99).  In the case of MBP 85-99, there is a known inverse correlation 
between AEP activity and peptide concentration but mechanisms causing the peptide 
to become cryptic and presented by APCs are currently unknown (55). 
 
1.10. – Goodpasture’s disease and the Goodpasture antigen  
 
Goodpasture’s disease is a relatively rare autoimmune disease causing renal 
failure and pulmonary haemorrhage.  There are 1-2 cases per million people per year 
and, despite the scarcity of new cases, this disease has been well characterised (162). 
There is a strong association between Goodpasture’s disease and the HLA-DR15 
molecule (approximately 80% of patients carry this HLA molecule), and the 
autoantigen has been well defined and major naturally processed antigen derived 
peptides have been identified.  The Goodpasture antigen was cloned in 1992 by 
Turner et al. (163), and since then the crystal structure of the α1(IV)NC1 chain has 
been determined (164), enabling some elucidation of the potential crystal structure 
for the α3(IV)NC1 domain.  This means that Goodpasture’s disease had potential for 
use as a model system to analyse the interactions between the antigen and the HLA-
DR15 molecule.  In particular, models of this disease have the potential to be used to 
clarify whether HLA-DR15 enhances the autoimmune response to α3(IV)NC1 
peptides by efficient presentation to the autoreactive T cells, or whether there is 
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failure to induce tolerance within the thymus by poor presentation of α3(IV)NC1 
peptides in the thymus (unlikely as α3(IV)NC1 has been shown to be presented in 
the human thymus (4)).  It could also be used to clarify the role of so-called 
protective class II molecules in deletion of autoreactive T cells or sequestering 
α3(IV)NC1 derived peptides (116). 
Research has shown that the presence of HLA-DR15 is unlikely to increase 
susceptibility to Goodpasture’s disease by presenting a peptide particularly well 
since, in general, α3(IV)NC1 derived peptides bound HLA-DR15 with similarly 
high affinity as they would HLA-DR7.  Only some of these peptides evoked patient 
T cell responses (peptides containing amino acid residues 71-90 and 131-150) and 
these were not the peptides found to be most abundantly presented on APC surfaces 
(peptides containing amino acid residues 21-40, 61-80 and 161-180) (41).  It was 
also found that HLA-DR7 or HLA-DR1, so-called protective haplotypes, on average 
were able to present particular α3(IV)NC1 peptides better than HLA-DR15, although 
HLA-DR15 did present some peptides better than HLA-DR7.  It has been suggested 
that HLA-DR7/1 could protect by capturing peptide and preventing their display 
bound to HLA-DR15.  Binding data obtained has indicated that biochemically 
detectable peptides isolated from HLA-DR15 homozygous APCs would 
preferentially bind HLA-DR7/1 binding grooves in HLA-DR15, HLA-DR7/1 
heterozygous APCs.  This implies that the protective effect of HLA-DR7/1 
molecules may be due to increased affinity for the peptides to which HLA-DR15 
binds in order to cause disease (41). 
1.10.1. – Goodpasture antigen and processing 
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Figure 1.4. – T cell immune responses to overlapping α3(IV)NC1 peptides in 
Goodpasture patients and HLA-matched control subjects. 
These charts show the percentage of the individuals tested whose peripheral 
blood mononuclear cells proliferated (Stimulation Index >2.5) to the indicated α3 
peptides. Immune responses to the overlapping 20mer peptides are shown from 
Goodpasture patients (figure A) and healthy, HLA-matched control subjects (figure 
B).  The major naturally processed peptides, determined by elution studies are 
marked *, do not elicit the greatest immune responses in either control subjects or in 
Goodpasture patients, suggesting that tolerance to the best presented peptides is 
secure in health and in Goodpasture’s disease.  (Chart adapted from Cairns et al. (1)). 













 In order to present peptides derived from the α3(IV)NC1 protein, specific 
cleavage events at certain points in the protein must occur in order to enable 
complete processing.  The Goodpasture autoantigen, requires a specific cleavage 
event that subsequently enables the rest of the molecule to the processed and 
presented.  Studies by Zou et al. determined that processing by cathepsin D/E was 
essential for the unlocking of the protein as the processing could be completely 
abrogated by pepstatin A, a specific cathepsin D/E inhibitor. They also found that 
purified cathepsin D generated the same major α3(IV)NC1 fragments as entire 
lysosomes, suggesting that the cathepsin D cleavage events are involved in 
α3(IV)NC1 processing (71). The differences between processing and T cell 
responses is illustrated by figure 1.4. in which immune responses to overlapping 
20mers derived from the Goodpasture antigen, α3(IV)NC1, were compared between 
Goodpasture patients and healthy HLA matched controls.  The figure shows that the 
major naturally processed peptides, as determined by in vitro elution studies 
(α3(IV)NC1 21-40, 61-80 and 161-180, marked *) are not the peptides that induced 
the greatest immune responses in 100% of the Goodpasture patients (α3(IV)NC1 71-
91 and 131-150)  (1).  It has also been shown that the α3(IV)NC1 protein, when 
processed and presented on the cell surface in conjunction with the HLA-DR15, is 
presented as two sets of three to five peptides centred on a common core sequence 
(nested sets) and that synthetic peptides within those sets bind the HLA-DR15 with 
intermediate affinity with IC50 values ranging from 1.1-6µM (165). These data imply 
that the peptides processed and presented have a major influence on tolerance. 
1.10.2. – Immunoglobulins and epitopes on the Goodpasture antigen 
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With the Goodpasture antigen being cloned (163) and the crystal structure 
determined (164), there have been increasing efforts to define the epitopes within the 
α3(IV)NC1 protein that cause the autoimmune responses seen in Goodpasture’s 
disease.  In particular, work has concentrated on determining which specific epitopes 
are targeted by antibodies and cause pathology.  Experiments by Prof. D. B. Borza’s 
and Prof. B. G. Hudson’s groups have shed light on various epitopes within the 
Goodpasture antigen.  In particular, it was shown that antibodies from Goodpasture 
patients could bind to specific epitopes – EA and EB.  EA corresponds to amino acid 
residues 17-31, while EB corresponds to amino acid residues 127-141 of the 
Goodpasture antigen (166).  The antibodies from three Goodpasture patients were 
classified as reacting to either epitope, both epitopes or neither epitope (117).  Of the 
two epitopes, EA was found to be consistently immunodominant with antibodies to 
this epitope accounting for up to 65% of reactivity to the α3(IV)NC1 molecule.  This 
implies that the EA epitope may have a role in pathogenesis since the T cell responses 
are seen mainly in response to this epitope.  It has also been shown that these 
antibodies are capable of destroying the intact hexameric structure of the type IV 
collagen non-collagenous domains.  This destructive binding could be  a mechanism 
by which the disease pathogenesis is propagated (117).  This binding is also 
interesting because the epitopes themselves are sequestered within the planes of the 
α3(IV)NC1 that interact with the other α chains forming the overall hexamer (117, 
167, 168). 
The differences seen between epitopes for antibodies and epitopes for T cells 
are not unexpected as B cells recognise overall conformation and protein quaternary 
structure, while T cells fragments of the amino acid sequence.  The epitopes to which 
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there is known antibody binding are not the epitopes to which there is a marked T 
cell response in humans (antibodies bind residues 17-31 and 127-141, whereas T cell 
responses are seen to amino acids 71-91 and 131-150).  These are also not the major 
naturally processed peptides generated from processing of the α3(IV)NC1 domain 
(residues 21-40, 61-80 and 161-180), although there is some sequence overlap 
between one of the major naturally processed peptides (21-40) and the antibody 
binding epitope, EA – 17-31.  This indirectly supports the idea that central tolerance 
is induced to immunodominant and major naturally processed peptides, such that 
immunosubdominant peptides become the peptide that induce a T cell response 
(120).   
The work within my supervisors laboratory has mainly focussed on processing 
and T cell responses to α3(IV)NC1, since processing is essential for T cell 
recognition to occur.  In particular, Dr J. Zou determined the sequence of processing 
events for unlocking the protein through specific enzymatic cleavage reactions and 
time frames within which these occur (71).  This was done by utilising lysosomal 
extracts and specific enzyme inhibitors to identify that cathepsin D is essential for 
the unlocking process.  In addition, work from this group has shown that α3(IV)NC1 
is expressed in the thymus by thymic epithelial cells. This suggests that fragments of 
α3(IV)NC1 may be presented to T cells during central tolerance, but that has yet to 
be verified (4).  Despite this finding, it has been shown that healthy human blood 
contains T cells activated by fragment of the Goodpasture antigen (3).  This supports 
the hypothesis that the T cells in a periphery are reactive to subdominant peptides 
against which central tolerance is not effective (120).  My project aims to determine 
fragments of the Goodpasture antigen to which a T cell response is generated without 
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central tolerance, expanding our knowledge regarding the impact of tolerance on 
processing and the way in which T cells react. 
 
1.11. – Summary and objective of thesis 
 
To summarise, immunodominance is determined by, at best, multiple factors 
including affinity and processing.  In Goodpasture’s disease, the immunodominant 
peptides presented by the HLA-DR15 molecule are not the most efficiently 
presented, and peripheral blood mononuclear cells from Goodpasture patients show 
no immune responses to the major naturally processed peptides as determined by 
elution studies.  A possible explanation for this is that central tolerance is to the most 
efficiently presented peptides and not those peptides with high affinity for the HLA 
molecule but that are less well presented.  This also questions the scope of central 
tolerance to the renal autoantigen α3(IV)NC1. 
Some data published to date has indicated that the epitopes that induce 
autoimmune disease are not major naturally processed peptides, and that both 
processing and tolerance have roles in the development of autoimmunity (1, 153, 
165).  The bulk of these data was obtained from investigating Goodpasture’s disease 
(1, 153, 165), but there has also been some work investigating thymic presentation of 
major naturally processed peptides in lupus (169) and diabetes (170).  The way in 
which peptide processing, affinity for HLA molecules and tolerance interact is 
unclear.  This study investigates T cell proliferative responses to specific peptides in 
the presence and absence of endogenous expression, therefore influencing central 
tolerance. 
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Potential epitopes can currently be examined by a combination of computer 
modelling and recall response assays.  The computational approach is extensively 
utilised in vaccine research, to determine potential targets on rapidly evolving micro-
organisms or viruses (171, 172).  In addition, antibodies obtained from patients with 
autoimmune disease can be characterised and epitope specificity determined (173).  
The combination of computational analysis through predictive algorithms and 
biochemical binding analyses can be used to identify potential epitopes.  Ex vivo 
cellular analysis through use of synthetic peptides and antigen fragments can then 
assess the accuracy of the computational and biochemical identification techniques.  
In combination, the methods can be powerful tools for the prediction of antigen 
epitopes, but one method should not be used at the exclusion of the others. 
One of the aims of this project was to investigate the effect of tolerance on the 
immune response in animals.  In particular, epitopes recognised within the 
Goodpasture antigen, α3(IV)NC1, in the presence and absence of tolerance, were 
studied.  These data could be compared with existing biochemical data.  The data 
generated during this project could then enable further investigations into how 
central tolerance mechanisms influence the development of autoimmune diseases.  
While this project concentrates on the well-characterised Goodpasture antigen, the 
underlying tolerance mechanisms are not exclusive to this disease.  The conclusions 
drawn during this project could therefore be applicable to other autoimmune 
diseases, and could aid development of successful treatment for autoimmune 
conditions. 
My working hypothesis was that the specificity of autoreactive T cells is 
diverted from major naturally processed peptides because of tolerance mechanisms.  
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This predicts that if tolerance was removed, the immune response would focus on 
major naturally processed peptides as it would for exogenous antigen.  It also 
suggests that, in the absence of tolerance, immune responses could be skewed in 
favour of specific peptide fragments by use of a B cell specific adjuvant. 
The project plan was therefore to: 
1 – Examine presentation of specific epitopes by developing a new antigen 
delivery system.  This system could enable elements in the overall influence of 
antigen structure on immunogenicity to be distinguished, and isolate those elements 
that are due to effects on antigen uptake or on antigen processing (Chapter 3). 
2 – Generate transgenic mice which expressed HLA-DR15 and could be KO or 
WT for α3(IV)NC1 (Chapter 4); 
3 – Prepare as far as possible ‘natural’ conformation antigen (Chapter 5); 
4 – Immunise HLA-DR15 expressing α3(IV)NC1 WT mice and determine the  
various T cell specific immune responses (Chapter 6); 
5 – Immunise HLA-DR15 expressing α3(IV)NC1 KO mice, determine 
immune responses and to generate hybridomas for future analysis of peptides, 





Chapter 2 – Materials and Methods 
 
2.1. – Materials 
 
2.1.1. – General Chemicals and Reagents 
Chemicals and reagents were obtained as follows: human immunoglobulin G 
(IgG) was provided by the Scottish National Blood Transfusion Service (Glasgow, 
Scotland).  Coomassie stain and prestained protein marker ladders were from 
Fermentas (Glen Burnie, Maryland, USA).  Acetic acid, ethanol, ethidium bromide, 
hydrochloric acid, histoclear, imidazole, isopropanol, nickel chloride, 
paraformaldehyde, sodium acetate, sodium dodecylsulphate and sodium hydroxide 
were from Thermo Fisher Scientific (Loughborough, UK).  All  murine genotyping 
primers were produced by GATC biotech (Konstanz, Germany) and were subjected 
to BLAST searches to ensure minimal cross-reactivity.  Protein L primers and 
corrective adaptors were produced by VH bio Ltd (Gateshead, UK).  Nitrocellulose, 
PuReTaq Ready-To-Go PCR beads and tritiated thymidine were from GE Healthcare 
(Buckinghamshire, UK).  Lipofectamine was from Invitrogen (Paisley, UK).  Dried 
milk powder was from Morrison’s supermarket (Bradford, UK).  NovaBlue singles, 
DH5 and BL21 E. coli were from Novagen (Merckbiosciences, Darmstadt, 
Germany).  DNase and all restriction enzymes were from Promega (Madison, 
Wisconsin, USA).  Midiprep kits and proteinase K were from Qiagen (Crawley, 
UK).  Phenol was from Thistle Scientific (Glasgow, UK).  Acrylamide, agar, 
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agarose, ampicillin, borate, bovine serum albumin (BSA), 5-bromo-4-chloro-3-
indolyl phosphate (BCIP), calcium acetate, calcium chloride, casein, collagenase 
(type VII), cyanogen bromide-activated sepharose beads, deoxycholic acid, 4',6-
diamidino-2-phenylindole (DAPI), dimethylsulphoxide (DMSO), dithiothreitol 
(DTT), eosin, ethylenediamine tetraacetic acid (EDTA), fluorescein isothiocyanate 
(FITC), Freund’s adjuvant (both complete and incomplete),  glucose, glycerol, 
glycine, guanidine, haematoxylin, hen egg lysozyme (HEL), hexamine cobalt 
chloride, iodoacetic acid-linked sepharose beads (IAA beads), isopropyl β-D-1-
thiogalactopyranoside (IPTG), Luria-Bertani (LB) broth powder, magnesium 
chloride (MgCl2), magnesium sulphate, manganese chloride, 
morpholinoethanesulphonic acid, nitro blue tetrazolium (NBT), ovalbumin, 
phosphate buffered saline tablets, polyethylene glycol (PEG), potassium acetate, 
potassium chloride, sepharose beads, sodium chloride (NaCl), sodium hydrogen 
carbonate,  Tris, Triton X100, Tween-20, urea and yeast extract were obtained from 
Sigma-Aldrich (St Louis, Missouri, USA). 
2.1.2. - Tissue Culture reagents 
Tissue culture plates and dishes were purchased from Corning Life Sciences 
(Lowell, Massachusetts, USA).  Mouse IL-2 In vivo Capture assay kits, 40µm cell 
strainers, 15ml and 50ml conical tubes were purchased from BD Biosciences (San 
Jose, California, USA).  Tissue culture reagents Dulbecco’s Modified Eagle’s 
Medium (DMEM), RPMI, Hanks’ Balanced Salt Solution (HBSS), Dulbecco’s 
Phosphate Buffered Saline (PBS), Heat-Inactivated Foetal Bovine Serum (HI-FBS), 
penicillin/streptomycin, geneticin and L-glutamine (200mM) were purchased from 
PAA (The Cell Culture Company) (Pasching, Austria). Beta-mercaptoethanol (βMe), 
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Hypoxanthine- Aminopterin- Thymidine (HAT) and Hypoxanthine- Thymidine (HT) 
supplements were from Sigma-Aldrich (St Louis, Missouri, USA).  
 Recombinant mouse interleukin (IL)-2 was purchased from Sigma-Aldrich 
(St Louis, Missouri, USA).  The cytokine was reconstituted as indicated in the 
datasheet and stored in aliquots at -80°C.  Concalavalin A (ConA) was purchased 
from Sigma-Aldrich (St Louis, Missouri, USA), reconstituted as indicated in the 
datasheet and stored in aliquots at -20°C.  Peptides AS345, AS346 and α3(IV)NC1 
15mer peptides were synthetic and sequenced as described in appendix I, arrived 
lyophilised and were redissolved at 10mg/ml in DMSO before storing at -20°C.  
These peptides were HPLC purified to 90%. 
2.1.3. – Animals 
Generation of mouse class II knock out, HLA DR15-expressing, α3(IV) 
(COLIVA3) knock out or wild type is described in Chapter 3.  α3(IV) knockout mice 
were obtained from Dr J Miner in St Louis, Missouri, USA (174).  Mouse class II 
knock out, HLA-DR15 expressing mice were obtained from Prof D Altmann in 
London, UK (175).   Prof Altmann’s group inserted the HLA DR15 double transgene 
into the mouse class II knock out line generated by Cosgrove et al. (176) in 1991.  
C57Bl/6 mice used as controls were bred on site.  All procedures were undertaken 
with approved licence from the Animal Scientific Procedure Division of the Home 
Office. 
2.1.4. – Cell lines 
BW5147 cells – T cell myeloma line used for fusion reactions to produce T 
cell hybridomas (ATCC, LGC standards, Teddington, UK). 
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CRC013 cells – Epstein-Barr Virus transformed B cells, transformed to 
express HLA-DR15 by Prof. D. Crawford’s group, University of Edinburgh. 
HEK293 cells – Human embryonic kidney cells, used for transfection 
reactions (ATCC, LGC standards, Teddington, UK). 
2.1.5. – Antibodies 
Antibodies were obtained from the following sources: mouse anti- human 
CD19-phycoerythrin (PE) and IgG2-PE isotype were from Caltag (Buckingham, 
UK).  Mouse anti-HSVtag was obtained from Novagen (Merckbiosciences, 
Darmstadt, Germany).  Anti-Igκ-fluorescein isothiocyanate (FITC), anti- Igλ-FITC, 
anti-HLA DR-FITC, anti-mouse class II and IgG2-FITC isotype were from AbD 
Serotec (Oxford, UK).  Anti-mouse IgG FITC and anti-human IgG Alkaline 
phosphatase (Alk phos) were from Sigma-Aldrich (St Louis, Missouri, USA). 
2.1.6. – Plasmid vectors 
Restriction maps for all plasmid vectors are shown in Appendix II.  Plasmids 
used were the pET25b expression vector (Novagen, Merckbiosciences, Darmstadt, 
Germany), pGEM-T cloning vector (Promega, Madison, Wisconsin, USA), pCR-
BLUNT TOPO blunt cloning vector (Invitrogen, Paisley, UK) and pFLAG-CMV-3 
mammalian expression vector (Sigma-Aldrich, St Louis, Missouri, USA).  In 
addition, pVL530P- was used as a source of the human α3(IV)NC1 P- sequence (the 
P- sequence within the pVL530 vector, map not shown as restriction digestion not 
used and the vector not used). 
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2.2. – Production, purification and use of protein L 
 
2.2.1. – PCR for protein L fragment 
The protein L PCR reaction was set such that 1µl (430ng) source plasmid (Ulf 
Sjöbring, University of Lund) was diluted 1:50 to give 8.6ng/µl, and 21.5ng of this 
DNA was used to amplify the required fragment by PCR with the addition requisite 
restriction sites.  The primers were used at a stock concentration of 10µM.  The 
primers were designed to also include various restriction sites and were named PL1 
(forward primer) containing Eco RI (bold, underlined) and Nco I (Bold, italic) 
restriction sites and PL2 (reverse primer) containing Bam HI (italic) and Kpn I 
(underlined).  The primer sequences were subjected to BLAST search to ensure no 
cross-reactivity. 
PL1: 5’–GGAATTCCATGGAAAATAAAGAAGAAACACC – 3’ 
PL2: 5’–GGAATTCGGATCCCCGGTACCGTTTTTGTCAACTTTCTTACCTG–3’ 
The PCR programme was set up such that there included a hot start and a final, 
prolonged elongation step.   
Specific conditions: 
94°C for 10 min 
94°C for 60 s 
50°C for 60 s  for 30 cycles 
72°C for 90 s 
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72°C for 5 min then 4°C for 5 min. 
Following PCR, a 900bp fragment could be seen and purified from 1.5% 
agarose gel using PCR clean up kit (Qiagen). 
After frequent transformation failure using Nco I and Bam HI digested pET25b 
with similarly digested protein L, the fragment was sequenced to check whether 
there was a problem with the PCR fragment being amplified using the Protein L 
primers.  To do this, the purified protein L fragment was ligated into pGEM-T (a 
commercial vector designed to accommodate all PCR fragments with a single “A” 
overhang).  This ligation was carried out according to the pGEM-T datasheet, and 
transformed into E. coli as described in section 2.4.  Colonies were then grown up for 
miniprep, then midiprep (Qiagen midiprep kit) before being sent for sequencing 
analysis.  The sequence of the protein L fragment was correct, however the reverse 
primer, PL2, was lacking the Bam HI restriction site and contained some extra bases, 
explaining why all subsequent digestions failed. 
To try to recover the fragment, rescue oligos were designed, containing Kpn I 
and Sac I restriction sites. 
PL2rescuetop: 5’-ATGGTACCAGCGCTAGCTCGAGCT-3’ 
PL2 rescuebottom: 5’-CGAGCTAGCGCTGGTACCATGTAC-3’ 
These were resuspended to a final concentration of 100µM and annealed. 
Equal volumes were mixed, heated to 99°C for 10 min, and gradually cooled to 30°C 
over 30 min.  These annealed oligos could then be digested with Kpn I and Sac I and 
ligated into similarly digested pGEM-T-protein L.  Following this ligation, the 
pGEM-T ligations were transformed into DH5 E. coli as previously described 
(section 2.4), and test digested using Nco I and Nhe I.  Colonies with the correct 
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sized fragment were grown up for midiprep, digested with Nco I and Nhe I, then 
ligated into pET25b. 
2.2.2. – Production of protein L 
E. coli BL21 cells were transformed as described in section 2.6.2., such that 
they contained the correct pET25b-protL plasmid.  These were grown overnight on 
inverted LB-ampicillin plates, and colonies were picked to test for protein production 
(section 2.1.).  The most productive colony was used as a starter culture for a larger 
(2l) preparation and to use as a glycerol stock (section 2.10.3.). 
As for the bacterial recombinant α3(IV)NC1, the 2L culture was grown in LB 
broth with 50µg/ml ampicillin, to an optical density of 0.6 (520nm), then induced to 
produce the protein L for 3 h by adding 1mM IPTG.  After induction, the cell 
suspension was centrifuged at 2200g for 30 min, 4°C (Sigma 4K15), and the pellet 
frozen to crudely lyse the cells. 
2.2.3. – Production of a Glycerol Stock 
The glycerol stock was made by concentrating 4ml uninduced bacterial culture 
into 2ml LB with 50µg/ml ampicillin, and adding 500µl 80% glycerol in LB.  This, 
once mixed well, was snap frozen in aliquots in liquid nitrogen and stored at -80°C. 
2.2.4. – Immunoglobulin G-linkage to cyanogen-bromide activated 
sepharose beads. 
Cyanogen bromide-activated sepharose beads were linked to human IgG as 
recommended by the manufacturer.  In brief, 5g beads were swelled in sequential 
washes of 250ml ice-cold 1mM hydrochloric acid.  These were then washed with 
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175ml deionised water, filtered, and resuspended in 25ml 0.1M sodium hydrogen 
carbonate, 0.5M sodium chloride, pH 8.4.  To this solution, 1g purified human 
immunoglobulin was added and incubated on a rotor mixer at 4°C for 48 h.  The 
beads were spun at 700g for 5 minutes (Sigma 4K15) and the supernatant removed.  
The beads were then washed in 0.1M sodium hydrogen carbonate, 0.5M sodium 
chloride, pH 8.4 and spun 5 times.  After the final spin, the pellet of beads was 
resuspended in 0.2M glycine, pH 8 and left to block on a rotor mixer at 4°C for 18h.  
The beads were packed into a glass column using a peristaltic pump and washed with 
alternating buffers containing 0.1M sodium hydrogen carbonate, 0.5M sodium 
chloride, pH 8.4, or 0.1M sodium acetate, 0.5M sodium chloride, pH 4.  The column 
could then be used for protein L purification. 
2.2.5. – Purification of protein L 
Prior to use, the column was rinsed with alternating buffers containing 0.1M 
sodium hydrogen carbonate, 0.5M sodium chloride, pH 8.4, and 0.1M sodium 
acetate, 0.5M sodium chloride, pH 4, then equilibrated with 0.1M sodium hydrogen 
carbonate, 0.5M sodium chloride, pH 8.4.  The protein L pellet was resuspended in 
PBS prior to application to the column (10ml), and fractions of 25ml were collected 
of post-load, during washing (with PBS, pH 7.4), then elution with 100ml 0.1M 
glycine, pH 2.  The column was then further washed with PBS and 0.1M sodium 
hydrogen carbonate, 0.5M sodium chloride, pH 8.4.  During each step, 25ml 
fractions were collected and an aliquot from each was run on both an acrylamide gel 
and coomassie-stained, and transferred for western blotting and probing with anti-
HSVtag antibody (1µg/µl, 1:100 dilution).  The elution fractions were neutralised to 
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pH neutral pending analysis by western blot to determine the location of the protein 
L. 
2.2.6. – Labelling protein L with FITC 
In order to FITC label, the protein L, the IgG-linked column was used to 
immobilise the protein L while 2ml 1.5mg/ml FITC in DMSO was slowly run 
through the column.  The column was then incubated in the dark for  1 h and washed 
with 1L PBS, the protein L was eluted with 0.1M glycine, pH 2 and the column 
further washed with PBS, refreshed with 0.1M sodium hydrogen carbonate, 0.5M 
sodium chloride, pH 8.4, and 0.1M sodium acetate, 0.5M sodium chloride, pH 4, and 
filled with 1M sodium chloride for storage at 4°C.  The protein L-FITC was 
neutralised and ethanol precipitated before resuspension at 0.6mg/ml in PBS. 
2.2.7. – Flow cytometry with FITC-labelled protein L on B cells 
An EBV-transformed B cell line, positive for HLA DR15 was grown in normal 
R10 media.  The cells were counted and 2x105 cells were stained for each reaction.  
The cells were double stained with anti-CD19-PE (1:50 dilution), washed with PBS, 
then stained with protein L-FITC (1.2µg, 3µg or 6µg), washed well in PBS and read 
on a Becton Dickinson FACScan (BD Biosciences, San Jose, California, USA).  
Negative controls were the IgG2-PE isotypic control  (1:50 dilution) and unlabelled 
protein L, while each staining condition was measured in triplicate. 
2.2.8. – Confocal microscopy using protein L-FITC to test binding on B cells 
The DR15-positive B cell line used in flow cytometry experiments was also 
used for confocal microscopy and imaging of protein L-FITC binding to cells.  The 
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cells were resuspended at 5x106/ml, and staining was carried out in round-bottomed 
96-well plates.  In total, 3 different concentrations of protein L-FITC (1.2µg, 3µg or 
6µg) were used to label the cells for three different time points (15, 30 and 60 min), 
with one well remaining unstained.  At all points, the plate was protected from light 
as much as possible.  Each well was then washed well with PBS, and the cells were 
fixed with 4% paraformaldehyde for 30 min at room temperature.  After a further 
wash with PBS, the cells were counterstained with a nuclear stain, DAPI (1ug/ml in 
methanol, diluted 1:100 in PBS) for 2 min before washing well with PBS.  The cells 
were then mounted onto glass slides and subjected to confocal microscopy (Zeiss 
LSM510meta). 
 
2.3. – Genotyping polymerase chain reactions (PCRs) 
 
As the laboratory had had problems with the Taq enzyme source for our 
department, all the PCR reactions described in this thesis, unless stated otherwise, 
used illustra PuReTaq Ready-To-Go PCR beads – tubes containing a single bead.  
Each bead contained lyophilised 2.5 IU PuReTaq DNA polymerase, 10mM tris, 
50mM potassium chloride, 1.5mM MgCl2, 200µM dNTPs and BSA, such that the 
DNA, primers and water could be added directly to the tube and the reaction started 
(GE healthcare).  The PCR machine used was the ATC 201 from Nyxtechnik. 
2.3.1. – Extraction of DNA from mouse tissue 
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Earmarks were used both to identify individual mice and as a source of tissue 
for DNA extraction and subsequent genotyping.  Earmarks were digested for a 
minimum of 8 h with 100µg proteinase K in 200µl lysis buffer (0.2% SDS, 0.1M 
Tris, 5mM EDTA, 200mM sodium chloride) at 55°C.  This was then centrifuged at 
18000g for 10min (Sigma 3-15K) and the supernatant carefully transferred to a new 
Eppendorf tube.  This was then incubated with isopropanol for 30 minutes, 
centrifuged and the pellet washed with 70% ethanol.  After further centrifugation, the 
supernatant was aspirated and the pellet allowed to air dry before resuspension in 
200µl 10mM Tris, pH 8.5. 
2.3.2. – PCR for mouse class II 
These reactions test for the wild type mouse class II gene and the knocked out 
version of the gene (contains a neomycin cassette).  In the wild type reaction IAB 
(WT), (ABOL2 and ABOR2 primers), two fragments (169bp and greater than 
1000bp) were expected, while in the knock out (KO) reactions, Neo (Neo and 
ABOL2 primers) and NeoR (NeoR and ABOR2 primers), fragments of 340 and 
800bp were expected respectively.  Two µg DNA were used per reaction.  Primers 
were used at a stock concentration of 10µM (final conc 0.4µM) and were designed as 
follows: 
Neo: 5’- GAG GAT CTC GTC GTG ACC CA-3’ (forward) 
ABOL2: 5’- CAC CAA CGG GAC GCA GCG CAT AC-3’ (reverse) 
ABOR2: 5’- GGC CCT CGT TCG CTC CAG GAT CT-3’ (forward) 
NeoR: 5’- GCG ATA CCG TAA AGC ACG AG-3’ (reverse) 
Conditions for IAB (WT) PCR: 
75°C - 10min, hot start 
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95°C - 1min, denaturing    
67.8°C - 1min, annealing 30 cycles 
72°C – 90 s, elongation   
72°C for 10min then 4°C for 10 min 
Conditions for Neo and NeoR (KO) PCRs: 
75°C - 10min, hot start 
95°C - 1min, denaturing    
64°C - 1min, annealing 30 cycles 
72°C – 90 s, elongation   
72°C for 10min then 4°C for 10 min 
2.3.3. – PCR for human MHC class II, HLA-DR15 
These reactions test for the inserted MHC class II double transgene (DRA and 
DRB).  In the DRA reaction, a fragment of 124bp was expected, while in the knock 
DRB reaction, a fragment of 190bp was expected.  Two µg DNA were used per 
reaction.  Primers were used at a stock concentration of 10µM (final concentration 
0.4µM) and were designed as follows: 
TgDRAL: 5’- CTC CAA GCC CTC TCC CAG AG-3’ (reverse) 
TgDRAR: 5’- ATG TGC CTT ACA GAG GCC CC-3’ (forward) 
TgDRBR: 5’- CTG CAC TGT GAA GCT CTC-3’ (forward) 
TgDRBL: 5’- TTC AAT GGG ACG GAG CGG GTG-3’ (reverse) 
 
 
Conditions for DRA and DRB PCRs: 
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75°C - 10min, hot start 
95°C - 1min, denaturing    
64°C - 1min, annealing 30 cycles 
72°C – 90 s, elongation   
72°C for 10min then 4°C for 10 min 
2.3.4. – PCR for α3 
These reactions test for the WT α3(IV) gene and the KO version of the gene 
(contains a neomycin cassette), in the WT reaction, a fragment of 1000bp was 
expected, while in the KO reaction, a fragment of 850bp was expected.  Two µg 
DNA were used per reaction.  Primers were used at a stock concentration of 10µM 
(final concentration 0.4µM), and 4A3 KOWTL is the reverse primer for both 
reactions.  In addition, 1µl 25mM MgCl2 was added to each reaction to give a final 
concentration of 2.5mM MgCl2 for these reactions. 
Primers: 
4A3 KOWTL: 5’- ACG ACC TTT GTT AAA CTA GAA GAA GTC-3’ (reverse) 
4A3 WTR: 5’- TTC CCC TGT CAC CAG GAT TTC CC-3’ (forward) 
4A3 KOR: 5’- TGC TAA AGC GCA TGC TCC AGA CTG C-3’ (forward) 
Conditions: 
75°C - 10min, hot start 
95°C - 1min, denaturing    
60°C - 1min, annealing 30 cycles 
72°C – 90 s, elongation   
72°C for 10min then 4°C for 10 min 
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2.3.5. – Visualisation of bands 
The PCR reaction bands were visualised by running the reaction mixture on a 
1.5% agarose gel containing 50µg ethidium bromide and made using 89mM Tris 
Borate,  2mM EDTA (177) solution.  The gels were run at 100V for 30 min using a 
Mini Easigel Gel Electrophoresis System (VWR International) and visualised using a 
UV transilluminator (Uvidoc) and camera (Uvitec). 
 
2.4. – Flow cytometry of MHC class II on mouse lymphocytes 
 
Lymphocytes from the NTxDR15 transgenic mouse line were tested, by flow 
cytometry, for expression of the mouse class II molecule and the human HLA DR15 
molecule, and compared with lymphocytes from a non-transgenic C57Bl/6J mouse.  
Lymph nodes were removed from each mouse and disaggregated by mashing 
through a 40µm cell strainer.  The cells from each mouse were counted and 
resuspended at 2x106/ml in HBSS.  Both the anti-human DR15-FITC (0.1mg/ml, 
AbD Serotec) and the anti-mouse class II-FITC (0.1mg/ml, AbD Serotec) antibodies 
were used at 1:20 dilution and incubated on the cells for 30 min, room temperature, 
in the dark, prior to washing with 100µl HBSS and reading on the Becton Dickinson 
FACScalibur. 
 
2.5. – Production of bacterial recombinant antigen 
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2.5.1. – Culture and induction of recombinant α3(IV)NC1 in bacteria 
A glycerol stock containing transformed E. coli BL21 bacteria containing the 
pET25b-α3(IV)NC1 plasmid (produced by Dr R.G. Phelps, (165)) was used to streak 
an LB-agar-ampicillin (50µg/ml) plate and grown inverted overnight at 37°C.  
Colonies were picked and grown into 5ml LB –ampicillin starter cultures.  3ml was 
used to test protein production by induction with 1mM IPTG.  The colonies were 
assessed for production of α3(IV)NC1, by protein concentration on sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS PAGE), using a 12% acrylamide 
gel and the Laemmli buffer system (178), with the gel then stained with Coomassie 
blue.  The colony with the greatest production of α3(IV)NC1 was used as the starter 
culture for a larger (2L LB-50µg/ml ampicillin) preparation.  When at an optical 
density of 0.6, the bacteria were induced with 1mM IPTG for 3h, in an orbital shaker 
(200rpm, 37°C). 
2.5.2. – Purification of bacterial recombinant antigen 
The induced cultures were spun down at 2200g, 4°C, 30 min (Sigma 4K15) 
and the pellets resuspended in 35ml ice cold PBS, before sonication (Ultrasonic 
processor, Jencons) for 2 min on 50% duty cycle (sonicator at this setting only 
sonicates the sample in pulses equivalent to 50% of total time).  This was then 
incubated with 0.2mg/ml HEL at 4°C for 1h on roller, then 2µg/ml DNase, 2mM 
MgCl2 and 0.1% deoxycholic acid were added and incubated at 4°C, with constant 
movement, overnight.  These suspensions were centrifuged at 9500g, 4°C for 30min 
(Centrikon T-42K) and the supernatant discarded before the pellets were resuspended 
in 30ml PBS, sonicated for 60s on 50% duty cycle and spun at 9500g, 4°C for 25min 
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(Centrikon T-42K).  Again, the supernatant was discarded and the pellet resuspended 
in 25ml 0.5% triton X-100, 5mM Tris, and sonicated for 60s on 50% duty cycle and 
left on roller at 4°C for 30min.  This was then spun at 9500g, 4°C, for 25min 
(Centrikon T-42K) prior to washing the pellet 3 times with PBS, sonicating between 
washes to resuspend the pellet.  The pellet was weighed and resuspended in 6M 
guanidine, 50mM tris and incubated at 4°C on roller platform overnight. 
To purify the recombinant α3(IV)NC1, an IAA bead column was used.  The 
column was rinsed with 50mM Tris, pH 7.5 and loaded with 0.1M nickel chloride.  
The column was then washed twice with 50mM Tris, pH 7.5, followed by three 
washes with 6M guanidine hydrochloride, 50mM Tris, 20mM Imidazole, pH 7.5.  
5ml of the α3(IV)NC1 preparation was applied to the column and allowed to drip 
through the column under gravity.  The column was then washed a further three 
times with 6M guanidine hydrochloride, 50mM Tris, 20mM Imidazole, pH 7.5, 
before the protein was eluted with three applications of 2ml 6M guanidine 
hydrochloride, 50mM Tris, 100mM EDTA, pH 7.5.  The column was washed with 
20ml 50mM Tris, pH 7.5 and reloaded with nickel chloride for the remaining 
α3(IV)NC1 guanidine solution to be purified.  The eluted protein was ethanol 
precipitated and the pellet resuspended in 8M urea. 
Once resuspended in the urea, the protein concentration was measured by SDS 
PAGE using a 12% acrylamide gel and the Laemmli buffer system (178).  The gel 
was coomassie stained for 1 h before washing and checking the amount of 
contamination and the approximate concentration of the protein.  The protein 
solution was also subjected to spectrometry (280nm) so a more precise concentration 
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could be determined.  The remaining protein solution (recombinant human 
α3(IV)NC1, rhα3) was then frozen in aliquots at -20°C.  
 
2.6. – Extraction of α3(IV)NC1 from tissue 
 
2.6.1. – Disaggregation of tissue and disruption of cells 
Tissue was disaggregated as previously described by Spiro (179) and Borza et 
al. (168).  In brief, cortex was sliced off semi-frozen human kidneys (after careful 
decapsulation) and sliced into small strips.  Sieves (Endecotts) were stacked such 
that the order of mesh size is (top to bottom) 150nm, 63nm, 250nm.  Cortex strips 
were added a little at a time into top sieve and mashed through with base of a conical 
flask and washed thoroughly with PBS.  Glomeruli collect on 63µm sieve, while 
tubules go through it.  All sieves were washed well to ensure maximal yield.  
Glomeruli were washed twice with PBS and spun at 700g at 4°C for 30min (Sigma 
4K15).  Supernatants were discarded and the pellet resuspended in 10ml PBS then 
frozen at -20°C. 
The glomerular pellet was thawed then sonicated (Ultrasonic processor, 
Jencons) for a total of 2.5min (5 times 30s) (50%), output dial on 4, per tube.  The 
matter was checked microscopically for glomerular disruption and lack of cells, then 
was washed 3 times with PBS, with each centrifugation step at 700g, 15min, 4°C.  
The pellets were then washed 3 times with deionised water, each spin at 700g, 
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15min, 4°C (Sigma 4K15).  After the final spin, the supernatant was discarded and 
the pellet frozen. 
To extract the NC1 domains, the glomerular preparation was collagenase-
digested.  To the thawed glomerular preparation, 0.7% type VII collagenase and 10% 
v/v 10x collagenase buffer (0.1M Tris, 0.05M calcium acetate, pH7.4) were added 
and the resultant solution incubated at 37°C on orbital shaker for 5h.  After the 
digestion, the NC1 domains are solubilised so the solution was spun at 700g, for 
30min, at 4°C and the supernatant was carefully removed and kept frozen prior to 
purification by cation exchange chromatography. 
2.6.2. – Purification of human α3(IV)NC1 by cation-exchange 
chromatography 
For cation exchange chromatography, sepharose beads were used in a 1ml 
column on a Biocad HPLC machine.  The programme for isolation of the human 
α3(IV)NC1 domains was optimised using HEL and BSA – two proteins with 
different atomic masses and ionic characteristics.  The column was equilibrated with 
10ml buffer A (2M Urea, 0.05M sodium acetate, pH5) prior to sample loading.  
Subsequently, the column was washed with 2ml buffer A before implementation of 
an automatic pH gradient of 100% buffer A to 100% buffer C (2M Urea, 0.05M Tris, 
pH10) during 15 column volumes (final volume approximately 15ml).   Buffer C was 
used to wash the column for a further 4ml, before a salt gradient was implemented 
over 15ml (100% buffer C to 100% buffer B (2M urea, 0.05M Tris, 1M sodium 
chloride, pH10)).  4ml Buffer B was used to wash the column, before cleaning the 
column with buffer A for 15ml.  The flow rate was 5ml/ minute, the sample size was 
5ml, and 5ml fraction collection was begun immediately after sample injection.  
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Each fraction was ethanol precipitated and the fractions containing peaks were tested 
for the presence of human α3(IV)NC1 (huα3) by western blotting. 
The western blotting was carried out using the Laemmli buffer system on a 
12% acrylamide gel (178), before transfer to nitrocellulose membrane.  The 
membrane was blocked using 5% milk in PBS with 0.1% Tween, probed with 
Goodpasture patient sera (1:40 ratio of sera to milk solution), washed (PBS with 
0.1% tween) then probed with a secondary, alk phos-conjugated anti-human IgG 
polyclonal antibody (1:10 000 ratio in milk solution).  The transfer was washed as 
above and visualised using BCIP and NBT.  
 
2.7. – Production of α3(IV)NC1 antigen by eukaryotic cells 
 
2.7.1. – Production of construct for antigen production 
The pVL530P- was used as a source for the human α3(IV)NC1 sequence and 
amplified by polymerase chain reaction (PCR) using the following primers: 
A3BglonlyF: 5’- CCAGATCCTGAAAGGAAAACGTGG 
HA3EXP2R2: 5’- CCATGGTACCTCGAGTTCTGCTGTC 
A3BglonlyF contained a Bgl II (bold) restriction site, while HA3EXP2R2 
contained the Nco I (italic), Kpn I (italic, underlined) and Xho I (bold, italic, 
underlined) restriction sites.  The PCR reaction was carried out using PCR beads, 
10µM stock primer and 84.8ng DNA.  The PCR conditions were optimised such that: 
75°C – hot start 
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94°C – 1 min, denaturing 
65°C – 1 min, annealing 30 cycles 
72°C – 30 s, elongation 
72°C – 5 min, then 4°C – 5 min. 
This programme successfully amplified a fragment of 900bp, which was then 
extracted from an agarose gel using the GE healthcare illumina kit as per the 
manufacturers instructions (GE Healthcare, Buckinghamshire, UK).  The PCR 
product was cloned into the TOPO blunt end vector as per vector instructions, and 
transformed into commercially sourced NovaBlue singles (Novagen, 
Merckbiosciences, Darmstadt, UK). 
Colonies were grown in a 5ml LB culture for miniprep, the DNA extracted and 
test digested with Bgl II and Nco I.  The expression vector pFLAG-CMV-3 was 
digested simultaneously and the two digests were ligated prior to transformation into 
NovaBlue singles. 
Again, colonies were picked for miniprep, test digested with Bgl II and Nco I, 
and positive digests were grown further for midiprep using a commercially available 
kit (Qiagen, Crawley, UK) as per manufacturers recommendations. 
2.7.2. – Transformation of E. coli DH5 cells 
Transformation of E. coli DH5s to produce pFLAG-α3(IV)NC1 P- was carried 
out using standard techniques for making and transforming competent cells.  In brief, 
DH5s were grown in a 50ml LB culture to an optical density of 0.3-0.4 (520nm).  
The cells were centrifuged at 2900g, 4°C for 10 minutes (Sigma 4K15), the 
supernatant decanted and resuspended in 15ml ice-cold transformation buffer 
(100mM potassium chloride, 45mM tetrahydrous manganese chloride, 10mM 
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dihydrous calcium chloride, 3mM hexamine cobalt chloride, 10mM 
morpholinoethanesulphonic acid).  After incubating the cell suspension on ice for 15 
minutes, the centrifugation step was repeated and the cells then resuspended in 2.5ml 
ice-cold transformation buffer.  Immediately after resuspension, 140µl DTT- DMSO 
solution (1M DTT, 90% DMSO, 10mM potassium acetate) was added to the cells, 
mixed by swirling and chilled on ice for 10min.  A further 140µl DTT-DMSO 
solution was added and swirled, then chilled on ice for 20 minutes.  Into 1.5ml 
Eppendorf tubes, 5µl plasmid was pipetted, plus 50µl cell suspension and chilled on 
ice for 30 minutes prior to heat shock (42°C water bath, 90 seconds) and placed back 
on ice for a further 2 minutes.  To each tube, 200µl SOC media (2% casein, 0.5% 
yeast extract, 10mM sodium chloride, 2.5mM potassium chloride, 20mM MgCl2/ 
magnesium sulphate, 10% glycerol) was added and incubated at 37°C for 45 
minutes.  This was then spread onto LB agar plates containing 50µg/ml ampicillin 
and incubated for 18 hours. 
Colonies were then picked from the plate, and grown for a 5ml miniprep 
culture in order to amplify the amount and extract plasmid DNA.   Of this culture, 
3ml were used to extract DNA, with the remaining 2ml kept in case of need for 
repetition or for a starter culture.  For the miniprep, 3ml of culture was centrifuged at 
10000g for 3 min (Sigma 3-15K).  The supernatant was discarded and the pellet 
resuspended by vortexing in 100µl Glucose – Tris – EDTA buffer (50mM glucose, 
25mM tris, 10mM EDTA).  With the pellet resuspended, 200µl 0.2M sodium 
hydroxide, 1% SDS was added, mixed by inversion and chilled on ice for 5 minutes.  
When chilled, 150µl 3M potassium, 5M acetate solution was added, mixed by 
vortexing and chilled for a further 15 minutes on ice.  The tubes were then 
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centrifuged at 10000g for 5 min (Sigma 3-15K) and the supernatant carefully 
decanted to a new Eppendorf tube.  To precipitate protein out of the solution, 200µl 
phenol was added, mixed by vortexing and centrifuged at 10000g for 2 minutes 
(Sigma 3-15K).  The upper phase was removed and pipetted carefully into a new 
Eppendorf tube with an equal volume of isopropanol, mixed by vortexing and 
centrifuged at 10000g for 5 min (Sigma 3-15K).  The pellet was kept and washed 
with 1 ml 70% ethanol, centrifuged at 10000g for 5 minutes (Sigma 3-15K), and the 
supernatant carefully decanted.  The remaining pellet was allowed to air dry prior to 
resuspension in 10mM Tris, pH8. 
2.7.3. – Transfection of human embryonic kidney 293 cells 
HEK293 cells were grown to confluence, then seeded at 1.5x105 into 6 well 
plates and allowed to grow.  When the wells were 80% confluent, they were washed 
well with HBSS and 1ml minimal media (DMEM) was then added. 
DNA was diluted to 0.75µg/µl and 2µl was pipetted into 98µl minimal media.  
Lipofectamine was diluted 1:25 in minimal media, allowing 100µl per well for 
transfection.  The DNA and Lipofectamine solutions were mixed and incubated at 
room temperature for 30 min.  A further 200µl minimal media was added to each 
transfection mixture (400µl final volume). 
The media was removed from the cells and replaced with 400µl minimal media 
and 400µl lipofectamine-DNA mixture, then incubated for 5h at 37°C.  Following 
the incubation, the lipofectamine was removed and replaced with 1ml DMEM media 
(DMEM, 10% HI-FCS, 1mg/ml L-glutamine, 1.2mg/ml penicillin/streptomycin).  
The following day, the transfected cells were trypsinised and resuspended in 
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selective media (DMEM with 0.4mg/ml geneticin) at serial dilutions.  As the 
tranfects grew, they were tested for α3(IV)NC1 expression by incubating with 
minimal media for 12h.  This media was then subjected to western blot and probed 
with patient sera to test for α3(IV)NC1 protein production. 
 
2.8. – Lymphocyte stimulation assay 
 
Mice of the relevant genotypes were given subcutaneous immunisations with 
50µg antigen (rhα3, huα3 or ovalbumin) emulsified with complete Freund’s 
adjuvant by sonication (0.5µg/µl antigen in PBS, plus equal volume adjuvant, 
sonicated 3 times, for 30s on 50% duty cycle), left for 7 days, then given a booster 
immunisation containing the antigen emulsified (by sonication, as above) with 
incomplete Freund’s adjuvant.  After a further 7 days, the mice were culled and the 
lymph nodes extracted for mechanical disaggregation.  
Cells from the disaggregated lymph nodes were resuspended in 3ml DMEM 
containing 10% HI-FCS, Penicillin/Streptomycin and L-Glutamine.  The cells were 
counted and diluted to 1x106/ml and 1x105 plated/well 96 well round bottomed plate.  
Cells were stimulated with 100µl non-specific protein Ovalbumin (20µg/ml), T cell 
mitogen Con A (5µg/ml), peptide AS345 (20µg/ml), peptide AS346 (20µg/ml), rhα3 
(50, 100 or 200µg/ml).  In addition to the aforementioned proteins and peptides, the 
cells were stimulated with overlapping 15mers of the α3(IV)NC1 domain, 
α3(IV)NC1 -9-5 – α3(IV)NC1 221-235 (50µg/ml), the sequences with start and 
finish amino acid positions of each peptide are described in detail in Appendix I.  
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Each stimulant or peptide was plated in triplicate with the final concentrations of 
stimulant listed above and a final cell count of 1x105 per well.  The plates were 
incubated at 37°C, 5% CO2, for 72h, prior to pulsing for 18h with 0.5µCi 3H-
thymidine.  The cells were harvested onto filters using a Tomtec cell harvester and 
the tritium incorporation counted using a β-Counter (Wallac 1205 Betaplate reader). 
 
2.9. – Haematoxylin and eosin (H&E) staining of tissue sections 
 
Slides containing paraffin embedded kidney sections (made from 
formaldehyde-fixed kidneys isolated at same time as lymph nodes, and sectioned and 
mounted by Bob Morris in the histopathology laboratory within the University of 
Edinburgh) were placed in a slide holder (glass or metal) and deparaffinised in 
histoclear, then rehydrated using sequential dilutions of ethanol: 100%, 90%, 75% 
then water.  Haematoxylin was skimmed to remove oxidised particles prior to 
staining.  After the haematoxylin step, the slides were rinsed in deionised water and 
dipped fast in acid ethanol (70% ethanol, 0.25% glacial acetic acid) to destain, before 
further washing with water then deionised water.  To counterstain the sections, the 
slides were dipped briefly in eosin prior to dehydrating the sections in increasing 
concentrations of ethanol (75%, 90% then 100%), before soaking in histoclear.  
Coverslips were mounted with DPX mounting medium, before being left to dry 
overnight in the fume hood.  Photographs were taken using a Zeiss Axioskop 2 
microscope at x400 magnification. 
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2.10. – Production of hybridomas 
 
Mice with the genotype mouse class II knock out, DR15 positive, α3(IV) 
knock out were immunised with rhα3 using the same method as described in the 
lymphocyte stimulation assay (section 2.8.).  Upon sacrifice, the lymph nodes were 
extracted and disaggregated.  The cells were resuspended at 1x106 with 50µg rhα3 in 
DMEM.  After 3 days, cells were washed and plated at 4x105  with 20IU/ well 
recombinant IL-2 in DMEM. 
In order to create a hybridoma, the T cell must be fused with an immortal cell 
line, in this instance BW5146 cells, a myeloma line.  The different cell types were 
washed individually with HBSS, then counted and combined in equal numbers at 
2.5x106 of each cell type in 15ml.  After centrifugation (450g, 4°C, 5min, Sigma 
4K15), the supernatant was aspirated and 700µl PEG added dropwise over 90 sec 
(timed), with gentle tapping to mix.  This was followed by 5ml HBSS added 
dropwise over 2 min (timed) and 15ml HBSS added dropwise over 3 min (timed), 
each stage mixing by gentle tapping.  The cell suspension was then spun gently and 
the supernatant removed.  To the pellet, 30ml R10 media (RPMI, 10% HI-FCS, 
1.2mg/ml penicillin/strepomycin, 1mg/ml L-glutamine, 1µl/ml media βMe) was 
added over 3 min (timed) with gentle tapping.  20ml of the resultant suspension was 
poured into a petri dish and 100µl pipetted per well of 2, 96 well flat-bottomed plates 
(stock).  To the remaining 10ml cell suspension, 20ml R10 media was added, gently 
mixed and 20ml was further pipetted at 100µl/well into two plates (1:3 dilution).  For 
the final dilution (1:9), a further 20ml R10 media was added, gently mixed and 
pipetted as for the previous plates.  These plates (6 per fusion) were then incubated at 
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37°C for 24h, before 100µl HAT media (R10 plus HAT supplement) (180) was 
added to each well and incubated at 37°C. 
Clones were picked after 7 days and expanded gradually to 8 wells of a 24-well 
plate, then into T25 flasks before weaning off HAT to HT (R10 plus HT supplement) 
media then to R10 media.  The HAT then HT media provide selective components to 
encourage growth of the hybridomas and selectively kill unfused cells.  The 
aminopterin is toxic unless the cells can bypass certain cellular mechanisms, so 
unfused myeloma cells and myeloma-myeloma hybridomas are selectively 
destroyed.  The gradual weaning is required as the cells need to utilise different 
pathways for DNA synthesis in the presence and absence of aminopterin.  The cells 
that are unable to utilise the salvage pathway do not survive, but those that do need 
time to readjust to using the main DNA synthesis pathway, as the two pathways are 
not both constitutively active. 
Hybridomas were tested using the lymphocyte stimulation assay technique 
described in section 2.7., but instead of being tested against individual peptides, were 
tested against peptide sets with a final concentration of 50µg/ml overall.  Each set 
contained 5 of the 47 overlapping 15mer peptides spanning the α3(IV)NC1 domain 
and are described in more detail in Appendix I.  This was done to reduce the amount 
of individual peptide used, and to reduce the number of peptides for testing in a 
complete assay. 
 
2.11. – Flow cytometry for Igκ  and Igλ  
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The same EBV-transformed B cell line used for testing Protein L-FITC binding 
was also tested for Igκ and Igλ proportions.  For this, 2x105 cells were stained, in 
triplicate, with either mouse anti-human Igκ-FITC (4mg/ml, diluted 1:100), or mouse 
anti-human Igλ (1mg/ml, diluted 1:10) and goat anti-mouse IgG-FITC (1mg/ml, 
diluted 1:100).  Each antibody was incubated on the cells for 30 min at room 
temperature and the cells were washed between antibodies in HBSS, before running 




Chapter 3 – Use of Protein L to improve antigen uptake 
into B cells 
 
3.1. – Introduction 
 
In order to activate T cells, B cells bind whole antigen through the B cell 
receptor (BCR) and internalise the molecule for processing into fragments that can 
bind MHC class II molecules. Uptake of antigen and presentation of the processed 
peptides are linked.  If the uptake process could be manipulated such that an excess 
of a specific antigen enters the APCs in use,  it could be argued that any immune 
responses by specific hybridomas are directly linked to processing and presentation, 
as they will respond to a specific peptide fragment in proportion to the amount of it 
that is presented on the APC surface (181).  One method to augment cellular uptake 
is to develop fusion proteins that can be linked to the protein of interest (181-183).  
These fusion proteins frequently include elements of the immune system, for 
example, ligands for B cell surface molecules, and have included different C3 protein 
fragments from the complement cascade (184).  To improve uptake of the α3 
molecule into HLA-DR15 specific B cells, it was hypothesised that α3 or α3 
fragments could be linked to a B cell surface ligand to make a fusion protein able to 
access receptor-mediated uptake pathways.  
Fusion proteins can be defined as novel proteins made by molecular 
engineering and have many possible applications beyond those described below.  
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When debating the use of a fusion protein, there are several things to consider, 
including the purpose of the protein, the type of target cell and how the cells would 
react to the fusion protein, and how to determine efficiency of binding and measure 
cellular responses.  Here, the fusion protein is used to improve cellular uptake of 
antigen, and to enable targeted labelling under physiological conditions.  Proteins 
from the immune system lend themselves particularly well to these scenarios as, 
broadly speaking, the immune system recognises antigen, enabling endocytosis and 
processing of the antigen, and development of further immune responses where 
required.  Two classical examples of proteins used as fusion proteins include the Fab 
fragment of immunoglobulin, and the complement protein C3. Examples of their 
usage include using the Fab fragment targeted against CD19 linked with 
superantigen to induce uptake and lysis of B cells (185), or targeted against CD86 to 
induce uptake into neutrophils (186).  C3 fragments have been used to target T cells 
(187), or linked to colloidal gold to track uptake of antigen into B cells by electron 
microscopy (184).  Carbohydrate moieties have also been suggested to improve 
uptake into cells – Adams et al. produced a high mannose carbohydrate bound to 
ovalbumin to determine uptake by dendritic cells (188) and that resulted in the 
antigen entering either the MHC class II processing pathway or the MHC class I 
processing pathway, and the carrier therefore having increased versatility for use in 
generating broad-spectrum T cell responses. 
While these proteins (and carbohydrates) remain a very useful tool for 
focussing and improving purification, uptake or measurement of uptake, for this 
project, it was decided that characteristics seen in a relatively newly discovered 
bacterial protein, protein L, could be exploited (189).  Protein L is a marker of 
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virulence expressed by 10% of the most infectious strains of Peptostreptococcus 
magnus.  It was first identified in 1988 and is a possible candidate for use as a fusion 
protein to augment uptake of antigen into B cells because of its binding specificity.  
It binds with high affinity to the extracellular part of membrane bound 
immunoglobulin, in particular the Igκ chains (specifically, the variable light chain 
(190)), but not to the antibody-binding fragment.  Protein L also binds Igλ variable 
light chains, but with lower affinity.  Since the majority of  human B cells 
(approximately 60%) express Igκ (the remaining ~40% being Igλ), this mechanism 
could be exploited to improve the uptake of α3 peptides into the DR15 positive B 
cells, by bringing the antigen fragment of choice in close proximity to the BCR 
(figure 3.1.1).  
The actual structure of protein L is very simple and consists of a 4-stranded β-
sheet packed with a single α-helix (191), with the binding domains on either side of 
each strand of the β-sheet.  The protein consists of various domains, with Igκ binding 
occurring through five highly homologous domains named B1-B5 as shown in figure 
3.2.1.  Each of these binding domains contains two binding sites for Igκ, 
corresponding to the two edges of the β-sheet (192).   
Protein L is also somewhat unusual since it demonstrates a large number of 
main chain interactions relative to side chain interactions (amino acid mutations at 
each point showed little effect on overall binding capacity) (192), and it has also 
been shown that binding through the B1-B5 domains is ambidextrous (meaning the 
Igκ chain can bind on either side of the protein binding domains, irrespective of 
direction of the target binding site).  
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Figure 3.1.1. – Schematic to illustrate BCR-mediated uptake of antigen and how the 
protein L-antigen may interact with B cells 
This schematic illustrates BCR mediated uptake of antigen into B cells (figure 
A) – whole antigens bind the BCR on the cell surface, the BCR: antigen complex is 
internalised and fuses with lysosomes to be processed and presented on the B cell 
surface in conjunction with MHC class II molecules.  Adapted from Wang et al.(9). 
Figure B illustrates how the protein L-antigen complex may bind to the BCR, 
















This insensitivity to side chain interactions possibly explains how this protein can 
bind with high affinity to Igκ light chains in different species and may have 
developed as an evolutionary adaptation in response to the development of immune 
systems of these different species.   
 These factors, plus the knowledge that the protein has already been sequenced 
and the binding domains B1-B4 cloned into a bacterial plasmid for recombinant 
protein production were an added incentive for determining the possibility of its 
usage as a fusion molecule.  In addition, purification of protein L can be done 
through binding the protein to an IgG-sepharose column, so the protein can be 
washed and eluted into a known volume of buffer (as described in full in Chapter 2) 
with relative ease. This can reduce the specificity of the responses as a mass influx of 
immune cells flood the affected area in an attempt to eliminate the source of 
infection (184, 187).  This chapter concentrates on the work undertaken to ensure the 
protein L was able to specifically bind and be taken up by B cells before ligating α3 




3.2.1. – Production of the Protein L construct 
The cloning strategy for production of the protein L fragment illustrated in 
figure 3.2.1. and described in figure 3.2.2. involved digestion of the protein L 
construct obtained from Dr Ulf Sjöbring at the University of Lund (192), ligating the 
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protein L into pET25b, and subsequent manipulation to add either whole 
α3(IV)NC1, or PCR products containing various fragments of the α3(IV)NC1 
protein, in particular α3(IV)NC1 136-150 and α3(IV)NC1 64-90, the fragments 
known to elicit immune responses in Goodpasture patients. 
The initial protein L construct consisted of the protein L B1-B4 fragment 
within a vector (shown in figure 3.2.2).  In order to insert the protein L into the 
pET25b vector and between the HSV and histidine tags, primers were designed to 
amplify the protein L fragment while incorporating the relevant restriction sites.  The 
forward primer (PL1) contained the Eco RI (bold, underlined, italic) and Nco I (bold, 
italic) restriction sites, while the reverse primer (PL2) contained the Bam HI (italic) 
and Kpn I (underlined) restriction sites: 
PL1: 5’- GGAATTCCATGGAAAATAAAGAAGAAACACC  
PL2: 5’- GGAATTCGGATCCCCGGTACCGTTTTTGTCAACTTTCTTACCTG 
These would produce the Protein L fragment with Eco RI and Nco I restriction 
sites at the 5’ end, and Bam HI and Kpn I restriction sites at the 3’ end.  With 
appropriate digestion and ligation, this PCR product could be inserted into the 
pET25b vector.   
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Figure 3.2.1. – Schematic of the Protein L molecule. 
Schematic of protein L structure illustrating different domains and functional 
regions.  In this diagram, A represents the amino terminus, B1-5 represent the 
binding domain repeats, C signifies a region of as yet unknown function while W 
and M are the wall-spanning and transmembrane domains respectively.  The region 
marked S contains a spacer region, while the region marked SS contains a signal 
sequence.  Between the red lines is the region that was amplified by PCR and ligated 




Figure 3.2.2. – Schematic of cloning strategy and potential fusion partners for 
Protein L 
This schematic shows the inserted protein L B1-B4 sequence within the 
pET25b vector, flanked by the HSV leader sequence, a histidine tag, with added 
α3(IV)NC1 (B), α3(IV)NC1 136-150 (C) or α3(IV)NC1 64-90 (D) as fusion 
partners.  The red vertical lines mark restriction sites (for a restriction map of the 









As described in sections 3.1. and 3.3., protein L can be utilised to improve 
uptake into B cells and investigate various aspects of antigen presentation by B cells.  
However, early cloning attempts failed due to a production error in the commercially 
sourced oligonucleotide primer, PL2.  This highly unusual and unfortunately late-
appreciated source of errors was finally determined by ‘blunt’ cloning the PCR 
product into pGEM-T (for restriction map see appendix II) and sequencing across the 
fragment.  
Adaptor oligonucleotide sequences were designed in order to insert additional 
restriction sites and correct the faulty construct, before protein production could 
begin (results figure 3.2.3. shows a schematic of the final pET25b vector containing 
the protein L insert), and the alterations made to the sequence during the scheme of 
work).  The adaptor sequences were dephosphorylated and annealed such that: 
   5’ -  ATGGTACCAGCGCTAGCTCGAGCT 
3’ – CATGTACCATGGTCGCGATCGAGC 
 
These adaptors contained the Kpn I (underline, italics) and Sac I (bold, italics) 
restriction site overhangs, enabling the use of the faulty construct already generated 
by altering the restriction site to include Kpn I and Sac I.   
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Figure 3.2.3. – Schematic of the protein L construct as initially designed, with 
additional changes from adaptors designed to correct errors. 
This diagram shows a restriction map of the pET25b plasmid with the protein 
L insert, plus the adaptors designed for insertion between the KpnI and Sac I 
restriction sites, in order to correct for the incorrect sequence derived from oligo 
synthesis.  This schematic shows the areas that could be used for identification 





The corrected sequence was then digested using Nco I and Sac I, and ligated 
into pre-digested pET25b to create the construct shown in figure 3.2.3.  Any 
subsequent manipulations to add α3(IV)NC1 or α3(IV)NC1 peptides used the 
pGEM-T construct as it proved easier to grow and use in bacterial transformations. 
The protein L sequence with additional restriction sites was ligated into the 
pET25b expression vector (restriction map in appendix I) and transformed into E. 
coli BL21s – a bacterial strain that can be induced to produce protein in response to 
the addition of IPTG in the culture medium.  This protein was not secreted into the 
surrounding media, so a considerable amount of purification was required before the 
protein preparation was suitable for use in cellular systems (for FACS or confocal 
microscopy). 
 
3.2.2. – Purification of the protein L fusion protein 
In order to purify the protein produced in this bacterial system, it was 
necessary to lyse the cells producing it, so I decided to utilise the ability of the 
protein L to bind IgG and make an IgG-linked sepharose column.  This would 
exploit the binding capacity of the protein L, while enabling any other proteins from 
the bacterial cell lysate to be washed away using copious amounts of buffer.  It 
would also test the protein for ability to bind IgG, while the His tag, although also 
suitable for purification, would not test this function.  The sepharose beads used in 
this process were cyanogen-bromide (CNBr)-linked and were rehydrated and washed 
well in buffer before linkage to human immunoglobulin (figure 3.2.4.). 
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Figure 3.2.4. – Immunoglobulin-linkage to sepharose beads for purification of 
protein L. 
This figure shows an acrylamide gel (A) with immunoglobulin (~120kDa) 
solution before and after exposure to sepharose beads, and a bar chart (B) plotting 
the concentration changes before and after exposure to the beads.  The pre-bead 
sample of immunoglobulin was highly concentrated and contained purified human 
immunoglobulin at a concentration of 40mg/ml - 10µl of this solution (400µg) was 
loaded onto the gel. The decrease caused by the beads binding immunoglobulin in 
solution is clearly seen in a right-hand lane.   It was found to contain 52µg/ml 
(column labelled post-beads), compared to a 1mg/ml start solution (column labelled 















Aliquots of the immunoglobulin solution were run on an acrylamide gel before 
and after incubation with the beads (figure 3.2.4A) and the protein content of the 
solution was measured before and after exposure to the beads by optical density at 
280nm (figure 3.2.4B).  Prior to exposure to the beads, the immunoglobulin solution 
was 40mg/ml (further diluted to 1mg/ml for O.D. measurement), while after 
exposure to beads, the concentration of the immunoglobulin solution was 
0.052mg/ml.  The concentration of antibody attached to the beads was therefore 
39.948mg Ig/ml beads.  
The bacterial lysate was applied to the column and incubated without any flow 
through for 1 hour prior to washing with PBS with at least 3 column volumes 
(approx 75 ml).  The protein L was eluted using a pH 2 glycine wash and 
concentrated by ethanol precipitation overnight (Chapter 2).  Figure 3.2.5. shows the 
coomassie stained acrylamide gel (figure A) and Western blot (figure B) of the 
protein solution before and after the purification step.  The Western blot shows no 
protein L in the post-load or washes (indicating that all the available protein L has 
bound to the IgG-linked sepharose) and substantial quantities in the eluates.  
On both the coomassie-stained gel (figure 3.2.5A) and the Western blot (figure 
3.2.5B), there are multiple bands.  The complete protein L insert should be 
approximately 40kDa, but as seen on the Western blot, the bands correspond to 
approximately 40kDa, 30kDa, 25kDa and 20kDa.  This suggests that the identical 
repeats within the protein L B1-B4 sequence causes misreading by the RNA 
polymerase and enables truncated forms of the protein to be produced.  
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Figure 3.2.5. – Purification of protein L from lysate using IgG-linked beads. 
This figure illustrates the various stages of the purification process using the 
column made from IgG-linked sepharose beads.  Figure A shows the coomassie 
stained gel, while figure B shows a Western blot (probed with anti-HSV antibody) of 
the different stages of the protein L purification processes.  From left to right on each 
gel: marker ladder, post load, two wash steps, four elution steps, then subsequent 
washing steps to refresh the column (elution buffer, then more wash buffer).  As can 
be seen, the protein L is eluted in the third elution step.  It also elutes at various sizes, 
this is due to production of the protein with different amounts of the binding domains 






Another explanation for the multiple bands could be that some other molecule within 
the bacterial lysate also bound to the IgG immobilised within the column, but the 
Western blot shown was probed with antibody directed against the HSV tag on the 
protein, making it unlikely that the additional bands are due to contamination. 
 
3.2.3. – Determination of protein L binding to DR15 B cells 
Having produced and purified the protein L, it was important to determine 
whether the protein did what had been previously described in the literature, namely, 
bind to surface immunoglobulin on B cells.  In particular, whether it bound Epstein-
Barr virus (EBV)-transformed B cell lines that express the HLA-DR15 molecule was 
tested. Initial experiments binding the purified protein L to B cells and probing 
binding with anti-HSV, detected by flow cytometry proved problematic.  Despite 
blocking between antibody steps, the protein L bound the kappa fraction of the 
detection antibodies and generated a lot of false positive data.  This was a particular 
problem with murine antibodies, as the vast majority of the IgG contain κ light 
chains (95%) (193), so it was decided to directly conjugate the protein L with FITC. 
 While the FITC-conjugated protein L was relatively easy to produce (Chapter 
2), maintaining the protein in solution was more difficult.  The conjugated protein L 
precipitated out of solution more easily than unlabelled protein L.  However, 
provided labelling and usage were within 2 weeks and storage was in the dark at 4°C, 
the same batch of protein L could be used for flow cytometry experiments (figure 
3.2.6.) and allowed consistency between experiments and the resultant data. 
In addition, the protein L-FITC was tested on a mixed population of human 
peripheral blood mononuclear cells (figure 3.2.7.).  This work found that 0.36% of 
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the cells were positive for both CD19 and Igκ (figure 3.2.7B), compared with 
unstained cells (figure 3.2.7A).  This is approximately 20% of the total CD19 
positive population (1.53%), so lower than the expected 50-60% Igκ more 
commonly seen in human cell populations (193).  A further set of samples from the 
same cell population found that 8.68% of the cell population was double-labelled for 
the protein L and CD19 (figure 3.2.7C).  As the CD19-PE antibody was monoclonal  
and generated in mouse, it has been characterised as IgG1 with κ light chain, 
therefore suggesting that the protein L bound to the B cells also bound anti-CD19-PE 
giving false positive data.  However, the value for staining CD19 alone (1.53%) is 
very low so this data should be approached with caution.  These data suggest that the 
anti-CD19 antibody was defective.  These data also emphasise a potential problem 
with using protein L as a fusion partner for α3(IV)NC1 or peptides derived from the 
α3(IV)NC1 sequence.  Since the protein L is ambidextrous, it can bind Igκ on either 
side.  If one side of the protein L binds Igκ on B cells, there is still another binding 
site capable of binding Igκ on neighbouring B cells (unlikely due to spatial 
constraints) or in the surrounding solution.  Care must therefore be taken that no 
additional antibody is within the cell suspension to ensure that reactions are due to 
α3(IV)NC1 or α3(IV)NC1 peptides, rather than any other antibody simultaneously 
binding to the protein L and being internalised by the B cell.  
Protein L is supposed to be specific for Igκ but the flow cytometry data shown 
in figure 3.2.6. suggested that 74.33% of the cells tested bound the protein L.   
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Figure 3.2.6. – Flow cytometry analysis of protein L-FITC binding DR15 positive B 
cells. 
This data shows the binding of protein L-FITC to an EBV-transformed DR15 
positive B cell line (CRC013).  Figure A shows the forward and side scatter plot for 
the cell line with the gated cell data for unlabelled DR15 positive B cells showing no 
fluorescent labelling in figure B.  Figure C shows the B cells double-stained with 
CD19-PE (a B cell marker molecule, Y axis) and protein L-FITC (X-axis).  As is 








Figure 3.2.7. – Flow cytometry analysis of Igκ and protein L-FITC binding CD19 
positive B cells. 
This figure illustrates the data obtained from labelling human peripheral blood 
mononuclear cells with CD19–PE and Igκ-FITC or protein L (unlabelled protein L, 
so secondary, anti-HSV,  and tertiary, anti-mouse-FITC, antibodies used for counter 
staining).  Figure A shows the unlabelled cell population and gate, figure B shows 
the gated cell population dual labelled with anti-Igκ-FITC and anti-CD19-PE to give 
a double positive population of 0.36% (total CD19 positive population of 1.53%).  
Figure C shows the data obtained from double labelling with protein L-FITC  and 
CD19-PE.  This shows a double positive population of 8.68%, suggesting that the 
protein L also binds mouse anti-CD19-PE antibodies, which are likely to be Igκ and 
therefore generating false positive data. 
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Figure 3.2.8. – FACS plots showing Igκ and Igλ staining on DR15 positive B cells. 
These plots illustrate the proportions of Igκ expressing B cells compared with 
Igλ expressing B cells from a B cell line expressing DR15 molecules.  Figure A 
shows unstained cells (isotypic controls for the antibodies gave a similar plot, data 
not shown).  There is a 96.28% population shift when staining the B cells with anti-
Igκ-FITC (figure B) and a 22.06% population shift when staining the cells with anti-














Therefore, it was decided to test the cell line used, by flow cytometry, for Igκ and 
Igλ surface expression (figure 3.2.8.).  This was surprisingly inconclusive, as the 
data suggests that 96.28% of the B cells expressed Igκ, but that 22.06% expressed 
Igλ (dual labelling was not possible as both antibodies were directly conjugated with 
FITC).  This suggests that some B cells were expressing both κ and λ chains, so 
implies cross-reactivity of the Igκ antibody as normal B cells only express one of 
either Igκ or Igλ.  However, these B cells are EBV-transformed so cannot be 
described as normal.  Furthermore, B cells in some cancers do express both Igκ and 
Igλ (194).   This finding is emphasised by the data being consistent at two different 
dilutions of the anti-Igκ antibody (1:10 and 1:100). 
It could be argued that some sample populations may have included 100% of 
Igκ-expressing B cells.  However, each label was investigated in triplicate, and at a 
minimum of two dilutions, so fluctuations in population proportions should be 
expected and should show levels more approximate to normal reported expression of 
Igκ  - approximately 60% Igκ, 40% Igλ (193).  In mice, B cells express 95% Igκ and 
5% Igλ (195), but since the EBV transformed B cells were derived from human B 
cells, the former proportions would be expected.  These data suggest that the protein 
L is not as specific for Igκ as has been suggested (192, 196, 197), since the flow 
cytometry data using the Protein L-FITC suggested that 74.33% cells used 





3.2.4. – Confocal microscopy of protein L binding to DR15 B cells 
Confocal microscopy was used as an alternative method to determine whether 
the protein L-FITC bound to B cells. The images obtained by confocal microscopy 
negate the binding on such a high percentage of cells, as there were clearly more than 
the remaining percentage (3.72% seen by flow cytometry) unstained in various fields 
of the microscope slide (data not shown).  These cells were stained with 1.5µg 
protein L-FITC for 15, 30 or 60 minutes (figures 3.2.9B-D) and counterstained with 
DAPI (a nuclear stain, shown without the protein L-FITC, in figure 3.2.9A).  All of 
the time points showed some binding of the protein L-FITC, but by 60 minutes, it 
was clearly intracellular (white arrow, figure 3.2.9D), although it remained in the 
cytoplasm.  It was not possible to determine exactly where the protein L-FITC 
localised to, as there were some problems with the FITC bleaching under sustained 
excitation.  The images shown are composites of multiple images taken through a Z-
stack, but multiple Z-stacks on multiple fields proved difficult owing to bleaching. 
An alternative explanation for the excessive binding of protein L to the B cell 
line, other than cross-reactivity and non-specific binding, could be that the protein L- 
FITC preparation was not sufficiently clean of excess, unconjugated FITC 
molecules.  This would mean that the flow cytometry data also shows cells that have 
bound FITC alone, rather than protein L-conjugated FITC.  This is possible as the 
conditions for FITC binding to a purified protein are quite specific and needs to be 
performed in the absence of amine groups.  The FITC will preferentially bind amine 
groups over alternatives, thus reducing the labelling on the requisite protein.   
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Figure 3.2.9. – Confocal images of Protein L-FITC binding DR15 positive B cells, 
double stained with DAPI. 
These composite images show DR15 positive B cells double stained with 
DAPI (a nuclear stain, blue) and protein L-FITC (green).  Each cell population was 
incubated with 1.5µg protein L-FITC for various time points; figure A shows 
unstained cells (DAPI only), then stained for 15 minutes (figure B), 30 minutes 
(figure C) and 60 minutes (figure D).  As can be seen, staining does not occur on all 
cells, but the protein L-FITC does appear to be internalised into the cells to which 
binding is seen (figure D, white arrow) and occurs with relative speed as binding is 
observed after 15 minutes of incubation (white circle, figure B). 
 




The active group is also destroyed by water so is never present in FITC-protein 
conjugates.  It does mean that the FITC-labelled protein is hydrophobic and can 
“stick” without being actively bound, therefore generating false positive data.  The 
presence of excess unbound FITC within the protein L-FITC solution was minimised 
by utilising molecular weight spin-columns with a cut off of 10 000Da – these 
ensured that the majority of unbound FITC was centrifuged away from the final 
protein L-FITC solution used for the experiments described. 
 
3.3. - Discussion 
 
Having shown that protein L produced was capable of binding to DR15-
expressing B cells, the next stage of this project was to produce protein-L conjugated 
to a specific peptide and show whether it improves antigen presentation by 
increasing the amount of IL-2 produced by peptide specific hybridomas, compared to 
hybridomas stimulated with B cells and peptide without the protein L. 
Briefly, the α3 sequences focussed on for addition to the protein L were the 
α3(IV)NC1 136-150 peptide, to which 100% Goodpasture patients generate an 
immune response and to which 100% DR15 A3v α3KO mice also generate an 
immune response.  This peptide was also suitable for use in these constructs as there 
was already a hybridoma responsive to this peptide available.  The second peptide  
considered for addition to the fusion protein was the α3(IV)NC1 64-90 peptide, a 
peptide with known immunological activity in Goodpasture patients, but which is 
also known to be cleaved almost immediately within the lysosome. 
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The α3(IV)NC1 136-150 fragment is a region of the α3(IV)NC1 sequence to 
which 100% patients with Goodpasture’s Disease have a measurable proliferative T 
cell response compared to HLA-DR matched control samples.  In this thesis, it is 
also a region to which the transgenic KO mouse model produces an immune 
response (as discussed in Chapter 6).  With this in mind, oligonucleotide sequences 
were designed to amplify the α3(IV)NC1 136-150 sequence of the α3(IV)NC1 with 
specific restriction sites on either end.  This fragment could then be ligated into the 
protein L construct plasmid, resulting in production of a fusion protein complex 
called protein L-A3 136-150.  The primer and relevant PCR products were produced, 
but ligations into the protein L plasmid failed and test digests for the WISL sequence 
in conjunction with the protein L sequence proved negative (data not shown). 
Other uses for protein L include it being used as part of a hybrid protein, and 
have been projected to improve extraction of immunoglobulins in general (198, 199).  
Many antibodies are purified using protein G, but this has a more limited binding 
capacity than protein L.  In particular, protein L could be very useful in the 
purification of murine antibodies from serum since these are mostly Igκ (~95%).  A 
hybrid protein between protein G and protein L could therefore dramatically improve 
the rate of recovery of antibody from serum samples (199).  A hybrid protein 
consisting of protein L and protein A would have similar applications.  Protein A is 
also used in the purification of immunoglobulins and binds IgG Fc regions, so a 
hybrid protein could also improve the recovery of antibodies from a given serum 
sample (198). 
Overall, it appears that protein L is capable of binding to B cells and that it 
could be used as a potential fusion protein with which to improve uptake into B cells.  
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However, more work will need to be done in order to understand the mechanism of 
uptake and the route within the cell to ensure processing pathways are not different 
from the normal mechanisms.  This could include labelling the protein L with a 
different fluorescent molecular to reduce bleaching, combined with time-lapse 
confocal at higher resolution to track the progress of the protein L into cells, as well 
as continuing the projected work attaching an α3 peptide to the protein and 
determining whether peptide-specific hybridomas respond.  Overall, protein L would 
enable the direct comparison of immune responses in vitro, and would increase the 
chances of a specific antigen being taken up into the cells, thereby improving the 
levels of different peptides presented.  Protein L could be used to improve the 
presentation of more rare peptides with lower capacity to induce an immune response 
on the B cell surface.  These peptides may have a major role in the induction of 
tolerance during T cell repertoire development, so protein L could enhance 
understanding of central tolerance and its role in the development of autoimmune 
disease. 
To summarise, protein L appears to recognise Igκ, to specifically bind B cells, 
and to be internalised by B cells upon binding.  This information suggests that 
protein L could be an efficient fusion partner when studying antigen presentation and 
could be exploited to study and enhance B cell uptake of specific fragments of 
antigen.  Unfortunately, time constraints meant that it was not possible to link protein 
L to α3(IV)NC1 or fragments of the α3(IV)NC1 protein during this project.  
However, the constructs were stored such that additional work could be undertaken 
to further explore potential uses for this protein as a means by which to improve 
antigen uptake into B cells. 
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Chapter 4 – Development of transgenic mouse line 
 
4.1. - Introduction 
 
The purpose of experiments described within this chapter was to develop a 
transgenic mouse expressing the human MHC class II molecule HLA-DR15, which 
also expressed or did not express the Goodpasture antigen, α3(IV)NC1.  These mice 
were used to study immune responses and antigen presentation in the presence and 
absence of endogenous α3(IV)NC1, and therefore in the presence or absence of 
tolerance. 
Before creating a transgenic mouse line, it is important to consider what 
alternatives are available and how much will actually be gained from using mice.  
Mice differ from humans in physiology, and some different biochemistry.  This 
means that while some parallels can be drawn, particularly in the use of transgenic 
animals where the animal has to some extent been “humanised”, it is only really 
possible to investigate mechanisms and discuss possibilities rather than certainties 
(200, 201).   The main reason for development of animal models of disease is in 
order to identify processes that occur before and during disease to determine 
mechanistic features with a view to either inhibiting or preventing disease 
progression.  There are two different types of disease model – those that develop 
disease spontaneously, for example non-obese diabetic (NOD) mice (202, 203), and 
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those in which disease is induced, usually by a drug administered in the diet, for 
example streptozocin induced diabetic mice (204, 205).   
In this project, the model developed had known MHC class II expression 
restricted to HLA DR15, enabling control of when the immune responses to a 
specific antigen were initiated.  It would therefore be possible to investigate specific 
features of the immune response in a way that is not possible with human 
Goodpasture patients or normal HLA-matched volunteers.  In particular, it would be 
unethical to immunise humans with an antigen that could potentially cause 
autoimmunity and renal failure.  The experimental protocol would be very different 
and would utilise blood samples from untreated Goodpasture patients and HLA-
matched controls, but while work has been published using samples from untreated 
human Goodpasture patients to study their immune responses (206, 207), it is 
difficult to gain sufficient blood and sufficient numbers of patients to make this work 
statistically significant.  This is mostly due to the scarcity of new patients and the 
overall rarity of Goodpasture’s disease, but also because newly presenting 
Goodpasture patients are very ill and withholding treatment for the sake of additional 
blood samples, if needed, is unethical. 
Although some aspects of this disease have previously been studied (41), in 
particular experiments to determine cellular responses to specific fragments of the 
Goodpasture antigen, it has not been possible to investigate the immune responses in 
the presence and absence of tolerance.  Another disorder involving the collagen IV 
chain is Alport’s disease.  Patients with Alport’s diseases have impaired renal 
function as a result of lacking or expressing mutated the α5(IV) collagen chain, and 
similar disease aetiologies have also been reported to occur with alterations in the α3 
105 
 
or α4 chains (208).  Treatment for Alport’s disease can include transplant, and these 
patient’s can develop Goodpasture-like autoimmunity as a result of not developing 
tolerance to the normal α(IV) chain (209-211).  This disorder could be considered a 
viable human comparison regarding immune responses in the presence and absence 
of tolerance.  However, Alport’s disease is also very rare; it is a known X-linked 
genetic disorder rendering it dissimilar to Goodpasture’s disease; and sufficient 
samples to enable study of immune responses would be extremely difficult to obtain.  
Despite these limitations, this a potential route for investigating immune responses to 
specific autoantigen given time and sufficient samples. 
It has also been suggested that environmental factors have a role in the onset of 
Goodpasture’s disease (212, 213).  It is far easier to control the surrounding 
environmental influences on mice than it would be to restrict the environment in 
humans.  In particular, approximately 10% of patients used to present with 
pulmonary haemorrhage, but this number has reduced over time (closer to 5%) and 
there is a positive correlation between pulmonary involvement and smoking (p>0.01) 
(213, 214).  It was also shown that some of these patients worked with toxic 
chemicals and the haemorrhage could have been allowed by inhalation of these 
chemicals (212), which may have then increased the accessibility of the underlying 
collagen structure and enabled the autoimmune reactions seen in the kidney to also 
occur within the delicate lung tissue.   
The consensus for onset of autoimmunity is that there is a “double hit”.  It is 
thought that there is an underlying predisposition for the disease (the first “hit”), at 
least by HLA type as well as other, less well-described immunological molecules, 
and then some additional stimulus, a second “hit”.  For example, in Goodpasture’s 
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disease, it has been shown that patients usually express HLA-DR15.  It has also been 
reported that some kind of trauma within the kidney – surgery, lithotripsy for kidney 
stones for example - may have had an influence upon the disease development, but 
these patients are in the minority (215).   
Another limiting factor is the availability of blood samples.  Unless the patients 
were untreated, the immunosuppressive therapy involved in treatment of this disease 
would destroy subsequent experiments studying the specific T cell responses. A 
mouse model could help overcome this problem.  The scarcity of new patients would 
also be a considerable hindrance to this project as, on average, there is estimated to 
be fewer than 1 patient per million people per year, although there is limited 
information about the population incidence and prevalence (216).   
In addition to the advantages to using a mouse line rather than human samples, 
the mouse line allows us to study the influence of tolerance on the immune response, 
as animals can be bred both with and without endogenous α3.   It would be logical to 
assume that mice that do not express the α3(IV)NC1 domain, when immunised with 
exogenous α3(IV)NC1, would treat the protein as ‘foreign’ and mount an immune 
response to it.  This response could then be tested to determine which peptide 
fragments of the α3(IV)NC1 domain produce the greatest immune response.  By 
comparison, the mice that express the α3(IV)NC1 protein would be tolerised to the 
protein so it would be more difficult to induce an immune response to any part of the 
protein.  In these mice, it is possible that any immune responses are to so-called 
cryptic epitopes and could help determine where the cryptic epitopes lie, and any 
specific similarities between these peptides. 
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These factors considered, a transgenic mouse line was the most feasible option 
for studying the immune responses to the Goodpasture antigen.  A major 
characteristic of Goodpasture patients, is that 90% express the human MHC class II 
molecule HLA-DR15 (as discussed in Chapter 1), while the target antigen, the α3 
chain of type IV collagen (α3(IV)NC1), has also been well characterised.  
Development of a mouse line with a CD4 immune response restricted to presentation 
of peptides only by HLA-DR15, both with and without endogenous α3, would 
enable determination of immune response by antigenic fragments.  These responses 
could then be studied to determine which antigenic peptides produce an immune 
response both in the presence and absence of endogenous α3 and therefore to study 
the influence of self upon responsiveness to self-antigen. 
 
4.2. – Results 
 
4.2.1. – Cross-breeding to generate the DR15 A3v transgenic mouse line 
Two mouse lines were available for this project: 4A3 carries a mutation that is 
α3KO (α3(IV) knock-out): the progeny can be wild type (α3-WT), heterozygous 
(α3-Het) or knock-out (α3-KO) for the α3 chain.  This line was developed by Miner 
et al. in St Louis, Missouri (174) and has been used to investigate the influence of 
genetic deletion of a component of the α3-α5 collagen IV network analogous to 
Alport’s disease phenotype in which the α5 chain is absent.  The second line used 
was the DR15 mouse line, which is knocked out for mouse class II molecules, but 
transgenic for the human genes that encode the HLA-DR15 molecule, HLA-
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DRB1*1501 and HLA-DRA1*0101.  The original mouse class II KO was produced 
by Cosgrove et al. (176), with the DR15 double transgene insertion added by Prof 
Altmann’s group in London (175).  It was therefore decided to cross-breed these 
lines and generate a mouse line with a restricted MHC class II repertoire.  There was 
also the potential for an increased propensity towards the development of 
glomerulonephritis as a side effect of the cross-breeding. 
The breeding process was more difficult to implement than implied above, as 
both lines are relatively complex to breed.  The 4A3 line (on a 129sv background) 
(174) cannot breed from A3-KO female animals, as they die during pregnancy or 
immediately postnatal.  It is thought that the kidneys of the A3-KO animals are 
unable to cope with the additional filtration required and pressures of pregnancy and 
enter acute renal failure (personal observations).  The choice of breeding animals to 
produce the required genotype and maintain the colony was therefore A3-KO stud 
males breeding with A3-Het females producing both A3-Het and A3-KOs pups per 
litter.  The A3-KO mice do have a tendency to be smaller than their littermates, but 
this is by no means a reliable way to identify the A3-KO mice from the others. 
The DR15 line (on a C57BL/6 x CBA background) (175, 217), as mentioned 
above, is also complicated.  The mouse class II molecule, when knocked out within 
an animal by insertion of a neomycin cassette within the gene, appears to have no 
effect on the breeding capacity of that animal, so class II-KO males can breed with 
class II-KO females without repercussions.  However, the additional level of 
complexity arises with HLA DR15 expression.  The HLA DR15 molecule is 
expressed as 2 chains, α and β, both of which have to be expressed in order for the  
109 
 
Figure 4.2.1. – Punnet square showing the initial cross to produce DR15 A3v line.   
The cross was set up with an F0 male α3 KO (vertical axis) bred with a F0 
female mouse class II KO, double transgene human MHC class II insert (horizontal 
axis).  The second from right and right hand columns show the frequencies of the 
resultant female and male genotypes.  The overall yield is calculated by multiplying 
the frequencies together.  The desired female genotype was mouse class II het, 
HLA-DRA positive, HLA-DRB positive, α3 het. 
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molecule to be produced and function on the cell surface.  In the cross, hereafter 
called DR15 A3v (DR15 expressing, α3 variable), both of these breeding issues have 
to be taken into consideration.   
The initial cross was such that male 4A3 mice KO for α3 were set up in 
breeding pairs with females KO for mouse class II, but positive for the DR15 genes.  
The resultant F1 genotypes and frequencies are shown in figure 4.2.1.  
The subsequent F1 breeding pairs used male IAB+/- COLIVA3+/- mice crossed 
with female IAB+/- DRATg/- DRBTg/- COLIVA3+/- and the resultant F2 genotypes and 
frequencies are shown in figure 4.2.2.  As seen in these figures, the genes affected 
are listed as IAB, DR15 A/B double transgene, COLIVA3.  The shorthand developed 
to describe this line lists the genes in this order and as KO, Het or WT for the IAB 
and the COLIVA3 genes, with the DR15 transgene described as -/- (not present) or 
A/B (both chains present).  Therefore, all the males used in breeding when the 
colony was established were either KO -/- KO (IAB KO, DR15 negative, COLIVA3 
KO) or KO -/- Het (COLIVA3 Het if COLIVA3 WT offspring were required for use 
as controls) and females were KO A/B Het (IAB KO, DR15 α/β positive, COLIVA3 
Het).  Throughout this thesis, this is the annotation used to designate the animals 
used for any experiments.  Additionally, only females were shown to carry the HLA 
αβ transgene, so all experimental mice were female. 
All subsequent breeding to generate a colony were male IAB-/- COLIVA3-/- 
bred with female IAB-/- DRATg/- DRBTg/- COLIVA3+/- to give a frequency of 50% 
total male offspring IAB-/- COLIVA3-/- and 25% total female offspring positive for 
the DRAB double transgene.  Of these females, 50% are COLIVA3+/- and 50% are 
COLIVA3-/- to give an overall frequency of 12.5% total females (Figure 4.2.3.). 
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Figure 4.2.2. – Punnet square showing the F1 cross, the resultant genotypes and 
frequencies.   
This diagram illustrates the second cross of F1 offspring: F1 male, mouse class 
II het, HLA-DRA –ve, HLA-DRB –ve, α3 het  (vertical axis) x F1 female, mouse 
class II het, HLA-DRA +ve, HLA-DRB +ve, α3 het (horizontal axis). The calculated 
frequencies of females (desired, MHC IAB-/-, HLA DRAB, COLIVA3+/-) and males 
in the second from right and right hand columns.  Again, overall yield was calculated 
by multiplying the frequency of each genotype (ms class II x MHC class II x α3). 
 























































 50%†  
COL IV  
A3+/- 
(mouse) 




    Overall 
yield: 
3.125% 6.25% 
† Only female offspring carry the MHC class II A or B chain transgenes. 
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Figure 4.2.3. – Punnet square illustrating all subsequent breeding pairs and possible 
genotypes to maintain the new colony. 
This diagram illustrates the third cross of F2 offspring: F2 male mouse class II 
KO, DRAB –ve, α3 KO  (vertical axis) x F1 female mouse class II KO, MHC class II 
AB positive, α3 het (horizontal axis), with the calculated frequencies of desired 
females (mouse class II KO, HLA-DRA +ve, HLA-DRB +ve, α3 het (breeding) or 
KO (experimental)) and males in the second from right and right hand columns.  
Again, overall yield was calculated by multiplying the frequency of each genotype 
(mouse class II x MHC class II x α3). 
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4.2.2. – Genotyping reactions 
In developing this transgenic mouse line, a number of obstacles had to be 
overcome, the major regarding appropriate breeding pairs in order to maintain the 
cross.  In setting up the optimal breeding pairs to maintain the cross and generate 
healthy pups, it was necessary to breed from COLIVA3 heterozygous females and 
therefore detailed genotyping of each animal was required (results figures 4.2.1.-3.).  
The primers and conditions used for each PCR reaction are described in chapter 2, 
but additional details are given below. 
For identifying whether animals were knocked out for the mouse class II gene 
(figure 4.2.4.) the following primers were designed: 
ABOL2: 5’-CAC CAA CGG GAC GCA GCG CAT AC-3’ 
ABOR2: 5’-GGC CCT CGT TCG CTC CAG GAT CT-3’ 
These primers bind the mouse class II gene (this strain only carries the IAB 
gene and not the IEB mouse class II gene) and result in a wild type fragment of 169 
base pairs (bp) if the gene is intact.  If the gene has successfully been disrupted, a 
cDNA cassette encoding neomycin has been inserted into the mouse class II gene.  
This disruption gives a fragment that includes the neomycin as well as the IAB gene 
fragment and is 1000bp (figure 4.2.4A).   In addition, a second PCR reaction was 
carried out to check the presence of the neo cassette and used the ABOL2 primer 
with an additional primer: 
Neo: 5’-GAG GAT CTC GTC GTG ACC CA-3’ 
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The Neo primer binds within the neomycin cassette and, when used in a pair 
with the ABOL2 primer, results in the amplification of a fragment 340bp in length 
(figure 4.2.4B). 
 
The insertion of the MHC class II transgene was also tested by PCR reactions.  
The primer pairs each recognise either the HLA DRA1*0101 gene or the HLA 
DRB1*1501 gene so two PCR reactions were performed to determine the HLA 
status.  The primers were designed as follows: 
TgDRAL: 5’-CTC CAA GCC CTC TCC CAG AG-3’ 
TgDRAR: 5’-ATG TGC CTT ACA GAG GCC CC-3’ 
TgDRBR: 5’-CTG CAC TGT GAA GCT CTC-3’ 
TgDRBL: 5’-TTC AAT GGG ACG GAG CGG GTG-3’ 
In combination, the TgDRAL and TgDRAR result in the amplification of a 
fragment 124bp in length, while the TgDRBL and TgDRBR amplify a fragment 
approximately 190bp, as shown in figure 4.2.5. 
The final set of PCR reactions were to determine the α3 status of the mice.  In 
this case the mouse COLIVA3 gene was also disrupted by insertion of a neo cassette 
and could be detected by targeted PCR specific for this cassette.  The primers are 
shown below:  
4A3 KOWTL: 5’-ACG ACC TTT GTT AAA CTA GAA GAA GTC-3’ 
4A3 WTR: 5’-TTC CCC TGT CAC CAG GAT TTC CC-3’ 
4A3 KOR: 5’-TGC TAA AGC GCA TGC TCC AGA CTG C-3’ 
These primers were designed such that the 4A3 KOWTL primer could be used 
with both the 4A3 WTR and 4A3 KOR primers and produces different sized bands in  
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Figure 4.2.4. - Mouse class II PCR reaction.   
Gel showing results from PCR reactions for IAB (WT) and for the neomycin 
cassette inserted into the IAB gene to disrupt and prevent transcription of the gene 
(KO) (figure A).  From left, Hae marker ladder, IAB WT, IAB KO as shown by 
increased size within the IAB (mouse class II) gene. Also shown are Neo PCR 
results for the neomycin insert in the IAB gene (figure B).  From left, 100bp marker 













Figure 4.2.5. – MHC class II PCR reaction for genotyping.  
Image derived from a gel on DNA samples tested for the MHC class II 
transgene.  From left, Hae marker ladder, DRA chain positive, DRA chain negative, 
DRB chain positive, DRB chain negative.  The DRA positive reaction generates a 
fragment of approximately 124bp, while the DRB reaction generates a fragment of 


















Figure 4.2.6. – PCR genotyping reactions for α3WT and α3KO.  
 Each image shows three lanes of a gel.  Lane 1 contains the Hae ladder, lane 2 
the α3 wild type DNA sample and lane 3 the α3 knockout DNA sample.  Wild-type 
positive band is approximately 1000bp (figure A), while the KO band is 
approximately 850bp (figure B).  In figure A, the band appears lower than 1000bp, 
however the entire gel ran faster in lane 2 than 1, 3 than 2 and so on, rendering it 
difficult to determine exact size.  However, presence of the band is sufficient to 










each.  The WT reaction amplifies a fragment approximately 1000bp in length, while 
the KO reaction amplifies a fragment approximately 850bp in length (figure 4.2.6.). 
4.2.3. – Frequency of genotypes 
Since this was a new transgenic crossed, the frequency of occurrence of each 
genotype derived from a specific breeding pair was investigated and used to 
maximise chances of obtaining mice that both expressed the MHC class II AB 
transgene and were knocked out for the α3 gene.  Prior knowledge about the effects 
of the transgenes was taken into consideration for these studies, as the requirements 
for breeding the various required genotypes were maintained by experienced animal 
technicians. The data obtained from this study is shown in figure 4.2.7.  This figure 
illustrates the possible genotypes derived from specific breeding genotype pairings, 
the expected frequencies and the observed frequency of each.   
In a study of 200 mice, chosen for the genotype of the parents, two things 
became very obvious.  Firstly, there is a positive skew in favour of producing female 
mice.  Out of the 200 mice studied, 50 were male and 150 were female.  While some 
strains of mouse do have a tendency towards producing more of one sex than the 
other, this observation is a statistically significant difference (χ21= 50, P = 1.2x10-5).  
In addition, out of the 50 males born, only 5 genotypes of a possible 8 were actually 
seen and the majority of those (38/50) were either DRAB-/- COLIVA3+/- (22/50), or 
DRAB-/- and COLIVA3-/- (16/50).  The other genotypes seen were DRATg/- 
COLIVA3+/- (2/50), DRBTg/- COLIVA3+/- (9/50), and DRBTg/- COLIVA3-/- (1/50).  
This suggests that the AB combination of genes does not support the male genotype 




By way of comparison, of 150 female mice, 65 were DRABTg/- COLIVA3+/- 
and 13 were DRABTg/- COLIVA3-/-.  The DRABTg/- COLIVA3-/- numbers are 
reasonably close to the expected frequency of 6.25% per genotype (observed 
frequency of 6.5%), assuming that each characteristic has a 50% chance of 
occurrence: 
sex 0.5 x A 0.5 x B 0.5 x α3 0.5 = 0.0625, therefore 6.25% frequency of occurrence.   
In reality, the range of frequencies and numbers within each genotype were 
dramatically different, the overall data being influenced by the frequency of the 
female DRABTg/- COLIVA3+/- and, following testing by chi-squared statistics gave a 
value of χ215= 347.36 (P= 7.5x10-65), showing that the observed frequency of total 
genotypes is significantly different from the expected frequency of total genotypes 
(figure 4.2.7.).  Females were born with the HLA DRAB double transgene more 
frequently than was expected (32.5% when also COLIVA3+/-, a lower frequency 
6.5% when COLIVA3-/-), especially when compared to the numbers from males of 
the same genotypes (0% of either).  In both sexes, the HLA DRAB-/-, COLIVA3+/- 
genotype also occurred more frequently than was anticipated from prior calculations 
(males 11%, females 16%).  The genotype HLA DRAB-/-, COLIVA3-/- also occurred 
at 1.8 times the frequency in males than it does in females, so, to correct for the skew 
in favour of females, effectively occurs 5.3 times more frequently in males than 
females.  These considerations had to be taken into account when breeding required 
genotypes, both for subsequent breeding and to produce the appropriate genotypes 
for experimental purposes. 
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Figure 4.2.7. – Schematic of a typical breeding pair of the DR15 A3v line showing 
offspring genotypes and expected vs observed frequency. 
This chart shows the parent genotypes, possible offspring genotypes, the 
calculated expected frequency of occurrence, and the observed frequency of 
occurrence obtained from study of 200 offspring from breeding pairs with the same 
genotype as shown below (male DRA-/-, DRB-/-, COLIVA3-/- and female DRATg/-, 
DRBTg/-, COLIVA3+/-).  These parent genotypes were chosen for optimal breeding of 
the female DRATg/-, DRBTg/-, COLIVA3-/- genotype, which was required for 
experimental purposes.  Highlighted in red are the genotypes skewed towards female 
mice, while in blue is the genotype skewed towards male mice. 
 
 
In contrast, AB negative, α3Het is increased in both sexes to similar level 
when just taking overall occurrence into account.  In actual fact, this genotype is 
twice as likely to occur in males than in females.  The female genotypes were more 
diverse and only 1 of the possible 8 genotypes did not occur in this data set, however, 
from personal experience, if the numbers within the dataset were increased, this 
would probably cease to be observed. 
 






4.2.4. – Flow cytometry analysis of MHC/HLA expression by lymphocytes 
from transgenic mice 
Flow cytometry was used to investigate the cell surface expression of 
MHC/HLA DR15 molecules on lymphocytes from transgenic mice.  Lymphocytes 
from two transgenic DR15 A3v mice (IAB negative, HLA DRAB positive) were 
compared with lymphocytes from two normal C57BL/6 mice (IAB positive, HLA 
DRAB negative), each stained and measured in triplicate.  The results are shown in 
figure 4.2.8. and confirm the phenotype expected for PCR-determined genotypes for 
each mouse.  8.6% and 4.74% of cells isolated from lymph nodes of C57BL/6 mice 
expressed the mouse class II molecule (figure 4.2.8B-C), while 1.63% and 0.75% 
expressed the HLA-DR15 molecule (figure 4.2.8D-E).  This is in direct contrast to 
the lymphocytes isolated from the lymph nodes of DR15 A3v mice from which 
15.52% and 16.49% of the cells isolated expressed the HLA DRAB molecule (figure 
4.2.8I-J), while 1.14% and 0.87% only appeared to express the mouse class II IAB 
molecule (figure 4.2.8G-H).  All of the figures have the positive staining overlaid on 
cells stained with the relevant isotype control to allow for antibody-type non-specific 
binding.  These data showed that while the DR15 A3v mice did appear to be MHC 
class II positive, there was also some reactivity with the mouse class II antibody.  
This suggests that either the gene has not been knocked out properly, although this in 
unlikely as the PCR reactions were WT negative for these animals, or that there is 
some cross-reactivity between the anti-mouse class II antibody and the MHC class II 
molecules on the DR15 A3v mouse lymphocytes.   
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Figure 4.2.8. – FACS plots of DR15 A3v lymphocytes compared with those from a 
C57/Bl6 mouse stained for HLA-DR and mouse class II.   
This figure shows forward scatter and side scatter plots of unstained lymph 
node cells (figures A and F), plus overlay histogram plots of a population of cells 
bearing mouse class  II (figures B and C, G and H) or HLA-DR15 (figures D and E, I 
and J) determined by fluorescence detected on FL1 for lymph node cells from a 
C57BL/6 mouse (figures A-E) and a DR15 A3v mouse PCR genotyped as mouse 
class II KO and HLA DRAB positive (figures F-J).  Filled histograms show stained 

























Figure 4.2.8. – FACS plots of DR15 A3v lymphocytes compared with those from a 



































































These cell suspensions were also fairly crude preparations containing all cells 
disaggregated from whole lymph nodes, so the relatively high background staining 
and numbers of unstained cells may be due to other, contaminating cell types, such 
as B cells and monocytes. 
 
4.2.5. – Renal function of DR15 A3v transgenic mice 
It has been noted that, if allowed to die from natural causes, α3 KO mice die 
younger than their α3 Het or α3 WT littermates.  However, it is not known whether 
this is due to renal failure, or some other reason.  Since the DR15 A3v mouse line 
was bred to be more susceptible to glomerulonephritis and renal failure (through the 
DR15 link to Goodpasture’s disease and the α3(IV) KO likeness to Alport’s disease), 
it was decided to examine whether renal function was impaired pre- and post-
immunisation with antigen, and how this differed between α3 KO mice and their α3 
WT littermates.  Three different time points (before immunisation, after one 
immunisation with complete Freund’s adjuvant and after the second “booster” 
immunisation with incomplete Freund’s adjuvant) were used for each mouse, and 
renal function was estimated by determining the protein and blood content of the 
urine sample using Bayer urine dipsticks.  There was a clear increase in proteinuria 
and haematuria for both α3 KO and α3 WT mice, but it was not determined whether 
this was due to the Freund’s adjuvant used in the immunisation schedule.  There was 
a more rapid escalation of proteinuria observed in α3 KO mice compared to α3 WT 
mice, although none of the differences were found to be statistically significant, 
either between WT and KO at each time point or between time points within each  
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Figure 4.2.9. – Scatter plot showing the extent of proteinuria in α3WT and α3KO 
mice at different time points following immunisation against background. 
This scatter plot shows the different readings of proteinuria from different mice 
before, during, and after immunisation with α3 in adjuvant and compares α3WT 
with α3KO mice (mean and standard error marked).  In addition, to determine how 
the immunisations had an effect on proteinuria in these animals, urine samples were 
taken from two naïve animals of each genotype at 8 months of age to determine the 






genotype (P=0.3-0.9).  The immunised α3WT mice appeared to have increased 
proteinuria after immunisation with antigen in complete Freund’s.  This increase in 
proteinuria was followed by reduction (although not back down to baseline levels) 
after the second immunisation using incomplete Freund’s as the adjuvant.  
Additionally, the measurements were not quantitative as they were collected using 
urine dipsticks designed for human levels of proteinuria and haematuria, with larger 
volumes of urine, and were measured by eye against a colour chart.  The data 
obtained is shown in figure 4.2.9, with a calculated mean and standard error of the 
mean shown.  The differences seen in these samples are not statistically significant, 
either when comparing wild-type to knock out at each time point (P=0.348, 0.3961 
and 0.8577 at day 0, 7 and 14 respectively) or each time point to baseline (WT 
P=0.5796 and 0.6847 for day 7 and day 14, KO P=0.4458 and 0.337 for day 7 and 
14), by unpaired T-test.  The sample size shown here is also very small without 
control, unimmunised mice at the same time points, so this work needs further 
investigation before a real conclusion can be drawn.  
Since these mice were difficult to breed and obtain numbers sufficient for 
conclusive proof, this data should be treated as pilot data and more experiments 
should be done to determine the degree of impairment of renal function by means of 
increased creatinine in urine samples from these α3 KO mice.   
 
4.3. – Discussion 
 
The DR15 A3v line has been bred such that it does not express mouse class II 
molecules, can express the HLA-DR15 molecule - the HLA molecule known to be 
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expressed by 80% of Goodpasture patients - and can either express α3(IV)NC1 
collagen or be knocked out for the same molecule.  While this mouse line does not 
develop Goodpasture’s disease (at least with the conditions to induce immune 
responses used throughout this thesis), it should enable some elaboration on the 
immune responses generated by the Goodpasture antigen.  This line is therefore a 
valuable resource for exploring specific immune features of Goodpasture’s disease, 
most particularly antigen presentation by the HLA-DR15 molecule, and to determine 
how tolerance influences peptide presentation and immune response.   
It is worth noting that difficulties in breeding this line are likely to be constant 
– care must be taken to ensure the correct genotypes are used for breeding pairs or 
there is a risk of losing either the MHC class II transgene from the line, or the 
α3(IV)NC1 genotype.  In particular, no male mice (0/200) have been identified to 
carry the HLA DRAB double transgene or the HLA DRB gene – it seems likely that 
this is due to the genotype being either incompatible with the male phenotype or 
being embryonic lethal for males.  The former reason could include insertion of the 
HLA DRAB genes into a gene such that expression is incompatible with becoming 
male and forcing a more female appearance despite the XY genotype.  An extreme 
example of this could be that the HLA-DRB gene could have been inserted into the 
testosterone gene, disrupting testosterone production and resulting in offspring 
female in appearance.  This does not appear to be the case in the DR15 A3v line as 
these “females” would not be suitable for breeding or experimentation and would 
have different physiology from the true females, neither scenario was observed.    
Females with the correct genotype by PCR for the HLA DRAB are capable of 
breeding, whereas if they were genetically male, this would not be the case.  In 
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reality, the limiting factor for breeding was the α3 status of the female, as described 
above.  Without more specific data regarding the location of the insertion (for 
example, fluorescent in-situ hybridisation (FISH)), only conjecture is possible, 
however it is known that the insertions are not linked to the sex chromosomes.  If the 
insertion was only in the Y-chromosome, all male mice would have the gene and this 
is known to be untrue, as the mice are negative by PCR for the gene.  If the insertion 
was into the X-chromosome, 50% females (rising with time and subsequent in-
breeding) would have the insertion and some males would also have the insertion, 
which is also known to be untrue.   
As discussed earlier, additional reasons for lack of males with the DRAB 
genotype could also be due to segregation to chromosomes, however, if this were 
random chance of segregation during gametogenesis, it would be expected that some 
males would be born that express the double HLA DRAB transgene.  In the 200 mice 
counted here (figure 4.2.7.), males expressing HLA DRAB are never born, and in a 
total of more than 750 mice (all mice born, irrespective of α3 status of parent mice) 
this is also true (0/750).  This therefore further supports the suggestion that the HLA 
DRAB double transgene is incompatible with male mice.   
More work to study where the recombination event occurred on the genome 
following insertion of the HLA DRAB transgenes would help to understand the 
mechanisms and genes affected by the insertion events.  Genes studied that cause 
embryonic lethality in males include sxl in Drosophila melanogastor – Drosophila 
simulans hybrids (218) and sex-specific differences in embryonic lethality have also 
been observed in a mouse line containing a variegating green fluorescent protein 
(GFP) transgene.  Females with homozygous knockout died mid-gestation and were 
129 
” 
found to display abnormal methylation on the X chromosome, resulting in aberrant 
gene activity (219).   
Generally speaking, X-linked recessive disorders are more likely to be carried 
by females and be apparent in males (for example colour-blindness and Angelman 
syndrome), but it has been more difficult to pinpoint genes resulting in male-specific 
lethality.  One gene known to show such characteristics is the human IKKγ gene 
located at Xq28 – defects in this gene cause Incontinentia Pigmenti (also known as 
Bloch-Sulzberger Syndrome), a disorder that causes prenatal death in males and 
variable skin pigmentation combined with retardation and tetraplegia in females.  
The affected females show highly skewed X inactivation, with variable degree of 
corresponding disease (OMIM number 308300) (220).  It is not likely that this is the 
gene affected by insertion into the DR15 A3v mouse genome, as the female mice do 
not show any such abnormality, but defects in this gene do illustrate the potential for 
male-specific embryonic lethality. 
In the DR15 A3v line, females are therefore the sole source of the HLA DRAB 
double transgene and must also be COLIVA3 heterozygotes as COLIVA3 KO 
females die during pregnancy or immediately post-natal.  The breeding genotype is 
the most commonly observed and was seen to occur 32.5% of the time.  While the 
COLIVA3 gene is of interest in terms of exploring specific immune responses to the 
protein encoded by that gene, the development of the mouse line in which the CD4 T 
cell repertoire is restricted to the HLA-DR15 molecule is also of interest in exploring 




While this mouse line appears to be an appropriate system to investigate the 
immune responses to the α3(IV)NC1 protein, there are additional factors to bear in 
mind when designing experiments.  In particular, the fact that the mouse α3(IV)NC1 
has only 92% homology with the human and while the mice homozygous knock-out 
for the COLIVA3 gene may develop similar immune responses to the human 
α3(IV)NC1 protein, it is possible that mice that still express the COLIVA3 gene 
show different immune responses to the human α3(IV)NC1 protein compared with 
their self-protein.  It is also possible that, irrespective of tolerance, an aberrant 
immune response may occur solely due to slight differences in the COLIVA3 gene 
sequences of mice versus human. 
This line also has other limitations in that there is variability within the line.  
The COLIVA3 KO line was originally on the 129sv background, while the DR15 
line was on a C57BL/6 x CBA background.  While both of these backgrounds are 
inbred over hundreds of generations, by cross-breeding the two any advantage of 
inbreeding has been removed, so genetic variability becomes more apparent.  In the 
DR15 A3v line, variation was observed by coat colour (ranging from grey, agouti to 
black).  This variation in coat colour was removed following rederivation of the line 
when moving the animals to a new, clean facility, and selectively choosing agouti 
(the most prevalent coat colour) as the breeding pairs and source animals for the 
rederivation project.  As a general rule, it takes 16 generations for genetic variation 
between parents and offspring to be reduced to negligible (221).  That being the case, 
if each generation is counted from when the previous generation dies, and assuming 
that each generation will live 6 months, it could take 8 years to reduce genetic 
variation to nothing in this line.  If counted from when each generation breeds, and 
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provided each generation only breeds within that generation, this time period could 
be reduced to 4-5 years, but on the proviso that no back-crossing with previous 
generations was undertaken. 
Other rodent lines do exist to specifically investigate Goodpasture’s disease – 
in particular, work undertaken using rats enabled the autoimmune aspects of the 
disease by transfer of autoimmune serum to naïve animals and resultant disease in 
those animals (222, 223) and enabled the identification of specific autoantibodies 
(224).  These lines have also been used to explore the cryptic properties of the 
Goodpasture antigen (168, 223) and to therefore identify regions of immunological 
interest.  It has been possible to induce glomerulonephritis in some of these models 
(174, 224), but this required a longer time period of in vivo incubation prior to 
culling the animal and determination of glomeronephritis by histopathology. 
To summarise, a murine transgenic line with restricted class II repertoire 
(human HLA-DR15 molecule) and with or without α3(IV)NC1 protein expression 
was developed.  This transgenic murine DR15 A3v line is used to determine specific 
immune responses to a specific antigen and two specific genotypes were used: mouse 
class II KO, HLA-DRA and -DRB positive, α3 WT and mouse class II KO. HLA-
DRA and –DRB positive, α3 KO, in order to compare immune responses both in the 
presence and absence of tolerance.  This transgenic line could help elucidate 
mechanisms that are prevalent in the development of Goodpasture’s disease.  It is 
also possible that similar mechanisms may cause other autoimmune diseases with a 
known HLA-restriction, so this transgenic mouse line could indirectly assist in 




Chapter 5 – Antigen Preparation 
 
Chapter 5.1. - Introduction 
 
The main aim of my project was to determine immune responses to a specific 
antigen in the presence and absence of tolerance.  To do this, transgenic mouse lines, 
with and without tolerance, were immunised with Goodpasture antigen, the non-
collagenous domain of the α3 chain of type IV collagen (α3(IV)NC1) and the 
immune responses against overlapping peptide fragments of this protein were tested.  
In order to do this, sufficient quantities of qualitatively adequate protein were 
purified from recombinant bacteria or purified from human tissue.   
Numerous methods exist for producing recombinant protein, including plants 
(225), mammalian cells or insect cells in vitro (226), or using bacterial expression 
systems.  In addition, it is possible to extract the α3(IV)NC1 protein from native 
tissue in this case, kidney tissue.  This method of extracting protein does not produce 
recombinant proteins and produces the α3(IV)NC1 reasonably close to the native 
conformation.  All of the methods have advantages and disadvantages and these were 
considered before deciding which technique was most appropriate for this thesis. 
Producing this particular protein in a plant system has not been attempted as 
this technique would produce insufficient quality and quantity of the α3(IV)NC1 and 
would require considerable initial outlay making this technique uneconomical (225).  
This protein has been produced in a transfected insect cell system, both within my 
laboratory, and by other groups (227), but was relatively inefficient. Although this 
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method could produce sufficient protein for the experiments planned, it was decided 
that two other well-established methods would be more appropriate – extraction from 
tissue and use of transformed bacteria.  It was also decided to bring another well-
established method to this research group by developing an α3(IV)NC1–containing 
construct for transfecting the human embryonic kidney cell line.  Each of the chosen 
techniques has advantages and disadvantages which are discussed here in more 
detail. 
 
5.1.1. – Production of recombinant protein by bacteria 
A general method for enhanced production of recombinant protein by bacteria 
was first described in 1979 (228) and has since been used for mass production of 
protein.  This paper described a method to insert the lac Z promoter at any distance 
upstream of a cloned gene and produce large amounts of protein.  In this case, the cro 
protein (cro being expressed by the bacteriophage λ and inhibiting expression of 
some genes within the infected bacteria) was tested and this technique achieved up to 
190, 000 cro protein molecules per cell. 
There are additional factors to consider before making large amounts of 
recombinant protein.  These include assessing inconsistency within and between 
batches of proteins manufactured in this way.  For example, proteins produced in 
bacterial recombinant systems have a different conformation, both from the native 
protein, and from each preparation, which can yield multiple conformations.  This 
can also be the case when using the same transformed bacterial strain, under identical 
growth conditions, and the same glycerol stock.  This is due to the fundamental 
differences between bacterial and mammalian cell protein production mechanisms.  
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One of these major differences is that bacteria use different protein-folding 
chaperones with structural preferences that differ from mammalian protein-folding 
chaperones.  Another major difference is that bacteria do not possess the capability to 
form disulphide bonds between cysteine residues thus producing proteins with 
differing conformations.  The cysteine residues form disulphide bonds with other 
available cysteine residues irrespective how the native protein folds (229).  This also 
means that proteins with very specific conformational dependence are not suitable 
for production using this technique.  As an example, the α3(IV)NC1 contains 12 
cysteine residues, so while it is possible to produce this protein in a recombinant 
system, there is variation both within and between batches.  In addition, the 
recombinant bacterial proteins are not glycosylated as bacteria (with the exception of 
Campylobacter jejuni) do not have the cellular machinery to glycosylate the N-
terminal end of proteins (230).  All work undertaken in this thesis using recombinant 
α3(IV)NC1, has utilised protein produced within the same batch.  
Despite the differences in structure and protein conformation seen when using 
a bacterial production system, the use of bacteria to produce protein does have 
advantages.  In particular, bacterial cultures are easy to grow and maintain and there 
are multiple vectors available that can be inserted into the bacteria through a process 
called transformation.  These vectors can be manipulated to contain the gene which 
encodes for the protein of interest, and, depending on the vector used, the protein 
production (as in the construct used for transforming this bacterial stock) can be 
induced at specific time points.  This enables the production of large quantities of the 
protein in short periods of time and with relatively little cost.  The protein can also be 
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‘tagged’ to target its location to a specific region of the bacterium post-production, 
for example into the periplasm or into inclusion bodies.   
The bacterial strain BL-21 was used for α3(IV)NC1 production, a strain of E. 
coli particularly suited to expression of large amounts of foreign protein after 
successful transformation.  BL-21 bacteria do not express the Ion or the ompT 
proteases ensuring that the protein produced remains intact.  BL-21 E. coli also 
contains a mutant gene for lac permease (lacY) that ensures uniform entry of 
inducing agent (IPTG), thus producing an IPTG concentration-dependent 
homologous level of protein expression.   In this project, BL-21 bacteria were 
transformed using the plasmid pET25b containing a construct designed to direct 
expression of α3(IV)NC1 with a histidine tag, an HSV tag and a biotinylation tag 
(schematic of construct, Figure 5.1.1.).  This plasmid also contains various restriction 
sites that can be exploited to add extra components to the protein, should they be 
required (for example a fluorescent tag such as green or yellow fluorescent protein – 
GFP or YFP).  
While it is not the most common use for the technique, bacterial protein 
expression systems have been used for the production of protein for use in medical 
applications.  The most well known example of this is the production of insulin for 
the treatment of type I diabetes.  Other proteins produced in this way include rennin 
(or prochymosin, for use in culturing cheese) and production of the alkaline 
proteases used in dehairing hide to make leather.  Bacterial protein expression 
systems can also be used for production of enzymes and proteins for use in the food, 
leather and pharmaceutical industries (231-233).  
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Figure 5.1.1. – Schematic of the plasmid used to transform BL21 E. coli to produce 
recombinant α3(IV)NC1. 
This diagram illustrates a schematic of the plasmid used to transform the BL21 
strain of E. coli bacteria.  Induction with IPTG drives production of α3(IV)NC1 
within inclusion bodies.  The plasmid not only contains the human α3(IV)NC1 
sequence, but also has a histidine tag, an HSV tag, and a biotin sequence within the 
expression vector, pET25b.  The vector pET25b uses the highly specific T7 promoter 
system for production of protein and contains a second sequence under the control of 






This application of the technology to produce protein emphasises the advantage of 
producing large quantities of protein from a relatively small preparation.  However 
the extraction procedure is different to that used for extracting native antigen so the 
resultant protein preparations are not strictly comparable. 
 
5.1.2. - Extraction of antigen from tissue  
Extraction of antigen from human tissues has the distinct advantage that the 
protein conformation is in a similar conformation to the same protein found in the 
body.  However, there are also major disadvantages in terms of availability of tissues 
for protein extraction, and the yield of the protein extracted is usually small.  If the 
protein can be extracted from blood there is usually greater accessibility, but there is 
still a reliance on either volunteer donors or patients.  In this project, the best source 
of human protein was the kidney.  Although kidney samples were difficult to obtain, 
under certain circumstances it was possible to get human kidneys that had been 
rejected for use in transplant surgery by transplant surgeons (usually as result of 
damage to the blood vessels entering or exiting the organ (168, 179)), but offered for 
research by the donor.  Whilst not an ideal source of material, this was the only 
option available during the course of this project for native human antigen extraction.   
Another significant disadvantage in this system is the amount of time required 
to purify the tissue and to produce significant amounts of native protein.  As a result, 
it is a very expensive process.  The extraction process, as described in Chapter 2, is 
time consuming with manual disaggregation, sonication and enzymatic digestion 
steps.  None of these processes are known for being gentle, even if the destruction of 
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tissue is effective enough to extract the requisite protein by chromatographic means.  
In brief, the cortex was stripped off the whole kidney and sieved through specific 
sized filters to isolate whole glomeruli (179).  These were then sonicated to destroy 
the glomerular structure and frozen prior to enzymatic digestion of the suspension.  
The freezing also helped destroy the glomerular structure, while the collagenase 
treatment released the soluble non-collagenous domains.  
Column chromatography is a well-established technique for separating out 
proteins according to specific characteristics, be it size, charge, binding capability or 
binding to protein-specific immunoglobulins (224, 234).  In ion-exchange 
chromatography, the conditions can be manipulated such that the protein of interest 
remains bound to the column until it has neutral charge and is released from the 
column and collected.  In purifying the α3(IV)NC1 protein from human kidneys, two 
specific characteristics of the protein were exploited: the overall insolubility of the 
protein; and the high positive charge on the protein.  In order to elute this protein, a 
high salt concentration (1M) and high pH (pH 10), in concert, were required. 
These procedures, while allowing me to isolate some of the protein required for 
my project, may also have destroyed the protein structure by mechanical, sonic or 
enzymatic means prior to manipulation and purification using solutions in which it 
should retain its native conformation and properties.   However, if the structure had 
been completely destroyed, it would also follow that the properties associated with 
the protein in its native state would also be lost, so care must be taken when eluting 
the extracted protein, and the different fractions should be tested, by Western blot for 




5.1.3. – Production of recombinant protein by eukaryotic cells 
Production of recombinant protein by transfected mammalian cells reduces the 
problem of producing protein in an altered conformation, but may still result a in 
different glycosylation state and, for the α3(IV)NC1 protein, may produce issues 
with variable trimerisation since the most energy efficient state for the α3(IV)NC1 
protein is as part of a trimeric molecule.  This can be a major drawback to producing 
the protein satisfactorily in vitro.  The α3(IV)NC1 protein naturally interacts with 
other α chain proteins to maintain specific structural features.  As a result, when 
expressed in isolation by transfected mammalian cells, the α3(IV)NC1 protein may 
well have a different conformation compared to native proteins in conjunction with 
the relevant associated proteins.  Producing the α3(IV)NC1 domain alone will 
almost certainly result in some conformational differences, even if spontaneous 
polymerisation does not occur when the protein is secreted.   
The technique for producing proteins from overexpressing mammalian cells 
was first described in 1982 by Schumperli et al.. (235) and was developed in order to 
produce and purify more galactokinase within mammalian cell systems.  This was 
found to be a transient transfection (i.e. the protein is only expressed temporarily 
over a short period of time), but could be a stable transfection if an additional 
dominant genetic marker was cotransfected (for example, a gene for antibiotic 
resistance and the cells grown in the presence of that antibiotic).  Under these 
conditions the transfected mammalian cells have the potential to produce more 
protein than would be derived from native tissue, but in a similar conformation to 
native protein.  This technique neatly bridges bacterial recombinant expression 
systems and protein extraction from native tissue but also has drawbacks, in 
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particular the time involved in selecting the correctly transfected colony that 
produces sufficient protein.  This process involves the growth of the cells in selective 
media and testing the media (in this instance) for the secreted protein (as described in 
Chapter 2).  The most accurate way to do this is by Western blotting, using non-
denaturing gels, and probing the transferred proteins for the protein in question, but 
with fairly large numbers of supernatants to test, this can be relatively time-
consuming.  In addition, antibodies are very conformation-dependent, so to 
determine existence of correctly folded protein, a very conformation specific 
antibody should be used to screen the supernatants obtained from the transfected 
colonies.  There is another issue with detecting protein by Western blotting – some 
proteins change conformation when transferred to nitrocellulose.  In that situation, it 
has been shown that altering components of the transfer buffer or renaturing gels 
after electrophoresis can help reduce the detrimental effects on the protein (236).  It 
is also best to test supernatants without serum so small amounts of secreted protein 
can be detected.   
Since the α3(IV)NC1 protein retains the ability to bind patient sera on Western 
blots, this also enables rough quantitation of the amount of protein produced, 
provided a concentration curve of known amounts of protein is also probed on the 
same blot.  The protein concentration was also tested on a spectrophotometer to 
verify the concentration determined from the Western blot. 
As mentioned above, transfected cells can either show transient expression of 
protein, or form stable transfects and grow into a colony of successfully transfected 
cells that permanently express the protein.  As is also mentioned above, this depends 
on the other genes or proteins that are co-transfected with the gene of interest.  For 
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stable transfects, the plasmid construct usually also contains a gene for some method 
of selection, for example antibiotic resistance.  This enables selection of successfully 
transfected cells/ colonies and also ensures stable transfection of the plasmid 
construct as cells that express the antibiotic resistance genes have a survival 
advantage.   
 
Chapter 5.2. – Results 
 
5.2.1. – Production of recombinant α3 from bacteria 
Production of the recombinant protein involved growth of transformed BL21 
E. coli in a 2 litre culture, followed by extraction of the protein from the bacteria.  
This is described in full in Chapter 2, but in brief, involves growth of transformed 
bacteria to an optical density (OD550) of 0.6, and induction of protein expression with 
IPTG.  The bacteria were then pelleted and subjected to enzymatic digestion (using 
hen egg lysozyme, DNase, magnesium chloride and deoxycholic acid) in order to 
isolate the inclusion bodies and digest other cellular proteins.  Inclusion bodies are 
very robust so were then sonicated in the presence of detergent (Triton-X100) in 
order to lyse the bodies and release the induced α3(IV)NC1 protein.  This was then 
purified by ion-exchange chromatography and the fractions from each stage of the 
chromatography process were run on a 12% acrylamide gel prior to staining, to test 
for the presence of the α3(IV)NC1 protein.  This process is illustrated in Figure 
5.2.1A.  The second gel shown in this Figure shows serial dilutions of successfully 
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purified recombinant α3(IV)NC1 and compares it to the positive control of bovine 
testis.  As can be seen from the gel, this preparation is far more concentrated and was 
used as the recombinant α3(IV)NC1 in all subsequent work.  The total yield was 
130mg α3(IV)NC1 from 2 litres of bacterial culture.   
  
5.2.2. – Isolation of native α3 from tissue 
The recombinant protein preparation from bacteria which was used in 
subsequent experiments produced approximately 65mg/l LB broth recombinant 
human α3(IV)NC1, whereas α3(IV)NC1 extracted from the cortex of 5 human 
kidneys, not an insubstantial amount of tissue, resulted in a yield of only 1.2mg 
α3(IV)NC1 (for Western blots and chromatograms see Figures 5.2.2 and 5.2.3. 
respectively).  The total amount of collagen IV was not measured as this would have 
required lyophilising the solubilised NC1 domains and potentially damaging the 
protein in the process.  In addition, the protein is relatively insoluble.  Even without 
lyophilisation, the protein is only stable in 8M urea or 6M guanidine hydrochloride.  
Since the human α3(IV)NC1 protein should be soluble, this problem with getting the 
protein into suspension suggests different conformation and tertiary structure 





Figure 5.2.1. – Coomassie-stained gels showing purified recombinant human 
α3(IV)NC1 
Coomassie-stained gels showing α3(IV)NC1 purification using ion-exchange 
chromatography.  Figure A shows aliquots removed at different stages of purification 
and shows (from left) the post-load, subsequent wash steps (1-4) illustrating the dirty 
nature of the preparation, and the α3 protein eluting within 3 elution volumes (within 
box).  By comparison, Figure B shows a successfully purified, high yield 
preparation, in contrast with bovine testis (positive control).  This is the preparation 
used in all subsequent experiments.  Figure C illustrates the result of addition of 








Other ways to measure the total protein yield include weighing the whole 
contents and extrapolating the weight of the same volume of suspending buffer (a 
very classical method), or by measuring the actual protein concentration using 
commercially available kits that use spectrophotometry to measure a proportional 
colorimetric reaction to protein concentration.  Both of these methods are potentially 
useful, however, weighing the sample would not specifically measure the protein in 
solution, while the BCA assay would not give an accurate result due to the amount of 
urea also within the solution. 
The disparity in amounts of protein obtained can be partially explained by the 
fact that the α3(IV)NC1 chain is one of the more scarce collagen IV chains within 
the kidney, and a more accessible source of α3(IV)NC1 was very much required.  
The low yield also suggested loss of protein at a stage during the purification 
process.  This is most likely to be during the enzymatic digestion and wash stages 
prior to ion-exchange chromatographic purification.  These stages are the least 
regulated and defined, but in order to check this theory, tests would need to be run on 




Figure 5.2.2. – Stages in the purification of human α3 NC1 domains from kidneys.   
Figure A shows glomeruli isolated from human kidneys prior to extensive 
sonication, Figure B shows the resultant solution post-sonication (microscopic 
analysis, x400 magnification).  Figure C shows the purified material by coomassie 
gel, a Western blot and on a Western blot and coomassie gel overlay, from left to 
right is prestained marker ladder, post-collagenase digestion (lane 1) and pre-
collagenase digestion (lane 2).  The α3 protein should show two bands, a ~28kDa 
monomer and a ~50kDa dimer, but always runs heavier on SDS-PAGE gels, 
probably because the isolated α3(IV)NC1 protein is highly cationic and, once 
isolated, forms a different conformation to protect hydrophobic residues normally 














Figure 5.2.3. – Cation exchange chromatography profile for the isolation of the 
α3(IV)NC1 from collagenase digests of human kidney.  
This line chart shows the pH and salt gradients and the UV trace for protein as 
used in the isolation of the α3(IV)NC1 protein.  The salt gradient is plotted in blue, 
the pH gradient is plotted in green, the UV trace is pink, while fraction is plotted 
along the X axis.  Most of the protein is eluted from the column during the initial 
wash stages and during the pH gradient, however the NC1 domain of the human α3 
chain is highly cationic so is only eluted during a high pH and a high salt 



















Figure 5.2.4. – Western blots of fractions following cation-exchange 
chromatography for the human α3(IV)NC1 domain. 
These gels and blots compare unpurified NC1 domains with various protein 
containing fractions following cation-exchange chromatography.  As can be seen in 
Figures A (coomassie) and B (Western blot), some fractions contained protein but 
tested negative for α3(IV)NC1, while Figures C (coomassie) and D (Western blot) 
show 2 fractions (24 and 25) positive for reasonably pure and much cleaner 
α3(IV)NC1 domains (inside boxes, equivalent to volumes 44-49ml on 














5.2.3. – Production of α3 from mammalian cells 
This knowledge and data emphasises the application of the third technique 
illustrated in the schematic in Figure 5.2.4. – transfection of mammalian cells.  
Although the yield of protein may not be as high as from a bacterial system, the 
overall conformation of the protein is more likely to be in the native state making 
any comparisons to the human disease processes, as in the case of this thesis, more 
relevant.  It is, however more difficult to purify the protein and to maintain the cell 
line producing it effectively. 
Figure 5.2.5. shows a schematic of the construct used in tranfections to produce 
the Goodpasture antigen in human embryonic kidney cells.  The vector used 
(pFLAG-CMV-3) is a commercially available vector with a secretion sequence on 
the N-terminal end of the protein (Sigma).  Although the insert was more difficult to 
source, within the laboratory there were two constructs containing the sequence for 
α3(IV)NC1 named P+ and P- respectively.   
P+ is the α3(IV)NC1 domain as found in patients with Goodpasture’s disease 
as well as normal controls and is named for the presence of a Pst1 restriction enzyme 
site part way through the sequence.  The P- construct lacks this Pst1 restriction site.   
I tried amplifying each construct by PCR, but was only able to amplify the P- insert 
successfully.  This insert was then ligated into the pFLAG-CMV-3 vector in 
preparation for transfection into HEK293 cells (a human embryonic kidney cell line).   
The transfection process was performed 3 times but failed to produce a cell line 
capable of expressing the α3(IV)NC1 protein in secreted form. 
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Figure 5.2.5. – Schematic of the construct used to transfect HEK293 cells and induce 
α3 production. 
This schematic shows the pFLAG-CMV-3 plasmid with the α3(IV)NC1 P- 
sequence insert.  The plasmid contains a FLAG sequence (a marker tag), a gene for 
geneticin resistance (Neomycin) and a tag (PPTLS) that ensures extracellular 
secretion of the protein, when produced by a cell.  The α3 gene is controlled by a 
CMV promoter, while the gene for neomycin resistance is controlled by an SV40 
promoter.  Shown in blue is the start methionine residue, while restriction sites from 
within the multiple cloning site and used to insert the α3(IV)NC1 P- sequence are 


















5.3. – Discussion 
 
During the course of this project, particularly during the production of antigen 
for experimental purposes, there were many problems to overcome.  In terms of the 
bacterial recombinant protein, there were problems with yield and there was definite 
inconsistency between batches of α3(IV)NC1 produced by E. coli.  
In obtaining human α3(IV)NC1 domains from tissue, there were different 
obstacles to overcome – the major one being to minimise loss of protein throughout 
the extraction procedure.  Losses become more significant when a dilute solution is 
used in multiple steps.  In this procedure, the early steps involving sieving the tissue, 
sonication and enzymatic digestion of the sieved protein mixture produced a very 
viscous mixture that also increased the likelihood of loss at each step.  As shown in 
the chromatogram (Figure 5.2.4.), there were very low levels of α3(IV)NC1 present 
in the solution.  This may be due to availability of the protein within the tissue; the 
α3(IV) is one of the more scarce type IV collagen chains, so less would be present in 
any human tissue-derived and collagenase-digested solution.  Additionally, the losses 
described above would not just affect the α3(IV)NC1 domains, but all the α chains 
isolated from the kidney tissue.  This is most likely to be proportional, so the 
proportion of the α3(IV)NC1 isolated, when compared to the other protein peaks on 
the chromatogram, is likely to be accurate.  However, this was still a very low yield 
(1.2mg) compared to the amount of protein isolated in earlier peaks of the cation-
exchange process (not measured, but illustrated in Figure 5.2.3.). 
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The technique used to purify the α3(IV)NC1 protein from human tissue had 
not changed significantly from the method published by Spiro in 1967 whose group 
studied the chemical composition of the glomerular basement membrane (179).  
Since 1967, there have been several endorsements of this method (237-240) although 
there are associated difficulties with obtaining large amounts of human tissue.  
Newer techniques for larger scale production of the α3(IV)NC1 protein including the 
production of recombinant protein by bacteria (241) and transfected cell lines that 
secrete the α3(IV)NC1 protein into the surrounding media (166, 167) are quicker and 
less expensive in terms of reagents and starting material.  
Problems with yield of the α3(IV)NC1 protein from human tissue and high 
levels of variation between concentrations of recombinant protein batches produced 
by E. coli emphasised the need for a reliable and consistent source of the α3(IV)NC1 
protein for our group.  In order to produce the protein, developing a transfected 
eukaryotic cell line that would secrete α3(IV)NC1 in a comparable  conformation to 
native protein in the native state was attempted.  There were two possibilities for 
this: either transfection of an insect cell line to produce the α3(IV)NC1 protein, or   
transfection of a mammalian cell line.  The mammalian cell route was chosen, partly 
to utilise skills already available in mammalian cell culture, but also due to the 
number of papers published that used α3(IV)NC1 and other α(IV) chains produced 
in this way (166, 242, 243), plus the ready availability of reagents, suitable 
equipment and expertise within the research centre.  While initial attempts at 
transfection were unsuccessful, the construct was produced in sufficient quantity and 
frozen so it would be possible for new attempts to be made in the future and could be 
a valuable resource for the group.   
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The purification techniques used during the antigen preparation mainly 
involved exploiting specific characteristics of the protein such that it would be the 
only protein isolated within a specific fraction.  In particular, the high positive charge 
on the α3(IV)NC1 protein enabled isolation by cation-exchange chromatography.  
While this does enable very specific isolation and purification, the volume in which 
the purified protein is eluted can be much greater than the original volume depending 
on the column volume.  This lead to a need for concentrating the purified protein, 
either by ethanol precipitation, using concentrator spin columns (molecules above a 
certain molecular weight are retained by a filter) or by using dialysis tubing on dry 
polyethylene glycol, which then absorbs water from the protein solution.  This is 
another area in which protein losses can occur, through inability to resuspend 
precipitated protein, the protein sticking to the filter or sides of the spin column or 
through the protein sticking to the dialysis tubing.  In addition, the protein aggregates 
and gets dehydrated (particularly while using dialysis tubing), which will also 
encourage formation of protein complexes and encourage the protein to protect areas 
of importance, thus reducing the possibility of a single specific conformation.  In this 
project, ethanol precipitation has predominantly been used as this minimises losses 
through use of the same tube for both precipitation and resuspension in a smaller 
volume.  It does, however, require the protein to have been frozen in the ethanol 
mixture and could cause conformational defects or protein degradation. 
Other types of chromatography, for example size-exclusion or antibody-
binding chromatography were also options. The former would have resulted in less 
specifically pure antigen preparations due to selection by size rather than charge and 
was rejected for this reason.  The latter would have involved the time consuming 
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process of purifying α3(IV)NC1-specific antibody from patient sera by 
chromatography or buying a commercial monoclonal antibody to the α3(IV)NC1, in 
sufficient quantities to enable beads to have been labelled with the purified antibody, 
packed into a column and to bind the recombinant α3(IV)NC1 protein.  This 
technique was rejected as although it would produce a very pure protein preparation, 
the time involved to produce the column was not viable in a project with a very 
limited time frame.  It would also have required a significant amount of Goodpasture 
patient sera; this is a scarce and valuable resource as it has to be obtained prior to 
immunosuppressive treatment so the technique was not deemed economical in either 
time or reagents. 
An alternative method of purifying the protein includes extracting from an 
acrylamide gel.  This method separates the protein by size within the gel matrix so 
the specific gel band containing the protein can be isolated.  The gel can then be 
denatured and the protein extracted.  This method resulted in a large amount of loss 
and was not suitable for use on bands containing very little protein.  Certainly, bands 
that contained so little protein they were undetectable by coomassie staining, proved 
impossible to purify in this way (data not shown).  The actual extraction method also 
required some harsh chemicals (including acetonitrile and iodoacetamide) and 
resulted in a lyophilised protein preparation.  This method is more suitable for 
protein fragments undergoing mass spectroscopy and it proved very difficult to 
isolate sufficient protein for any experiments. 
Overall, producing the α3(IV)NC1 protein in transformed bacteria provided 
the greatest quantities of protein and this was able to bind antibodies in Goodpasture 
patient sera when immobilised on nitrocellulose membranes.  The protein isolated 
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from human tissue was most likely in as close to the native conformation as possible, 
but this was very scarce and when purified resulted in a very low concentration and 
was insufficient for use in multiple experiments.  The final method, transfection of 
eukaryotic cells to secrete the protein, was unsuccessful.  Had it been successful, it 
would have most likely produced protein at concentrations greater than the protein 
extracted from human tissue, but lower than the concentrations produced by the 
recombinant bacteria.  However, this would be more likely to be in a conformation  
similar to the native protein.  None of these methods would produce the protein in 
exactly the same conformation as would exist in situ in tissue, because of the close 
interactions between the α3(IV)NC1 domain and the NC1 domains of the other two 
α chains in the whole type IV collagen chain, α4(IV)NC1 and α5(IV)NC1.  These 
effectively wrap around each other so removal of one chain or separation of the three 
would result in the isolated protein folding differently to protect any hydrophobic 
regions within the exposed protein. 
To summarise, three methods of producing the Goodpasture antigen 
(α3(IV)NC1) in sufficient quantities for experimental purposes were explored: 
bacterial recombinant expression systems, extraction of protein from human tissue 
and a mammalian recombinant protein expression system.   Of these, extraction of 
the protein from human tissue produced a very low yield of protein and was only 
used in very limited experiments described in Chapter 7, while preliminary 
transformation experiments using the mammalian recombinant  protein expression 
system did not yield measurable protein.  However, the bacterial recombinant system 
produced the greatest yield of α3(IV)NC1 and this was subsequently used for the 
majority of the experiments described within this thesis. 
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Chapter 6 - α3 wild type mouse responses to recombinant 
human α3 
 
6.1. – Introduction 
 
Experiments described in this chapter were designed to examine tolerance to 
α3(IV)NC1 in mice.  Work in man has indicated that T cells specific for α3(IV)NC1 
exist in healthy individuals, but in health they either do not ‘see’ (are ignorant of) 
endogenous α3(IV)NC1, or more likely they respond with a regulatory profile.  It 
was hypothesised that in the latter but not the former case, immunisation with a 
sequence altered form of α3(IV)NC1 would not yield a T cell response as any T cells 
responding to the altered part of the molecule would be subject to regulation by T 
cells recognising the greater proportion of self α3(IV)NC1.  To examine this 
hypothesis, DR15-expressing α3(IV)NC1-wild type mice were immunised with 
human α3(IV)NC1 emulsified with strong adjuvant.  The mouse and human forms of 
α3(IV)NC1 are 92% sequence homologous (244) so it was predicted that 
immunization should yield no response at all if regulation was dominant, or a T cell 
response directed against the few areas of sequence dissimilarity if regulation was 
not dominant. 
There are several ways to test T cell responses to antigen.  These can include 
directly measuring T cell proliferation by determining the level of incorporation of 
tritiated thymidine (245).  A more recent development is to measure uptake of 
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bromodeoxyuridine (BrdU), a thymidine analogue, which can then be detected by 
specific antibodies and the concentrations determined by spectrophotometry (246).  
There are also indirect (in that it does not allow for direct quantitation of activation 
of cells by determining proliferation and clonal expansion) ways of detecting T cells 
responses by measuring cytokine release in response to stimulation, for example IL-
2, a cytokine released by stimulated T cells to promote proliferation (247), and 
interferon γ (IFNγ) which stimulates cytolytic T cell activity (248). 
In order to characterise T cell responses in mice, a classical method to 
determine T cell proliferative responses was used.  T cells were extracted and 
stimulated and the level of response by the T cell was determined by uptake of 
tritiated-thymidine into the expanding T cell population.  This method was used 
partly for convenience – all reagents and equipment were within easy reach of the 
laboratory – and partly because other alternatives would have required more setting 
up and equipment not available to the lab at the time. 
Lymphocyte stimulation assays have been used to determine T cell 
proliferative responses for many years, initially to determine the effects of different 
molecules on the immune system in vitro, and subsequently for more specific 
purposes.  One publication of interest to me was the work of Abdel-Nour et al., who 
derived T cell lines from the synovial joint fluid of patients with rheumatoid arthritis.  
These cell lines were then used to characterise the immune responses to collagen II, 
in the presence or absence of EBV transformed B cells.  This work suggested that the 
synovial fluid itself contained a collagen II fragment that could only be presented by 
B cells, and that autologous B cells were also able to present the stimulatory 
fragment (249).  The experiments described within this thesis were designed to 
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determine whether any specific fragments of the Goodpasture autoantigen were 
presented by B cells and if so, which induced the greatest T cell response.  The work 
by Abdel-Nour et al. proved useful in determining how to undertake certain practical 
aspects of the project. 
 
6.2. - Results 
 
6.2.1. – Immune responses to α3 peptides in HLA DR15 positive mice 
The overall experimental design used in this thesis is illustrated in Figure 6.2.1. 
and described in full in Chapter 2.  In brief, the procedure involved emulsifying the 
antigen in complete Freund’s adjuvant (CFA) and administering the solution to the 
mouse in subcutaneous injections.  This was repeated a week later using antigen 
emulsified in incomplete Freund’s adjuvant (250), before culling the animal after 
another week.  Lymph nodes were extracted and disaggregated, the resultant cells 
were washed well with media before being counted and set up against a panel of 
overlapping 15mer peptides encompassing the entire sequence of the α3(IV)NC1 
domain.  After 4 days, the cells were pulsed with tritiated thymidine for 18h before 
harvesting and being read on a β-counter.  This data was generated as calculated 
counts per minute (ccpm), but this neither normalises the data nor makes it directly 
comparable with other experiments of the same design.  In order to compare the 
results from different mice, the data needed to be converted into a form that is 
comparable between samples. The calculation for stimulation index effectively 
158 
” 





































normalises the data as it takes into account both the background radiation levels in 
media and unstimulated cells: 
 
SI =          (mean ccpm sample – mean ccpm media only) 
 (mean ccpm unstimulated cells – mean ccpm media only)  
 
This equation gives a ratio value and, as such, enables direct comparison between 
samples in individual mice, for example the effect of peptide α3(IV)NC1 136-150 in 
each mouse.  In published experiments, there is a threshold level set that is a level, 
chosen as significant, of stimulation within that sample, compared to background.  
This is usually 2.5 or 3, for these experiments the threshold was set at 3 and is 
marked with a thick black line on all data presented in the form of a stimulation 
index.  This threshold translates to the point at which there is a 3-fold increase in T 
cell proliferation above background. 
Data sets are shown for all of the 10 α3WT mice studied.  There is no 
significant immune response to any of the overlapping peptide sequences.  Figures 
6.2.2A-J show the peptide stimulant on the X axis, while the calculated stimulation 
index is plotted, for each peptide, on the Y axis.  Although there is peptide to peptide 
variation, there are minimal responses to whole α3 (example shown in Figure 
6.2.3A) and an expected high response to the T cell mitogen concalavalin A 
(example shown in Figure 6.2.3B).  Ovalbumin was used as a negative control for 
recall responses – the T cells would not have “seen” fragments of the ovalbumin 
molecule as it is foreign to mice.  Therefore, the T cells should not proliferate in 
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response to it.  Overall, there is no consistent response with a stimulation index 
greater than 3 to any of the overlapping α3(IV)NC1 peptides. 
 
6.2.2. – Summary of data from α3 immunised DR15 positive mice 
Figure 6.2.4. shows a chart in which the T cell responses to each α3(IV)NC1 
peptide of all 10 mice have been averaged.   Taking the minimum threshold for 
immune response to be a stimulation index of 3, even whole antigen barely reaches 
the value.  The positive control concalavalin A (conA, a T cell mitogen and lectin 
derived from Canavalia ensiformis or the Jack bean) usually produced a response 
measured as a stimulation index of more than 100 (7/10).  This shows that the T cells 
from these mice were able to proliferate, the lack of proliferative response to 
individual α3(IVNC1 domain peptides is indicative of a lack of overall immune 
response to the α3.  This could be due to the cells requiring a combination of 
peptides for stimulation, so two different peptides stimulate two different cells that 
can then proliferate, resulting in a varied T cell population capable of responses to 
more than one specific epitope on an antigen.  Alternatively, this could be due to a 
single cell being stimulated by more than one peptide (epitope spreading).  There 
were limited responses seen to whole recombinant antigen, and these could be due to 
a bacterial contaminant in the rhα3 preparation used to immunise the mouse and then 
restimulate the cells.  Of these scenarios, the latter is more likely, especially as data 
discussed in Chapter 5 (shown in Figure 5.2.1B) shows that the preparation 
contained low level contamination with presumed bacterial protein.  This conclusion 
is also somewhat supported by the lack of immune response to α3(IV)NC1 peptides.  
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However, the recombinant antigen preparation used for all the experiments described 
within this thesis was maintained in 8M urea solution.  This solution without antigen 
could be incredibly toxic to cells, so it was decided to use a titration curve to 
determine the possible impact of the urea in cell culture.  To do this, T cells were 
isolated from a naïve DR15 α3WT mouse and  set up with conA, or conA plus 
various concentrations of urea (0.0188M, 0.188M and 1.88M).  The data obtained 
are shown both as uptake of tritiated thymidine (Figure 6.2.5A) and expressed as a 
stimulation index (Figure 6.2.5B).  This work showed that a relatively small amount 
of urea (0.0188M, the final concentration with the cells if 10µg recombinant α3 
solution were to be added to the well) had no significant impact on T cell 
proliferation in response to conA.  The difference in proliferative responses was very 
significant in the presence of 0.188M urea – the concentration with the cells upon 
addition of 100µg recombinant α3.  As a result of these data, it was decided to use 
50µg α3 as a control within the T cell recall response assays, since previous work 
had shown that T cells were unable to respond to as little as 10µg recombinant α3 (L 





Figure 6.2.2. – Stimulation profiles from WT mice immunised with rhα3, tested in 
vitro against overlapping peptide fragments of human α3(IV)NC1.   
Figures A-J show the data obtained from the T cell proliferative responses of  
10 α3WT DR15-positive mice, in response to overlapping 15mers of the α3(IV)NC1 
molecule, expressed as a stimulation index.  The threshold at which there is 
significant stimulation above background, a stimulation index of 3, is marked on 






















Figure 6.2.2. – Stimulation profiles from WT mice immunised with rhα3, tested in 

























Figure 6.2.2. – Plots showing the stimulation index for each peptide and for each 






Figure 6.2.3. – Example plots showing T cell responses to control stimulants. 
These data are examples of the controls included within each experiment (in 
this instance, n=1).  Figure 6.2.3A shows example plots (calculated as stimulation 
index) of the negative control ovalbumin and whole recombinant α3(IV)NC1, 
illustrating that there is no T cell proliferative response to these proteins.  Figure 
6.2.3B illustrates example plots of ovalbumin compared with conA.  These plots 
show that conA clearly stimulates the T cells to proliferate, compared with 
ovalbumin.  As with previous stimulation index data, the threshold of 3 is marked 







 Figure 6.2.4. – Summary chart plotting peptide against mean stimulation index for 
all mice studied.   
This chart shows the average SI obtained from 10 mice for each peptide.   As 
can be seen, none of the peptides used in the restimulation assay resulted in a 
proliferative response with a stimulation index greater than 3 (marked with a bold 
black line).  The error bars show the standard deviation above and below the mean 






 Figure 6.2.5. – T cell proliferative responses to conA in the presence of urea 
T cells from α3WT mice were stimulated with conA in the presence of 
increasing concentrations of urea (corresponding to 10, 100 and 1000µg recombinant 
human α3(IV)NC1.  Figure 6.2.5A shows proliferative responses expressed as 
uptake of tritiated thymidine (ccpm), while Figure 6.2.5B shows the same data 
expressed as a stimulation index.  As with previously shown data, a stimulation 








6.2.3. – DR15 positive mice do generate normal immune responses 
Since these experiments showed a general lack of reactivity to α3, it was 
decided to test the experimental system to an antigen expected to evoke T cell 
responses, in order to rule out any methodological explanations for the apparent non-
responsiveness of the mice. To do this, the same experimental design as for testing 
the immune responses to α3(IV)NC1 was used, but mouse class II null, HLA DR15 
positive, α3WT mice were immunised with ovalbumin (approximately 38% 
sequence homology with mouse albumin).  The cells were extracted from the lymph 
nodes using the same technique as for the α3(IV)NC1 responses, but set up against a 
more limited selection of stimulants.  
For this experiment, Con A was used as a positive control, the peptide 
sequence known as AS345 (α3(IV)NC1 65- 82 with an additional serine at the start 
of the selected sequence) was used as a negative control, ovalbumin was tested and 
rhα3 was also tested at three different concentrations.   
The sole response was to ovalbumin (SI ≈ 45, N=2).  This was surprising as 
Con A would be expected to produce a strong mitogenic response, but subsequent 
testing showed that the Con A used in these experiments was defective.  A new batch 
tested on naïve α3WT mice was found to produce good proliferative responses. This 
experiment was designed to test the immune responses to exogenous antigen, so the 
absence of a mitogenic control would only have been an problem if the mice showed 
no immune response to the foreign antigen. 
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Figure 6.2.6. – Mice immunised with ovalbumin were capable of generating an 
immune response.   
Figure A shows recall responses of lymphocytes from mice primed by 
immunisation with ovalbumin (background subtracted), while Figure B shows the 
same data normalised and expressed as a stimulation index.  In these mice, 
ovalbumin produced a T cell proliferative response, while rhα3 did not.  Con A did 
not stimulate a T cell proliferative response, but it was subsequently found that the 
con A preparation used in this experiment had suffered freeze-thaw damage.  An 
experiment using naïve mouse lymphocytes showed that a new batch of Con A was 
















 Figure 6.2.7. – Haematoxylin and eosin stained kidney sections from naïve and 
immunised mice.   
These photos show naive mouse kidney (Figure A), ovalbumin immunised 
mouse kidney (Figure B) and rhα3 immunised mouse kidney (Figure C).  As is 
shown, all glomeruli look normal irrespective of immunisation schedule.  Images 




   
 
 
Figure A – Naïve Mouse Figure B - Ovalbumin 
Figure C - rhα3 
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6.2.4. – Comparing morphology of immunised and unimmunised kidneys 
As well as testing for immune responses, evidence of morphological and 
potentially pathological responses to rhα3 within the kidney itself were studied.  
Effectively, evidence of immune injury in the kidney was investigated as this may be 
more sensitive to low level responses (as observed in Goodpasture’s disease in man) 
(251).  The kidneys from each immunised mouse were harvested and fixed in 10% 
neutral formalin, prior to paraffin embedding and sectioning.  By staining the 
sections with haematoxylin and eosin, the morphology of kidneys from immunised 
and naive control mice could be compared (Figure 6.2.7.).  This data showed that 
kidneys harvested from immunised mice did not show any morphological changes 
following immunisation, when compared with kidney sections from an unimmunised 
mouse.  However, the presence of anti-glomerular beasment membrane antibodies 
within the sections was not investigated due to time constraints. 
 
6.3. - Discussion 
 
The experiments described above form two sets of data.  The first set, testing 
the recall responses to rhα3 showed few immune responses to the α3(IV)NC1 
peptides, while the second set of data, showing the histology of the kidney following 
immunisations showed no obvious pathology.  Together, these suggest effective self-
tolerance dominates, despite some differences between human and mouse 
α3(IV)NC1 sequences (92% homology). 
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Despite a strongly stimulatory immunisation regime (one immunisation of 
antigen emulsified in complete Freund’s adjuvant, followed a week later by a booster 
immunisation for antigen emulsified in incomplete Freund’s adjuvant), mice with an 
intact α3 gene do not generate T cells that proliferate in response to any part of 
human α3 NC1 domain. The most likely explanation is tolerance mechanisms that 
prevent responses to mouse α3(IV)NC1 are able to extend tolerance to human 
α3(IV)NC1 despite its sequence dissimilarities.  The mouse α3(IV)NC1 domain has 
92% homology with human, but this degree of homology does not prevent T cell 
responses to other homologues of self proteins in mice.  Two such examples include 
collagen II and rheumatoid arthritis in which there is 95% protein homology between 
mouse and human protein sequences (252), and myelin basic protein and 
experimental autoimmune encephalomyelitis (akin to human multiple sclerosis) in 
which there is 92% protein homology between the mouse and human sequences 
(253).   Since these proteins show high levels of homology but can still induce 
autoimmunity, it suggests that the mechanisms preventing immune responses to 
α3(IV)NC1 are regulatory, rather than owing to sequence homology. 
For the experiments described, the peptides used were synthetic and arrived 
lyophilised and were stored in DMSO prior to use.  If the immune responses seen in 
the wells containing whole antigen were due to antigen recognition, the responses 
would also occur in wells containing pure fragments of antigen if all possible 
epitopes were represented.  Instead, because the peptides were not produced by 
bacteria, they are free from any additional bacterial proteins that could induce an 
immune response in the T cells.  This suggests that the T cell response to whole 
α3(IV)NC1 may be due to bacterial contaminants within the preparation. 
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In addition, the different conformation of the immunising antigen (rhα3) 
compared with native human antigen (huα3) is an issue.  The experimental design 
does not differentiate between B cell epitopes, which are conformation dependent.  
While my experiment does rely on there being APCs present in the lymph nodes to 
process and present the antigen from the surrounding media in vitro, these APCs do 
not have to be B cells and are mostly likely to be a mixture of B cells, dendritic cells 
and macrophages, owing to the relatively crude preparation of cells used as the 
source material.  This implies that the specific processing events vary and that 
different antigenic fragments are presented. 
The main result seen from my experiments as described above, is that 
immunisation with rhα3(IV)NC1 in mice expressing mouse α3(IV), does not result 
in a measurable immune response to α3(IV)NC1 peptides.  Importantly, this is not 
due to a general inability of the mice to generate a T-cell mediated immune response, 
as they are capable of generating a response to a foreign antigen ovalbumin (only 
38% sequence homology found between ovalbumin and mouse albumin) (section 
6.2.3.) and also to intact α3(IV)NC1 bacterial products.  This supports the hypothesis 
that the deficit of immune response may be due to tolerance mechanisms. 
This overall conclusion from the work in this chapter is not entirely 
unexpected, but it was anticipated that there would be some response to less 
homologous regions of the α3(IV)NC1 protein.  Other experiments have utilised 
ovalbumin (ovalbumin is foreign to mice and has 60% protein sequence homology 
(BLAST) with serpin B1, and 38% homology with mouse albumin) and tested 
immune responses to the protein compared with bovine serum albumin  and hen egg 
lysosomes (254), and have also used ovalbumin as a surface marker for targeted 
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destruction of solid tumours (247).  In comparison to ovalbumin, there is a higher 
percentage of homology between the human and mouse α3(IV)NC1 (92%) (244) so 
tolerance to homologous regions would be expected, however, even in areas with 
less homology, there was no measurable immune response.  This suggests that 
tolerance is induced to selected α3(IV) peptide fragments in the thymus, or within 
the periphery, which happen to be homologous with those derived from the human 
α3(IV)NC1 sequence.  Alternative explanations include that tolerance is induced to 
the complete α3(IV)NC1 protein, irrespective of peptide presentation or that 
tolerance is strictly regulated by T cells capable of recognising similar epitopes from 
both man and mouse α3(IV)NC1.  Of these hypotheses, the former is more likely.   
Many previous experiments have involved looking at peptide presentation and 
T cell stimulation in transgenic specific gene knock-out animals, as a way of 
circumventing tolerance.  This system ensures that the animal effectively treats the 
protein as a foreign antigen.  Other groups have approached studying tolerance by 
trying to break tolerance to a specific protein.  Breaking tolerance is notoriously 
difficult.  There is a lot of research ongoing to find ways to break tolerance and 
enable tumour destruction or conversely, to induce tolerance in autoimmune disease 
or to prevent transplant rejection.  Methods tested for their ability to break tolerance 
have included even more severe immunisation regimes, immunising with anti-CD40 
to increase CTL responses and immunising with sub-dominant peptides to which 
tolerance may be less secure (section 1.4.) (122).  Grossmann et al. compared these 
three methods of breaking immunological tolerance to prostate-associated antigens 
(PAA) in prostate cancer, and found that while the first two resulted in immune 
responses, neither broke tolerance, but the last both induced an immune response and 
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broke tolerance.  An equivalent experiment to study subdominant immune responses 
would have been to immunise the DR15 positive α3(IV)NC1 WT mice with 
α3(IV)NC1 peptides, isolate the T cells and assess the resultant immune responses.  
The work by Grossman et al. suggests that not all fragments of an antigen are 
presented in the thymus and further supports the hypothesis that tolerance is induced 
to the major naturally processed and immunodominant peptides presented by thymic 
epithelial cells (136).  In this context, only the immunodominant peptides from 
common proteins are presented to T cells during their maturation process, so 
tolerance is not induced to subdominantly presented peptides and therefore the 
subdominant peptides are a viable proposition for breaking tolerance to a specific 
protein.  This approach is currently under investigation as a way to induce an 
immune response to various cancers, all of which have some immune privileges 
(255) so are unable to be detected by the immune system.  This has been shown in a 
disparate group of cancers including prostate, leukaemia and some solid lymphatic 
tumours (122, 256, 257).  Despite investigating how to break tolerance and enable 
the immune system to destroy cancers, this is a highly unnatural sequence of events.  
None of the methods described for potentially breaking tolerance in laboratory 
models is likely to be a cause of autoimmunity in humans.  These methods could, 
however, lead to valuable information regarding the mechanisms that implement 
tolerance.  Two very specific and contrasting uses for this information would include 
how to up-regulate tolerance in order to prevent transplant rejection, or how to 
specifically down-regulate the effect of the same mechanisms to produce an immune 




The aim of this chapter was to study specificity of responses to α3 in presence 
of tolerance, although tolerance may be incomplete due to sequence differences 
(human vs mouse).  In this respect, it was determined that despite differences in the 
α3(IV)NC1 protein sequence between mice and humans, the overall tolerance to 
mouse α3(IV)NC1 is sufficient to prevent T cell proliferative responses to human 
α3(IV)NC1.  The differences between the human and mouse α3(IV)NC1 sequences 
are compared in Figure 6.3.1..  The mouse and human α3(IV)NC1 sequences are 
very similar (92% homology (244)).  Perhaps a better way to compare sequences 
with regard to their capacity to evoke T cell responses is to compare their content of 
sequences with higher affinity for HLA class II molecules that might act as T cell 
epitopes. 
These results suggest that there is secure tolerance to constitutively presented 
or most abundantly presented peptides.  Additional work undertaken within the 
laboratory used a different peptide, α3(IV)NC1 65-82, shown to occasionally elicit 
an immune response in Goodpasture patients (ex vivo), to immunise DR15 α3 KO 
mice.  These experiments were unable to detect a T cell proliferative response to this 
peptide (data not shown), despite showing a response to α3(IV)NC1 136-150.  This 
could be due to the peptide selected (α3(IV)NC1 65-82) being only able to generate 
a very low immune response generally.  Using an online algorithm, the predicted 
IC50 for this peptide is 9844.44nM, from input of the sequence into the website, 
http://tools.immuneepitope.org/tools/matrix/iedb_input?matrixClass=II. 
This is a tool that analyses the sequence for binding capacity to the specific 
MHC class II molecule and can be used to predict the concentration at which 50% of 
the MHC class II molecules are occupied (or inhibited) by the peptide fragment, the 
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IC50 (258-260).  Other peptides from the α3(IV)NC1 sequence may produce a 
greater response and prove more suitable for use in breaking tolerance.  It is not 
entirely surprising that the prominent HLA-DR15 epitopes within the sequences are 
not only similar, but overlap between the sequences.  The α3(IV)NC1 protein 
sequences illustrated (Figure 6.3.1.) were aligned using clustalX software (261, 262) 
and epitope binding sequences calculated using the online algorithm described above 
(258-260).  The epitopes show marked similarity between mouse and human binding 
regions, but also illustrates the overlap within the regions and show areas of the 
protein with multiple binding epitopes with different binding affinities for HLA-
DR15.  The Figure shows the top 10 binding epitopes for HLA-DR15 along the 
sequence of the α3(IV)NC1 proteins, estimated using the online HLA binding 
algorithm described previously, both for mouse and human proteins, enabling 
comparison between the two.  These similarities support the data shown in within 
this chapter, whereby mice with tolerance to murine α3(IV)NC1 did not produce 
immune responses to human α3(IV)NC1.  They also support the finding the 
α3(IV)NC1 136-150 is the immunodominant peptide as both the murine and human 
epitope with highest binding affinity bind within this region, while there are 
additional epitopes nearby. 
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Figure 6.3.1. – HLA-DR15 binding motifs on mouse and human α3(IV)NC1 protein 
sequences 
This Figure shows the protein sequences of mouse (top, mus) and human 
(bottom, homo) α3(IV)NC1, aligned using clustal software.  Conserved residues are 
marked *, residues marked : have similar properties and those marked . are less 
similar.  In addition, the 10 epitopes with the highest affinity for HLA-DR15 from 
each sequence are marked with lines highlighting the specific sequence (blue, top 
shows mouse epitopes; red, bottom shows human epitopes).  These lines are thickest 
where there is highest binding affinity (IC50 = 2.46nM for both mouse and human 
epitopes).  As can be seen, there is considerable overlap for DR15 specific binding 





In this thesis, the classical experimental design of immunisation, boost, recall 
response has been maintained, but other work has exploited new technology to 
improve the overall safety of the recall responses assay.  With concerns about the 
future impact on both the researchers and the surrounding environment, alternatives 
to radioactivity have been sought.  Of particular interest is the substance 
bromodeoxyuridine or BrdU, a fluorescent uridine analogue that can be incorporated 
into cells in a similar way to tritiated thymidine.  BrdU can also be administered 
directly into cells or animals, enabling direct imaging of specific events and regions, 
conferring a significant advantage to the molecule over the more traditional 
radioisotopes.  Again, this has been used in classical experiments to determine 
specific immune responses to processed proteins in disease conditions, for example 
the effect of HSP65 in Takayasu’s Arteritis (263), but has also been used to label 
cells for flow cytometry, and to track proteins and cell types in vivo. In doing so, it 
enabled the determination of key regulatory molecules for antigen-induced T cell 
activation and proliferation, that also have implications in suppressing tumorigenesis 
(264).  Although BrdU was tested for its suitability for use during this project, the 
facilities for measuring the output using tritium gave more consistent data, hence the 
use of tritiated thymidine throughout this project. 
More recent work by Ghaffari et al. (265) has focussed on different aspects of 
the lymphocyte stimulation assay, and involved trying to determine in vitro the T cell 
response to a novel antigen, rabies.  This was mainly carried out in vitro and the 
experiments involved immunising healthy volunteers with rabies vaccine, before 
isolating a sample of peripheral blood mononuclear cells and testing the immune 
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responses over a time course against phytohaemagglutinin (negative control), tetanus 
toxoid (positive control as most people in the UK are immunised against tetanus as 
standard) and the rabies antigen.  This work, while inconclusive about the actual 
mechanisms underlying the responses to a viral antigen, did however illustrate that 
the rabies vaccine has potential applications in determining the degree of 
immunosuppression in affected individuals (265).  Other work has studied the impact 
of macrophages from within the lung on T cells, trying to determine how lung 
homeostasis is maintained as this system is notorious for varied T cell responses.  On 
the one hand, it has been shown that there is T cell suppression by alveolar 
macrophages in young infants (266).  On the other hand, the lung is inextricably 
linked with the outside environment and comes in contact with massive numbers of 
potential pathogens daily (267).  This variability in immune response and T cell 
suppression versus activation can be partially explained by the difference in 
macrophage phenotype as there are both activating and suppressive phenotypes and 
this is mirrored by the cytokines they produce.  The two phenotypes work together to 
neutralise threat, and to prevent a systemic immune response to an already 
neutralised pathogen (6). 
To summarise, the work in this chapter suggests that tolerance mechanisms 
within the DR15-expressing, α3(IV)NC1 wild-type mice are robust when challenged 
by a strongly stimulatory regime.  This was despite immunising with human 
α3(IV)NC1, where tolerance was induced to mouse α3(IV)NC1.  The homology 
between the two sequences is 92%.  The lack of immune responses seen to 
overlapping α3(IV)NC1 peptides was not due to an overall inability to generate an 




Chapter 7 – Proliferative responses to α3 in α3 null mice 
 
7.1. - Introduction 
 
The experiments described in this Chapter were designed to further address the 
nature of tolerance to α3(IV)NC1 by determining the fine specificity of T cells 
responding to α3(IV)NC1 in mice where tolerance to α3(IV)NC1 is not present.  The 
results would inform as to the importance of T cell deletion in tolerance to 
α3(IV)NC1.  Since α3(IV)NC1 was found in the human thymus (4), it had been 
thought likely that at least the most abundantly presented α3(IV)NC1 peptides were 
likely to stimulate deletion of cognate T cells, and the T cells in the peripheral 
circulation should be specific for subdominant peptides.  Two lines of evidence 
challenged this view.  First, among the peptides shown to stimulate T cells from 
patients with acute Goodpasture’s disease were some from regions of α3(IV)NC1 
known to be very efficiently presented from biochemical elution studies (so should 
have been deleted).  Second, the fine specificity of α3(IV)NC1-reactive T cells in a 
broad panel of healthy individuals showed remarkable similarity in their 
responsiveness to a number of α3(IV)NC1 peptides.  This would not be expected of 
sub-dominant responses restricted by different HLA molecules in different 
individuals.  These lines of evidence could be further examined by determining 
which epitopes within α3(IV)NC1 were immunodominant in the context of HLA-
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DR15 by immunising α3(IV)NC1 null, DR15-expressing mice with human 
α3(IV)NC1 and investigating the peptide specificity of responding T cells. 
In this Chapter, although I tested the recall responses of the DR15 A3v α3KO 
mice in the same way as I tested the recall responses of the DR15 A3v α3WT mice, I 
also wanted to test the responses in a slightly different way both to corroborate date 
obtained from the recall response assay.  I decided to generate hybridomas from the 
T cells extracted from α3KO mice immunised with rhα3, that would enable me to 
test recall responses by production of IL-2.  These hybridomas could then also be 
used for future experiments testing responses to specific peptides and peptide 
presentation by APCs. 
Hybridomas were first created by Kohler and Milstein (268) in order to 
produce monoclonal antibodies.   Subsequently, selection procedures exploiting the 
T cell I-J determinants and the suppressor T cell ability to bind antigen were 
developed by Tanaguchi and Miller in 1978 (269) and increased the probability of 
isolating a suppressor T cell hybridoma.  Despite this, techniques to produce 
cytotoxic (CD8 positive) T cell hybridomas were not successfully utilised until 1980, 
by Nabholtz et al. (270).  Since then, T cell hybridomas have been used extensively 
in researching T cell immunology, including the determination of immunodominant 
responses (271-273).  One particular example is in that of the Fathman lab, where 
hybridomas are used to study and try to quantify the methods of T cell activation (49, 
274).  These studies found that avidity for the antigen by the T cell receptor, the 
concentration of the MHC: peptide complex on the APC, or density of the T cell 
receptor on the T cell surface were equally important in the activation of T cells.  
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During this project, I utilised the methods published by Prof C. G. Fathman (49, 274) 
and by Dr J. Robinson (275) to produce CD4 positive T cell hybridomas.   
 
7.2. - Results  
 
As in Chapter 6, DR15-expressing mice were immunised with α3(IV)NC1 in 
complete Freund’s adjuvant on day 1, boosted with α3(IV)NC1 in incomplete 
Freund’s adjuvant on day 8, then culled on day 15.  T cells were extracted from the 
lymph nodes and set up against a panel of overlapping peptides from the injected 
antigen, in a lymphocyte stimulation assay.  This technique is well established, but 
does have limitations.  The major one being that should the experiment fail for any 
reason (premature cell death or problems with harvesting, for example), the cells are 
lost and to all intents and purposes, the original animal has been wasted.  An 
alternative way of investigating the immune response is by turning the cells into 
hybridomas, and this was used to test recall responses in the α3 null mice and to 
validate the data obtained from testing the recall responses in primary cells. 
The experiments undertaken for this Chapter all use mice with the same 
genotype, mouse class II null, HLA-DR15 positive, α3(IV)NC1 null, and used to 
further characterise the immune responses.  These mice were immunised with rhα3 































7.2.1. – Immune responses to bacterial recombinant human α3(IV)NC1 
T cells from α3(IV)NC1-immunised mice were harvested and their fine specificity 
determined by lymphocyte stimulation assays set up in the same way as in Chapter 6.  
It was seen that, as with α3 wild type mice, there were consistent responses to con A, 
but also to whole α3 (example data shown in Figure 7.2.2.).  The decrease in 
stimulation index in the presence of higher concentrations of α3 is more likely to be 
due to the increased concentration of urea within the culture than toxicity from an 
increased concentration of α3 (urea titration shown in Figure 6.2.6.).  Figure 7.2.3. 
shows the data obtained from 7 α3KO mice, with each peptide induced response 
expressed as a stimulation index to enable direct comparison (calculation described 
in Chapter 6).  The responses to peptides seen in these α3 null mice were different 
from those seen in the α3 WT mice.  The immune response varied between 
individual α3 knockout mice, but most (5/7) of the mice responded to the peptide 
α3(IV)NC1 136-150.  Other stimulatory peptides included α3(IV)NC1 101-115, 
α3(IV)NC1 151-165, α3(IV)NC1 191-205 and α3(IV)NC1 206-220.  While these 
experiments did illustrate immune responses to some peptides within α3(IV)NC1, 
overall these responses were still at far lower level than expected.  This could be due 
to the α3(IV)NC1 preparation used for immunisation being more dilute than 
believed.  The data from all 7 mice have been combined to give a mean (shown in 
Figure 7.2.4).  As illustrated by the error bars (standard deviation from the mean), 
there is considerable variation for the level of stimulation by each peptide and some 




7.2.2. – Immune responses to exogenous antigen 
In order to check that the transgenic mice were capable of generating a normal 
immune response, the mice with the greatest amount of modification (ms class II 
null, HLA-DR15 positive, α3 null) were tested for their responses to a different 
exogenous antigen, in this case, ovalbumin.  T cells were harvested, incubated in 
vitro with ovalbumin and APC, and after 1-11 days, aliquots of the T cells were 
pulsed with tritiated thymidine and incorporation determined at 24 hours (Figure 
7.2.5.).  These results showed that the optimal time point for pulsing the cells in 
order to detect a proliferative response to in vitro restimulation was on day 6 to read 
the plates on day 7.  However, all other results of proliferation assays I have 
described were obtained by pulsing cultured cells with tritium on day 4 and reading 
the plates at day 5 following early experiments in which increased cell death was 
observed after day 5.  This increased cell death resulted in increased difficulty in 
interpreting data obtained from later time points (data not shown).  Therefore, these 
results show that the α3 KO mice were capable of generating an immune response to 
exogenous antigen, suggesting that their immune system is not especially defective. 
 




Figure 7.2.2. – Example controls from α3KO T cell proliferative responses 
These charts show example controls used when setting up each T cell 
proliferative response assay.  Figure 7.2.2A shows that ovalbumin does not result in 
T cell proliferation but that α3 results in stimulation suggesting that an immune 
response has been successfully generated to the immunising antigen (unlike in 
α3WT mice, Figure 6.2.3.).  ConA also results in T cell proliferation (Figure 7.2.2B).  
























Figure 7.2.3. – Proliferative responses to recombinant human α3 in α3 KO mice.   
Figures 7.2.3A-G show the calculated stimulation index for T cells from 7 α3 
null mice after stimulation with the indicated peptide.  As described previously, a 
stimulation index of 3 is marked with a bold, black line.  Compared with data from 
the α3 WT mice, there is more variation in T cell proliferative responses and 






















































Figure 7.2.4. – Mean proliferative responses to α3 peptides by α3KO mice 
This chart combines all the data shown in Figure 7.2.3. (n=7) and combines it 
into a single chart.  On the X axis is stimulating peptide, on the Y axis is mean 
stimulation index.  A stimulation index of 3 is marked with a bold black line.  From 
these data, four peptides give a mean stimulation index above 3, peptides ha3p11-25, 
116-130, 136-150 and 191-205.  These are marked with the number of animals out of 
the 7 tested that resulted in the stimulation index being above 3.  As can be seen, 
peptide ha3p136-150 most consistently stimulated T cell proliferative responses 










Figure 7.2.5. – Graph plotting time course of immune response to ovalbumin.    
Lymphocytes from α3 null, HLA-DR15 positive mice immunised with 
ovalbumin were incubated with ovalbumin for the indicated time intervals shown 
before proliferation was assessed by tritium incorporation (X axis shows time until 
pulsing).  An α3 peptide, AS345 or α3(IV)NC1 S65-82 was used as a negative 
control over the same period.  Tritium incorporation peaks at day 7 after in vitro 
stimulation with ovalbumin, while proliferative responses to the negative peptide 








As was mentioned in Chapter 5, bacterial cells have different processing 
mechanisms for the production of protein, compared with human cells.  The main 
difference being a lack of a crucial stage that enables the formation of disulphide 
bonds between specific cysteine residues and ensures a consistent conformation of a 
given cysteine-containing protein.  This is particularly important in a molecule such 
as α3, when the NC1 domain amino acid sequence contains 12 cysteine residues.  
While all sequences could be folded into multiple conformations, the relatively high 
cysteine content of the α3(IV)NC1 domain also increases the potential for various 
disulphide bond formation and therefore increased variability within the protein 
tertiary structure.  Both bacterial recombinant α3(IV)NC1 protein and human 
α3(IV)NC1 extracted from tissue were used in experiments described within this 
Chapter.  The experimental design is illustrated by Figure 7.2.1., and is the same as 
the experiments designed for the work described in Chapter 5. 
In a similar experiment to those described in section 7.2.1, α3 null mice (n=2) 
were immunised with the α3 antigen preparation derived from human kidneys and 
purified by cation-exchange chromatography.  The data obtained from mice 
immunised with human protein instead of recombinant protein also showed wide 
variation in the level of stimulation between peptides, and overall there was a 
stimulatory response akin to those seen following immunisation with recombinant 
α3.  Only 1/2 mice (although the second showed an SI close to 3) showed a 
stimulatory response greater than 3 to the peptide ha3p136-150, but that number 
could increase had more mice been tested with the human α3 preparation.  This was 




Figure 7.2.6.– Proliferative responses of α3KO mice to purified human α3(IV)NC1.   
These charts show the proliferative response data derived from mice 
immunised with human α3(IV)NC1.   The data is expressed as stimulation index (Y 
axis), with Figures A and B plotting the proliferative responses seen in T cells from 
two different mice, to the different peptides described on the X axis.  As with all the 










The lowish levels of recall response to human α3(IV)NC1 are unlikely to be as 
a consequence of too low a concentration of stimulatory peptides as the experiment 
employed the same concentration as used for the studies in α3 null mice immunised 
with rhα3.  It may also be possible that the concentration of immunising antigen was 
insufficient to generate an immune response to all but the most stimulatory peptides.  
However, it can be seen that the α3(IV)NCI 136-150 peptide did stimulate a 
proliferative T cell response in one of the two mice immunised (Figure 7.2.6A).  
The data obtained from immunising with human α3 is hard to interpret, mainly 
due to insufficient numbers to perform viable statistical comparisons.  Repetition 
may have shown consistent patterns in responses, and at least would have allowed 
the significance of any consistency to be tested statistically.  However, even in the 7 
mice immunised with rhα3, it was difficult to isolate a specific trend.  The peptide 
ha3p136-151, caused a proliferative response in 5/7 mice tested, while the equivalent 
peptide in the mice immunised with the human α3 caused a proliferative response in 
1/2 mice tested.  This is likely to be a genuine finding, and the fact that there is a 
recall response to the ha3p136-150 peptide following immunisation with the human 
kidney-derived antigen suggests that despite the difference in confromation between 
the human protein and the recombinant protein, there are similarities in processing 
and presentation.  It also suggests that there may be different ways to “unlock” the 
α3(IV)NC1 protein that do not destroy the ha3p136-150 peptide.  This could be 
through a different sequence of processin events, or through use of a different, 
possibly unidentified, processing enzyme.  
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The relative lack of consistent data may well be due to the fact that the murine 
line used in these experiments is not inbred, so variation is to be expected.  It could 
be argued that in ensuring this murine line is not inbred, the variation in immune 
response to different peptides are more akin to the human population.  However, 
when trying to isolate specific features of an antigen that could trigger autoimmunity 
or a lapse in tolerance, minimal variation renders data more easy to interpret.  
 
7.2.4. – Responses by hybridomas 
In order to make T cell hybridomas, isolated T cells (from a primed animal as 
for the recall response assay) are subjected to in vitro restimulation with antigen, 
followed by expansion with IL-2, before being fused to a myeloma line.  This 
immortalises the cell and, if the fusion and serial dilutions are successful, results in 
clonal populations of T cell hybridomas with specific reactivity to a fragment of the 
antigen.  This immortalisation enables multiple testing of the same clone using 
different antigenic fragments or antigen preparations and therefore offers a distinct 
advantage over primary cells.  It is also easier to test these cells against a panel of 
peptides or possible stimulants.  However, while hybridomas are good for specificity 
analysis, they do lose some of the qualities associated with primary immune cells.  
The hybridomas are specific for a very small fragment of a whole antigen.  This 
reduces the conformational and processing constraints enforced by the APC as the T 
cell hybridomas will respond to a minimum concentration of the peptide presented 
by the APCs within the system.  When T cell hybridomas are stimulated, they 
produce IL-2.  This can be measured as concentration from 24 hour supernatants, by 
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ELISA.  Another way of measuring the IL-2 produced would be by utilising cells 
that require IL-2 in order to survive, for example CTLL-2 cells (276).  The 
supernatants can be used as feed for these cells and IL-2 concentration can be 
determined by proportional cell survival.  However, these cells are notoriously 
difficult to grow in culture so it was decided to use the less sensitive ELISA instead. 
Overall, generation of hybridomas was attempted three times, using two mice 
on each occasion (six in total), but only one fusion reaction was successful.  The first 
two attempts at making hybridomas produced no viable cells following fusion.  The 
method to generate the hybridomas from DR15 A3v α3 KO mice is described in 
Chapter 2 (2.10.), but in brief, the mice were immunised as for the experiments 
described in sections 7.2.1 and 7.2.3 and as illustrated by Figure 7.2.1.  The 
lymphoid cells obtained from each mouse were then restimulated with recombinant 
human α3 for 3 days, washed, then expanded for a further 3 days with a high 
concentration of IL-2/well (approximately four 24-well plates per mouse).  These 
cells were then mixed at a 1:1 ratio with BW5146 cells and fused by disrupting the 
cell membranes with PEG.  After washing to remove as much as possible of the 
PEG, the cells were gently resuspended in media and plated out undiluted, and at 1:3 
and 1:9 dilutions in 96-well flat-bottomed plates.  Each dilution was plated in 
duplicate and resulted in 6 plates per fusion reaction (effectively 6 plates per mouse).  
After 24 hours, selective media (containing HAT supplement) was added, and clones 
were selected and picked from 7-14 days.  Cells were picked as showing clonal 
expansion if the expansion appeared to cluster in a specific region of the well and 
were picked when covering a maximum of 1/3 well surface area.  The higher 
concentrations of cells (particularly the undiluted cell suspension post fusion) was 
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less likely to produce a fairly clean clonal population as a result of containing more 
cells initially.  This in turn makes it more likely that more than one cell would 
undergo clonal expansion within the well, so a population of cells with responses to 
different regions of the α3(IV)NC1 would be picked.   
The hybridomas chosen to expand further and generate lines, were initially 
chosen for their survival in HAT then HT media, and then selected by a minimum of 
a 20% increase from background IL-2 production in response to α3(IV)NC1.  Using 
these criteria, 9 hybridomas were cultured (shown in Figure 7.2.7., * if P < 0.05, ** 
if P < 0.01, P is probability that amount of IL-2 produced above background 
concentrations was produced by chance, by unpaired T-test) and were shown to 
produce varying levels of IL-2 to whole α3(IV)NC1.  Of the clones selected, the 
highest consistent response to α3(IV)NC1 was by hybridoma 2A3.F10, to both rhα3 
(7.30pg, P = 0.00001)  and huα3 (4.99pg, P = 0.000007).  Another hybridoma 
producing a significant amount of IL-2 in response to α3 was hybridoma 2B1.F9, 
although the responses from this hybridoma were solely to recombinant α3, 
suggesting that the responses were to a contaminating protein within that preparation.  
Since hybridoma 2A3.F10 responded to both human and recombinant α3, it is more 





Figure 7.2.7. – Summary of IL-2 production by hybridomas. 
This data was derived from HLA DR15 expressing α3 KO mice that had been 
immunised with rhα3 and the T cells restimulated and fused to myeloma cells to 
produce hybridomas that can produce IL-2 when stimulated.  This chart shows each 
hybridoma line (plus negative clone as negative control and an older, well-
established hybridoma as positive control).  IL-2 concentrations produced in 
response to rhα3 are shown in red, to purified native huα3 in blue, using a  DR15-
restricted B cell line as APCs.  The final column in each set, shows IL-2 production 
in response to presentation of rhα3 by DR15-expressing, mitomycin c treated 





















7.2.5. – Further characterisation of hybridoma responses 
To determine which specific fragment of the α3(IV)NC1 molecule the 
hybridomas responded to, each was set up against a panel of overlapping peptide 
sets.  This was done to reduce the number of assays needed to test individual clones 
and to minimise reagent usage.  The details of the sets are included in Appendix I, 
along with each peptide sequence and location (by amino acid position number) on 
the whole α3(IV)NC1 domain.  It was found that each hybridoma exhibited a distinct 
profile of responses and whilst most clearly responded to a single peptide set, only 
one hybridoma (2A3.F10, Figure 7.2.8E)  showed responses to the major stimulating 
peptide seen in the initial lymphocyte stimulation assays (7.2.1. and 7.2.3.).  This 
could be interpreted to mean that T cells responsive to α(IV)NC1 136-150 do not 
survive the fusion process involved in making hybridomas, but this is pure 
conjecture.  It is more likely to reflect the fact that very few hybridomas were 
produced from three different experiments  (six mice). 
Time did not permit the intended next step of measuring IL-2 responses to 
individual peptides from the stimulatory peptide mixtures, so to gain some indication 
of the likely T cell epitopes within the stimulatory peptide sets, the sequences were 
examined for DR15-binding motifs employing epitope-detection algorithms based on 
large bodies of experimental peptide binding data (258-260).  Each MHC class II 
molecule, in this instance HLA-DR15, has an affinity for each peptide sequence that 
can be estimated.  The data from each hybridoma and strongest stimulation set have 
been shown in table 7.2.9., with the likely stimulatory peptide with strongest 
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calculated binding for the DR15 molecule.  This is calculated as an IC50 – that is the 
concentration of peptide predicted to displace 50% of labelled ligand from binding 
to, in this case, HLA DR15.  This is the predicted value at which 50% of the DR15 
molecules are inhibited (or occupied) by the peptide (nM).  Where the hybridomas 
respond to more than one peptide set, it seems likely that these are not pure clonal 
populations of hybridomas so contamination most likely occurred at picking the 
original clone following fusion.  This can be illustrated by comparing two of the 
charts within Figure 7.2.8.  Both charts (as with all shown within the Figure) plot the 
IL-2 concentration produced in response to different stimuli.  Figure 7.2.8F, a 
hybridoma line (2B1.A7) derived from the undiluted plates post-fusion shows a 
wider range of stimulation (sets 8, 14 and 15, 0.87pg/ml, 0.78pg/ml and 0.87pg/ml 
above background respectively, P=0.017, 0.033 and 0.036), compared with Figure 
7.2.8A, a hybridoma line (2B3.B2) derived from the 1:3 dilution post-fusion that 
shows very specific stimulation by set 4 and the highest concentration of IL-2 
produced (3.11pg/ml) in these experiments.  However, this was not found to be 
statistically significant, due to variation within the triplicates. 
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Figure 7.2.8. – Charts showing IL-2 production of T cell hybridomas when incubated 
with sets of α3(IV)NC1 peptides.   
IL-2 production measured by ELISA is shown in pg/ml for 8 hybridomas 
generated from α3(IV)NC1 immunised DR15-expressing, α3(IV)NC1-KO mice.  
Statistically significant difference from background are marked * if P < 0.05, ** if P 
< 0.01 (unpaired Student’s T-test, probability that IL-2 production in response to 
























Figure 7.2.8. – Charts showing differential peptide responses from different 
hybridomas in response to overlapping α3 peptide sets. 
As above, responses of hybridomas to overlapping peptide sets measured by 
IL-2 production.  Significant differences from the background are marked * if P < 























Table 7.2.1. – Table of hybridoma responses. 
Table showing, for each hybridoma, the peptide sets eliciting the strongest IL-2 
responses and likely epitopes within the constituent peptides deduced by determining 
to epitopes with greatest affinity for HLA-DR15 using the epitope prediction engine 
at: 
http://tools.immuneepitope.org/tools/matrix/iedb_input?matrixClass=II 
These numbers were obtained by pasting the peptide sequence into the website 
shown above and specifying which HLA-DR molecule was being studied.  As can be 
seen here, the peptide with the lowest IC50, so the lowest concentration required to 
inhibit 50% of the HLA-DR15 molecule, is α3(IV)NC1 136-150.  Despite that, only 
one of 9 hybridomas shows an increased IL-2 production in response to that set that 












2B3.E11 s7 2.71 α3(IV)NC1 86-100 LMPMNMAPI 19.28 
 s15 1.7 α3(IV)NC1 206-220 PIPSTVKAG 725.55 
2B3.B2 s4 3.11 α3(IV)NC1 36-50 FVQGNQRAH 257.04 
2B1.F9 s8 2.04 α3(IV)NC1 96-110 MAPITGRAL 2687.99 
2A9.A4 s2 2.95 α3(IV)NC1 11-25 TRHSQTTAI 7629.66 
 s10 2.2 α3(IV)NC1 136-150 LWKGFSFIM 2.46 
2A3.F10 s7 1.64 α3(IV)NC1 86-100 LMPMNMAPI 19.28 
2B1.A7 s6 1.58 α3(IV)NC1 86-100 LMPMNMAPI 19.28 
 s13 1.68 α3(IV)NC1 171-185 ASPFLECHG 9163.28 
2A3.C12 s1 2.41 α3(IV)NC1 11-25 TRHSQTTAI 7629.66 
 s11 2.62 α3(IV)NC1 146-160 SFIMFTSAG 93.51 




Clonality is more likely when the fusion products were plated at higher dilutions, but 
the single peak of IL-2 production in response to one specific peptide set is not 
always seen in the clones derived from these plates. In particular, hybridoma 2A9.A4 
(Figure 7.2.6A) was derived from the 1:9 dilution post-fusion and is seen to have 
four statistically significant peaks of IL-2 production (set 6, set 8, set 12 and set 14).  
This suggests either more than one clone within the original well was picked and 
expanded, or that there is some degree of similarity between peptides within those 
two sets (sets 6, 8, 12 and 14).  
The hybridoma 2A9.A4 also shows stimulation to sets 2 and 10, but this was 
not found to be statistically significant, again probably due to variation between the 
triplicate samples.  However, the sequences within these sets shows 60% the same 
sequence and was shown to be 73% homologous when aligned (by BLAST 2), 
suggesting that cell responsive to one peptide sequence within set 2 could also be 
responsive to peptides within set 10.  Of additional interest is the knowledge that set 
10 contains the Goodpasture antigen peptide α3(IV)NC1 136-150, the peptide to 
which all Goodpasture patients generate an immune response, and the 
immunodominant peptide within the Goodpasture antigen. 
Figure 7.2.8. also emphasises the point made above about clonality.  This is 
particularly well illustrated by comparing Figures 7.2.6A, 7.2.6E and 7.2.6G.  The 
hybridoma used in Figure 7.2.6C was grown from a single well in the 1 in 3 dilution 
plate and clearly shows a single peak of IL-2 production in response to peptide set, 
s4.  By way of contrast, the hybridomas illustrated in Figures 7.2.6F and 7.2.6H were 
both derived from the undiluted fusion mixture, and 7.2.6H shows no real peak of 
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response, more a generic production of IL-2, while 7.2.6F shows a few peaks of IL-2 
production, suggesting a lack of clonality. 
Student’s T-tests for these data found that, although the means of the data were 
significant by eye, these were not always statistically significant.  There was some 
variation between samples (each was carried out in triplicate), so many of the peaks 
that appear significant by eye are not statistically significant by Student’s T-test. 
Other peaks that appeared to be similar to the background were classed as 
statistically significant by an unpaired Student’s T-test.  While there was variation 
between triplicates, and those producing the greatest concentrations of IL-2 showed 
the greatest variation between samples, the statistics are such that increased variation 
detracts from the data.  For this data set, some mean values that are high have not 
been calculated as significant due to variation within the triplicates used to calculate 
the mean.  The T-test assumes that all data points are equally valid, so if there is 
wide variation within a sample, the sample itself must have wide variation.  This is 
unlikely to be the case for the data presented here, but time constraints meant that 
repetition was not possible.  This data should therefore be treated with caution.  It 
should not be discarded, but the peaks that were significant by eye but not statistics 
should not be treated as significant until further study regarding the IL-2 productive 
response of the hybridomas has been undertaken, and the data presented here, 
corroborated. 
  
7.2.7. – Histology from immunised α3 null mice 
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In keeping with experiments on α3 wild-type mice, kidneys were harvested 
from immunised mice and unimmunised control animals, fixed in 10% neutral 
formalin and paraffin wax embedded. Sections were then cut for haematoxylin and 
eosin staining, but, despite the differences in peptide responses compared to wild 
type animals, there were no morphological differences either between immunised 
and unimmunised α3 KO mouse kidneys (Figure 7.2.10.), or compared to wild type 
sections (Figure 6.2.7).  This is not entirely surprising – alterations in kidney 
morphology are notoriously hard to induce.  The experimental procedure followed is 
probably too short-term and more mild a schedule than would be required for distinct 
morphological differences to be induced and observed. 
 
7.3. – Discussion 
  
The variation seen between the two sets of data was somewhat surprising.  In 
particular, the variation in stimulatory peptides seen in the hybridomas, compared 
with the lack of variation within the lymphocyte stimulation assays.  However, the 
two sets of experiments, while suitable for validation, do determine different things.  
The lymphocyte stimulation assay assesses the immunodominant peptide and reflects 
collective immune response.  Hybridomas, by comparison, are derived from a single 
cell.  In order to use them to assess an immune response, hundreds of hybridomas 
from a single animal, reacting to the entire of an antigen are required.  This enables 
some comparisons to be made about the overall reactivity of each peptide in 
comparison to each other.  The original intention behind this work was to generate  
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Figure 7.2.9. – Photographs of haematoxylin and eosin stained kidney sections from 
immunised and unimmunised mice.   
These photos show unimmunised mouse kidney (Figure A), ovalbumin 
immunised mouse kidneys (Figure B), rhα3 immunised mouse kidney (Figure C) 
and huα3 immunised mouse kidney (Figure D).  The images were captured at x400 




   
 
   
Figure A – Naïve mouse Figure B - Ovalbumin 
Figure C - rhα3 Figure D - huα3 
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lots of hybridomas and corroborate the recall response data.  With the numbers of 
hybridomas actually generated in this work, this corroboration was not possible.   
While it would be expected that proportionally more hybridomas would respond to 
the immunodominant peptide, it remains possible that other T cells with affinity for 
less dominant peptides can be fused, selected and cultured prior to testing.  In effect, 
the production of hybridomas ensures that a single cell can be tested multiple times 
with different peptides to determine single cell peptide binding specificity.  The lack 
of hybridomas that respond to the immunodominant peptide is more likely to be a 
result of the few hybridomas successfully cultured, rather than an accurate reflection 
of the overall immune response in the animal from which the original T cells were 
obtained. 
These experiments do illustrate how variable the immune responses to 
exogenous antigen can be in relatively outbred mice and as in man.  On the one hand, 
α3 null mice immunised with either rhα3 or huα3 consistently generate the greatest 
immune responses to the Goodpasture α3(IV)NC1 fragment, α3(IV)NC1 136-150.  
On the other hand, cells from α3 null mice, immunised with the same rhα3 
preparation, then fused to myeloma cells in order to make hybridomas result in 
immune responses to a variety of peptide sets, but only 1 out of 8 hybridomas did 
respond to the set that contained the Goodpasture antigen.  This is probably due to 
the reasons described above. 
The consistent response to α3(IV)NC1 136-150 in the lymphocyte stimulation 
assays presents with a conundrum.  The peptide fragment α3(IV)NC1 136-150 that 
stimulated T cells from Goodpasture patients and HLA-matched controls (1), as well 
as the work described within this Chapter, encompasses a cleavage site for cathepsin 
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D, and in particular is the site of very early processing events for the whole α3 NC1 
domain (71).  This peptide should therefore be destroyed during early processing 
events and cleavage at this site is also known to be a key stage in “unlocking” and 
processing the rest of the molecule.  A possible explanation for this could be 
incomplete cleavage, in which the protein is cleaved enough to “unlock” the protein, 
but insufficiently to destroy the peptide.  It is also possible that this peptide fragment 
is presented as a result of aberrant processing through either faulty enzyme or faulty 
α3(IV)NC1 sequence.  The latter seems unlikely as the genetic sequence of the α3 
chain in patients with Goodpasture’s disease has been sequenced and no mutations 
have been found (277).  However, all published data from my supervisor’s laboratory 
regarding processing and presentation of α(IV)NC1 has used recombinant bacterial 
α3(IV)NC1 which has variable conformations within batches, and may well show 
different processing as a result of differences in accessibility for processing enzymes.  
The fact that data obtained using α3(IV)NC1 derived from human kidneys also 
resulted in recall responses to some of the peptides causing recall responses from 
mice immunised with recombinant α3(IV)NC1 suggests that this is a real finding.  
The faulty enzyme hypothesis seems unlikely as the work described in this chapter 
suggests processing is similar in mouse as in man and the mice used are not lacking 
cathepsins D or E, which would be the more obvious candidates as defective 
enzymes (71).  Another possible mechanism enabling presentation of a previously 
cleaved fragment is protein splicing, in which protein fragments are spliced together 
after processing in order to generate an immune response (278).  It has since been 
shown that even peptide fragments spliced incorrectly can enable an immune 
response to be generated following presentation on the APC surface (279).  This 
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remains a possibility for Goodpasture’s disease and in this transgenic mouse 
experiments, but far more work would need to be done including time-consuming 
and expensive protein tracking experiments to determine where the protein is being 
cleaved and subsequently, where it is then being spliced back together.  This also 
generates a question whether the peptides to produce the α3(IV)NC1 136-150 
fragment are being spliced back together deliberately, or whether it is purely due to 
the proximity of peptides to each other within the endosome.   
The work described within this chapter investigating immune responses to the 
α3(IV)NC1 protein in α3 null mice found a surprising variation in the level of 
immune response both to recombinant human α3(IV)NC1 and to human α3(IV)NC1 
isolated from tissue.  Using the recombinant protein, the most consistent immune 
response was generated to the Goodpasture fragment, α3(IV)NC1 136-150.  
However, since these mice do not express the α3(IV) protein, it was expected that 
more areas of the protein would result in T cell proliferation, since it is a foreign 
antigen to these animals.  Overall, these animals had lower than expected immune 
responses.  Even the whole recombinant α3(IV)NC1 at various concentrations only 
generated limited immune responses, but this could be because the protein was in 
highly concentrated (8M) urea so addition of large volumes of the rhα3 would not be 
particularly conducive to cell growth (maximum final concentration of urea in any 
experiment was 0.376M), this was tested and has been shown in Chapter 6 (Figure 
6.2.5).  This high concentration of urea was used to keep reasonably high 
concentrations of recombinant α3 in solution and subsequent dilution caused the 
protein to precipitate.  It is possible, although unlikely, that as α3(IV)NC1 naturally 
forms a trimer with α4 and α5(IV)NC1 domains, the precipitation was a direct result 
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of the protein aggregating to form a more stable di- or trimer and to protect otherwise 
exposed hydrophobic domains, in the more dilute urea solutions.   
The low level of in vitro immune response to peptides cannot be for the same 
reason, as the peptides are all chemically synthesised.  This could be due to two 
possibilities: firstly, that there is genuinely limited immune responses to peptides 
other than α3(IV)NC1 136-150; or secondly that the cells used during the 
experiment were not a healthy population, resulting in high levels of cell death and 
therefore limiting the immune responses seen following harvesting.  The second 
reason is possible, as the lymph nodes isolated were visibly in close proximity to  
adjuvant used during the immunisations.  While the cells were washed well prior to 
plating, the adjuvant used to generate an immune response (in conjunction with the 
recombinant α3(IV) protein) is fairly toxic and promotes T cell activation.  The 
adjuvant seen could have been near the lymph node for up to two weeks, with the 
potential to affect the health of cells within that area.  These concerns are also 
applicable to the data obtained from DR15-expressing α3 WT mice and presented in 
Chapter 6, although a lack of immune response in these mice does support robust 
tolerance. 
T cells from α3 immunised DR15 α3 WT mice do show in vitro immune 
responses to whole bacterial recombinant α3(IV)NC1, but not to individual peptides, 
suggesting that the rhα3 contains some additional contaminant and that tolerance to 
the α3(IV)NC1 protein is robust.  It was expected that more immune responses to the 
α3(IV)NC1 peptides would be seen in T cell from the DR15 α3 null mice, as the 
protein is foreign so would generate an immune response as seen to other exogenous 
proteins (ovalbumin, Figure 7.2.5.).   
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While this is true to some extent, the immune responses seen were at a lower 
level than was expected and suggesting that the antigen preparation used to 
immunise the mice was less concentrated than expected.  It also suggests that the 
protein itself may not be that immunogenic, a suggestion that may also partially 
explain the scarcity of disease in humans.  However, this would also infer that 
foreign proteins are subjected to different levels of immune response and this is not 
the case. 
It could be argued that the cells made into hybridomas have been through a lot 
more processing and manipulation than those obtained relatively simply by 
disaggregating lymph nodes and being kept in media containing a known 
concentration of α3(IV)NC1 peptide.  This, however, should not have altered the 
inherent ability of the T cell to recognise a specific fragment of antigen in 
conjunction with the presenting MHC class II molecule.  In particular, individual 
variation may well play a role, especially as all the hybridomas that were made 
successfully were derived from one mouse.  Two α3 null mice were immunised and 
used in the process, but all the hybridomas found to be specific for the α3(IV)NC1 
molecule were from  the second mouse (hence “2” at the front of the hybridoma 
nomenclature).  This automatically means that all the hybridomas are obtained from 
a limited immune repertoire and since the same mouse could not be tested 
simultaneously for peptide recall responses, it is not known whether this mouse just 
generally showed reduced recognition of the α3(IV)NC1 136-150 peptide fragment, 
or whether any cells that did recognise this fragment did not survive the fusion 
process.  The latter reason is unlikely because other T cells were perfectly able to 
survive the fusion and mount a cellular response to the relevant peptide fragment.   In 
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addition, there are already hybridomas that do recognise this fragment within our 
laboratory, having undergone exactly the same fusion protocol. 
Part of the aim of this chapter was to try to produce individual hybridomas that 
respond to different fragments of the α3(IV)NC1 molecule, and effectively 
producing a panel of hybridomas for in vitro immunological studies.  While this was 
well within the scope of my project, the practicality of actually being able to do so 
rendered this a very difficult aim to achieve.  To have established 8 new hybridoma 
lines with different peptide specificity is a substantial effort, but future work could 
definitely include taking this further and developing additional hybridoma lines with 
different specificities from those developed here.  As a panel, the 8 clones 
successfully cultured here, plus some clones to different peptide sequences 
previously developed within the lab, and with the future development of clones with 
fine specificities for the remaining peptides within the α3(IV)NC1 protein, could be 
used to determine T cell responses.  These could be to study responses to specific 
fragments and modified fragments to determine essential amino acid residues for 
recognition, binding and presentation by the MHC class II HLA-DR15 molecule.  
They would also allow more specific study of processing mechanisms and criteria. 
The work described within this chapter shows consistent immune responses by 
primary T cells derived from rhα3 immunised DR15-expressing α3-KO mice to the 
α3(IV)NC1 136-150 peptide.  This is the peptide to which T cells from 100% 
Goodpasture patients also respond.  This suggests that the α3(IV)NC1 136-150 
peptide is the immunodominant peptide, despite processing requirements that would 
suggest it should not be presented on the APC surface at all (71).  Despite the 
similarities between the results, the human and mouse responses cannot be directly 
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compared.  Firstly, the  in vitro responses discussed within this chapter are obtained 
from a humanised transgenic mouse with limited MHC class II repertoire, while the 
human data published, although based on Goodpasture patients, has no such 
limitation, despite all the patients described expressing HLA-DR15.  In addition, 
Goodpasture patients have tolerance mechanisms that do not prevent autoimmune 
responses, while the data presented within this chapter describes murine immune 
responses to exogenous antigen since these mice do not express α3(IV)NC1.  
However, this work shows that responses in DR15 positive, α3(IV) null mice, in the 
absence of tolerance, are similar to those seen in patients with Goodpasture’s disease.  
This implies that the mice used in Chapter 6, HLA DR15-expressing α3 WT, could 
be a useful tool for studying the mechanisms causing Goodpasture’s disease in more 
depth.  This is on the proviso that tolerance mechanisms in these mice can be broken 
(280).  Conversely, the mice used in this chapter, HLA DR15-expressing α3-KO 
mice, could be used to study induction of tolerance and whether the induced 
tolerance to the α3(IV)NC1 domain could subsequently be broken (281). 
In summary, the work described in this chapter suggests that the α3(IV)NC1 
136-150 is the immunodominant peptide against which immune responses are most 
likely to be directed, in the DR15-expressing α3-KO mouse developed in Chapter 4.  
The work undertaken to develop hybridomas suggests that  this peptide is not the 
sole immunologically responsive peptide, but that other peptides may need to be 
presented at much higher concentrations on APC surfaces in order to generate a 
similar immune response.  The work described in Chapter 3, in developing a peptide 
adjuvant to improve specific uptake into B cells is one way in which to potentially 
exploit this mechanism.  
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Chapter 8 – Final Conclusions and Future Directions 
 
This project investigated epitope selection in the presence and absence of 
tolerance and the subsequent immune responses.  While the majority of the work 
concentrated on generating antigen and testing the CD4 T cell responses, there was 
some additional work investigating the possibility of exploiting mechanisms of 
antigen uptake. 
Early work concentrated on improving specific B cell-mediated uptake of 
peptides by developing a B cell-specific fusion partner, protein L, could be explored 
further.  This protein shows promise for use as a fusion partner as data is shown 
illustrating the protein L binding and being internalised by B cells (Chapter 3).  In 
order to study the effect of processing on presentation, there are two influencing 
factors that should be considered, namely uptake and presentation.  If uptake can be 
made consistent, specific processing preferences are more easily identified.  Protein 
L has the potential to be used to augment uptake such that uptake is no longer a 
limiting factor in determining protein processing and presentation, enabling 
identification of specific immunological peptide sequences presented on the APC 
surface.  Future work could therefore include linking protein L to a peptide of 
interest and testing T cell responses using the pulsed B cells as APCs and using 
peptide-specific T cell hybridomas as a read out (IL-2 production).  The whole 
Goodpasture antigen could also be linked to protein L and resultant T cell immune 
responses tested from a panel of T cell hybridomas generated against overlapping 
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regions of the Goodpasture antigen (work started in Chapter 7 with the generation of 
8 hybridoma lines reactive to different fragments of the Goodpasture antigen).  This 
could enable further investigation of the processing mechanisms involved in 
processing and presentation of the Goodpasture antigen. 
The protein L studies were undertaken in order to produce a protein capable of 
specifically binding B cells and with potential for use as a fusion protein to improve 
uptake of specific antigen into the B cells for processing and presentation.  This 
protein was the bacterial protein L (as described in Chapter 3) and was shown to be 
capable of binding and being taken up into B cells, although further work to link the 
protein L to specific antigen was limited due to time constraints. 
Additional early work concentrated on generating an in vivo system within 
which it would be possible to test for immune responses to a specific antigen.  Two 
transgenic mouse lines were crossed to produce a new transgenic line that did not 
express mouse class II molecules, that expressed the HLA-DR15 molecule, and 
could be α3(IV)NC1 positive, heterozygous or null, enabling exploration of α3-
specific immune responses in the presence and absence of tolerance (Chapter 4).  
The transgenic mouse line generated showed promise for use investigating 
mechanisms underlying autoimmunity, particularly Goodpasture’s disease, but 
needed care to maintain.  There was a distinct female: male skew (3:1), certain 
genotypes never occurred in males, and some female genotypes were unsuitable for 
use in breeding.  
In addition to the generation of the transgenic mouse line, early work also 
concentrated on generating sufficient bacterial recombinant human antigen 
(α3(IV)NC1) for the immunisation experiments as well as isolating native human 
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α3(IV)NC1 from human kidneys.  Later in the project, work was undertaken to 
produce a vector for the transfection of human embryonic kidney cells such that 
successfully transfected cells would produce a soluble form of α3(IV)NC1 (Chapter 
5). 
Chapter 6 presents the work carried out using the mouse class II KO, DR15-
expressing, α3 wild-type mice to determine the immune responses to α3(IV)NC1and 
α3(IV)NC1-derived peptides.  These mice showed no responses to fragments of 
α3(IV)NC1 despite a moderately severe immunisation schedule.  These data 
emphasise the need for exceptional circumstances are necessary in order for the 
immune system to respond to self-antigen.  The fact that these experiments were 
unable to find any response to α3 suggests that tolerance is robust.  However, recent 
work by Zou et al. has shown that healthy humans do have circulating Goodpasture 
antigen reactive T cells (3).  They hypothesised that these autoreactive T cells 
escaped tolerance mechanisms as a result of reacting to a peptide fragment that 
should be destroyed by lysosomal processing.  No T cells specific for the rapidly-
destroyed peptides could be demonstrated in the α3(IV)NC1-expressing transgenic 
mice, even after immunisation with human α3(IV)NC1, but this observation does not 
greatly undermine the hypothesis as no peptide specific responses were detected 
whatsoever.  Additionally, these studies were undertaken using human α3(IV)NC1 
and human peptide sequences in a transgenic mouse model, so there may be some 
species-specific differences.  It would have been interesting to explore other means 
of breaking tolerance to α3(IV)NC1 in these mice, for example by removing 
immunosuppressive hormones, immunising with antigen and administering 
additional APCs or by antibody blockade of the CTLA-4 receptor (282). 
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The mice that did not express α3 (mouse class II KO, DR15-expressing, α3 
KO) did produce an immune response to α3(IV)NC1 and specifically to α3(IV)NC1 
136-150 – a region of the protein similar to the immunodominant peptide implicated 
in the development of Goodpasture’s disease in humans (α3(IV)NC1 131-150).  
Hybridomas generated using mice with this genotype had specificities to various 
peptides within the α3(IV)NC1 domain, including α3(IV)NC1 136-150.  It was not 
possible to fully characterise all the hybridomas made, but they have the potential to 
be useful reagents to probe specific processing mechanisms (Chapter 7). 
Overall, the data presented within this thesis is surprising compared with 
published data regarding immune responses in Goodpasture patients (1).  It shows 
that, despite the requirement for the α3(IV)NC1 protein to be “unlocked” by 
enzymatic cleavage in a specific sequence of processing events (71), the initial 
cleavage site is also the peptide sequence to which there is overlap between major 
immune responses seen in man (1) (α3(IV)NC1 131-150) and in α3 KO mice 
(α3(IV)NC1 136-150, Chapter 7).  In the mice more similar to man, the α3(IV)NC1 
WT mice, there were no immune responses to any human peptide following 
immunisation with human α3(IV)NC1.  This raises questions for further examination 
and investigation.  Possibilities include investigating the nature of the immunogenic 
peptide, reasons for it being presented and possible mechanisms by which it is 
preserved for presentation by the immune system.  They also include further 
investigating possible mechanisms causing the autoimmunity, mechanisms for 
breaking or avoiding tolerance, and whether tolerance can be reinstated in 
autoimmune disease. 
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As far as processing of the α3(IV)NC1 molecule is understood, like the tetanus 
toxin (68, 69), α3(IV)NC1 requires a specific cleavage event to occur before the 
remainder of the protein, and particular regions containing T cell epitopes, can be 
processed.  It has been shown that this cleavage event effectively “unlocks” the 
remainder of the molecule (71).  The peptide encoding that region (α3(IV)NC1 131-
150 and  α3(IV)NC1 136-150, in man and mouse respectively) has also been shown 
to be the most immunogenic in both humans (Goodpasture patients (1), healthy 
individuals (3)) and α3 KO mice (Chapter 7).  Since this peptide should be destroyed 
during processing events, the protein could be incompletely processed enabling 
presentation, or the peptide could be spliced back together during post-processing 
and MHC class II binding events.  The first hypothesis could be tested by generating 
point mutations within the peptides and determining which residues are essential for 
binding and generating an immune response, and determining which mutations 
render the peptide unable to be processed, so which residues are essential for 
processing, provided T cells recognise the APC.  The combined data could help 
determine essential residues for both binding and processing and also determine 
whether there is overlap between the two.   
The second hypothesis of peptide splicing would be more difficult to examine. 
Published work by Vigneron et al. in 2004 and Warren et al. in 2006 (278, 279)  
showed evidence of peptide splicing in immune responses from CD8-positive T 
cells.  They showed that specific peptides could be digested within the proteasome 
and spliced together such that a reactive peptide was presented, within MHC class I 
molecules, to the clonal CD8 T cell line isolated from a sample.  They subsequently 
showed, by high performance liquid chromatography (HPLC) and mass spectrometry 
 220 
(MS), that the proteasome was essential for the splicing reaction and that the 
cleavage events preceding splicing were essential for generating sufficient energy for 
the splicing reaction to occur.  The processing mechanisms are different for MHC 
class II molecules but the hypothesis could be tested by using the reactive peptide of 
the Goodpasture antigen (α3(IV)NC1 131-150) added to DR15-expressing B cells 
and determining immune responses in a hybridoma line specific for the peptide.  To 
test for splicing, an additional four amino acids could be added between the amino 
acids of the cathepsin D digestion site.  This synthetic peptide could then be added to 
the B cell culture medium, washed well before addition to the hybridomas, and the 
hybridoma culture media checked for IL-2 responses compared with background, 
before testing the APCs used for peptide expressed on their surfaces by HPLC and 
MS. 
The work in Chapter 6, as stated above, does not support the circulation of T 
cells specific for the Goodpasture antigen in normal circulating blood of the mouse.  
This could be due to lack of sensitivity of the assay, such that only a very few cells 
would be able to recognise the Goodpasture antigen and that within the experiments 
described, they were not in contact with the relevant stimulatory peptide.  This 
suggests that additional work could be done to characterise immune responses from 
α3(IV)NC1 wild-type mice.  However, there is a fundamental difference between the 
experiments described in Chapter 6 and the data published by Zou et al. (3).  The 
cells isolated from healthy volunteers were unprimed, whereas the wild-type mice 
used in the experiments in Chapter 6 were immunised prior to extraction of the 
lymph nodes.  It would be interesting to see whether the mice had circulating T cells 
to the Goodpasture antigen without prior immunisation as it is possible that 
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peripheral tolerance mechanisms were enhanced following immunisation with the 
Goodpasture antigen in complete Freund’s adjuvant.  This hypothesis suggests that 
activated Goodpasture-specific T cells could be subjected to overwhelming 
regulatory mechanisms resulting in deletion of the T cells and preventing an aberrant 
immune response.  It could also partially explain the lack of immune response to 
peptides in primed α3(IV)NC1 WT mice.  Certainly, it has been shown that B cell 
anergy caused by peripheral tolerance may be reversed with appropriate T cell help, 
causing autoimmunity in otherwise non-autoimmune mice (283), and that multiple 
species express autoreactive antibodies while in a normal, healthy state (284).  The 
converse may also be true (as hypothesised here) but would require further study.  In 
particular, peripheral tolerance mechanisms controlling T cell activation and the 
conditions required to delete the resultant clonal expansion of autoreactive T cells, 
should be investigated. 
It would also be interesting to ascertain whether tolerance could be broken in 
these animals or conversely, if tolerance could be induced in the animals that do not 
express endogenous α3, inducing tolerance to a foreign antigen.  Work by Reynolds 
et al. suggested that tolerance in rats could be induced by intranasal administration of 
recombinant Goodpasture antigen, resulting in failure to develop autoimmune 
glomerulonephritis (281).  It would be interesting to determine whether the same is 
true in the transgenic mice used throughout this project.  This has implications for 
treatment of Alport’s disease.  As described in Chapter 3, Alport’s disease occurs 
when (usually) the α5(IV) chain is not expressed, resulting in renal failure and the 
need for transplant.  These patients often develop Goodpasture-like 
glomerulonephritis by reacting to the α5(IV) within the donor kidney as foreign 
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(209).  If tolerance could be induced in humans, it could prevent allograft rejection in 
these patients. 
This work is different from much of the current studies investigating the role of 
central tolerance in determining susceptibility to autoimmunity.  Much of the 
published data involves introduction of a foreign antigen into a species in order to 
determine mechanisms involved in propagation of tolerance – Cibotti’s work using 
mice that express HEL for example (120, 153, 157, 161, 285).  In this work, the 
converse is true.  My project aimed to determine differences in immune responses to 
proteins to which central tolerance is never induced.  This approach has also been 
used to examine some aspects of multiple sclerosis, with the development of myelin-
basic protein deficient “shiverer” mice.  The genetic defect is an autosomal recessive 
mutation and symptoms in the form of tremors and convulsions are seen from 
approximately two weeks of age.  The mutation causes severe myelin deficiency in 
the central nervous system, due to defective myelin formation (286).  These mice 
have been extensively used to examine cell engraftment, migration and myelination 
with a long term aim of curing or ameliorating symptoms of MS.  Recent work has 
involved prenatal treatment of shiverer mice with stem cells, generating chimeric 
mice with strong MBP expression throughout the brain and significantly reduced 
behavioural difficulties (287).   
Research more pertinent to my work has been published less recently.  
Yoshizawa et al. showed that BALB/c mice (shiverer mice are on a BALB/c 
background), after immunisation with MBP do not develop EAE.  Experiments using 
shiverer mice found that there are specific epitopes on the MBP that induce T cell 
proliferation (residues 59-76 and 89-101) that these T cells are also able to induce 
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EAE upon injection into normal BALB/c mice (288).  It has also been shown that 
endogenous MBP induced profound inactivation of high avidity clones specific for 
the immunodominant determinant making that determinant appear cryptic.  
Immunisation of mice expressing MBP with MBP peptide 79-87 found that only low 
avidity T cell clones were generated and that these clones would not respond to the 
whole protein, only to the peptide in recall response assays (289).  My data studying 
immune responses to the Goodpasture antigen corroborates these data as the α3WT 
mice did not have an immune response to the antigen, while the α3KO mice did. 
It is difficult to study the effects of tolerance in humans, but one example in 
which it can be done is with the red blood cell antigen Rhesus D (RhD).  
Approximately 15% of the Caucasian population lack the RhD protein on a structural 
lipoprotein within the erythrocyte membrane (290).  This provides a rare opportunity 
to examine the response to RhD both in the presence and absence of tolerance in 
humans.  The most common situation involving this antigen is when a RhD-negative 
pregnant female carries an RhD-positive foetus causing erythroblastosis fetalis in 
which antibodies generated in the mother attack the unborn foetus (290).  Recent 
work has examined the T cell recall responses in humans (either following deliberate 
RhD-immunisation or RhD incompatible pregnancy) using overlapping 15mer 
peptides in much the same way as the recall responses to α3(IV)NC1 were 
determined within Chapters 6 and 7.  This work determined that there are 4 peptide 
sequences in particular that elicit a proliferative T cell response in more than 50% of 
the humans tested – amino acids 52-66, 97-111, 117-131 and 177-191 (291).  It has 
also been shown that of these peptides the amino acid sequence 52-66 induces IL-10 
production and therefore induces peripheral tolerance by suppression of effector T 
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cell responses (292).  Subsequent work has shown that tolerance can be induced to 
the RhD protein by immunising HLA transgenic mice with intranasal administration 
of these immunodominant peptides (293).  This induction of tolerance following 
intranasal immunization of antigen has also been successfully demonstrated in WKY 
rats and the Goodpasture antigen (281), but it remains to be seen how such 
knowledge can be utilized for the induction of tolerance to the Goodpasture antigen 
in humans. 
To summarise, this project studied immune responses to the Goodpasture 
antigen.  The data found was surprising.  It was shown that α3KO mice generate 
immune responses to a similar sequence as human Goodpasture patients (these 
patients express endogenous α3(IV)), a sequence that should be destroyed by 
cathepsin D processing mechanisms.  These responses were not seen in mice that 
express endogenous α3(IV)NC1, suggesting robust tolerance despite sequence 
differences (mice were immunised with human α3(IV)NC1).  Additional questions 
now arise: are MHC class II processing pathways different in mouse and man, and 
do the fine specificities of processing enzymes differ?  What role does peripheral 
tolerance play in regulating autoreactive T cells and can it be upregulated in response 
to a CD4 T cell autoimmune reaction?  Can tolerance be induced to specific antigens 
in order to prevent or treat autoimmunity? 
The work described here provides a solid foundation for further work to be 
undertaken to explore mechanisms preventing and causing Goodpasture’s disease, 
and these mechanisms may be applicable to other autoimmune diseases.  In 
particular, mechanisms controlling tolerance could be further investigated, since the 
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transgenic mice developed are equipped to compare responses in the presence and 







Appendix I - α3(IV)NC1 overlapping peptide sequences 
and peptide sets 






Sequence (FASTA format) 
α3(IV)NC1 -9-5 -9 5 GLKGKRGDSGSPATW 
α3(IV)NC1 -4-10 -4 10 RGDSGSPATWTTRGF 
α3(IV)NC1 1-15 1 15 SPATWTTRGFVFTRH 
α3(IV)NC1 6-20 6 20 TTRGFVFTRHSQTTA 
α3(IV)NC1 11-25 11 25 VFTRHSQTTAIPSCP 
α3(IV)NC1 16-30 16 30 SQTTAIPSCPEGTVP 
α3(IV)NC1 21-35 21 35 IPSCPEGTVPLYSGF 
α3(IV)NC1 26-40 26 40 EGTVPLYSGFSFLFV 
α3(IV)NC1 31-45 31 45 LYSGFSFLFVQGNQR 
α3(IV)NC1 36-50 36 50 SFLFVQGNQRAHGQD 
α3(IV)NC1 41-55 41 55 QGNQRAHGQDLGTLG 
α3(IV)NC1 46-60 46 60 AHGQDLGTLGSCLQR 
α3(IV)NC1 51-65 51 65 LGTLGSCLQRFTTMP 
α3(IV)NC1 56-70 56 70 SCLQRFTTMPFLFCN 
α3(IV)NC1 61-75 61 75 FTTMPFLFCNVNDVC 
α3(IV)NC1 66-80 66 80 FLFCNVNDVCNFASR 
α3(IV)NC1 71-85 71 85 VNDVCNFASRNDYSY 
α3(IV)NC1 76-90 76 90 NFASRNDYSYWLSTP 
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Sequence (FASTA format) 
α3(IV)NC1 81-95 
 
81 95 NDYSYWLSTPALMPM 
α3(IV)NC1 86-100 
 
86 100 WLSTPALMPMNMAPI 
α3(IV)NC1 91-105 
 
91 105 ALMPMNMAPITGRAL 
α3(IV)NC1 96-110 
 
96 110 NMAPITGRALEPYIS 
α3(IV)NC1 101-115 
 
101 115 TGRALEPYISRCTVC 
α3(IV)NC1 106-120 
 
106 120 EPYISRCTVCEGPAI 
α3(IV)NC1 111-125 
 
111 125 RCTVCEGPAIAIAVH 
α3(IV)NC1 116-130 
 
116 130 EGPAIAIAVHSQTTD 
α3(IV)NC1 121-135 
 
121 135 AIAVHSQTTDIPPCP 
α3(IV)NC1 126-140 
 
126 140 SQTTDIPPCPHGWIS 
α3(IV)NC1 131-145 
 
131 145 IPPCPHGWISLWKGF 
α3(IV)NC1 136-150 
 
136 150 HGWISLWKGFSFIMF 
α3(IV)NC1 141-155 
 
141 155 LWKGFSFIMFTSAGS 
α3(IV)NC1 146-160 
 
146 160 SFIMFTSAGSEGTGQ 
α3(IV)NC1 151-165 
 
151 165 TSAGSEGTGQALASP 
α3(IV)NC1 156-170 
 
156 170 EGTGQALASPGSCLE 
α3(IV)NC1 161-175 
 
161 175 ALASPGSCLEEFRAS 
α3(IV)NC1 166-180 
 
166 180 GSCLEEFRASPFLEC 
α3(IV)NC1 171-185 
 
171 185 EFRASPFLECHGRGT 
α3(IV)NC1 176-190 
 
176 190 PFLECHGRGTCNYYS 
α3(IV)NC1 181-195 
 
181 195 HGRGTCNYYSNSYSF 
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Sequence (FASTA format) 
α3(IV)NC1 186-200 
 
186 200 CNYYSNSYSFWLASL 
α3(IV)NC1 191-205 
 
191 205 NSYSFWLASLNPERM 
α3(IV)NC1 196-210 
 
196 210 WLASLNPERMFRKPI 
α3(IV)NC1 201-215 
 
201 215 NPERMFRKPIPSTVK 
α3(IV)NC1 206-220 
 
206 220 FRKPIPSTVKAGELE 
α3(IV)NC1 211-225 
 
211 225 PSTVKAGELEKIISR 
α3(IV)NC1 216-230 
 
216 230 AGELEKIISRCQVCM 
α3(IV)NC1 221-235 221 235 KIISRCQVCMKKRH 




Name of Set Start peptide Last peptide No. peptides 
s1 α3(IV)NC1 -9-5 α3(IV)NC1 11-25 5 
s2 α3(IV)NC1 6-20 α3(IV)NC1 26-40 5 
s3 α3(IV)NC1 21-35 α3(IV)NC1 41-55 5 
s4 α3(IV)NC1 36-50 α3(IV)NC1 56-70 5 
s5 α3(IV)NC1 51-65 α3(IV)NC1 71-85 5 
s6 α3(IV)NC1 66-80 α3(IV)NC1 86-100 5 
s7 α3(IV)NC1 81-95 α3(IV)NC1 101-115 5 
s8 α3(IV)NC1 96-110 α3(IV)NC1 116-130 5 
s9 α3(IV)NC1 111-125 α3(IV)NC1 131-145 5 
s10 α3(IV)NC1 126-140 α3(IV)NC1 146-160 5 
s11 α3(IV)NC1 141-155 α3(IV)NC1 161-175 5 
s12 α3(IV)NC1 156-170 α3(IV)NC1 176-190 5 
s13 α3(IV)NC1 171-185 α3(IV)NC1 191-205 5 
s14 α3(IV)NC1 186-200 α3(IV)NC1 206-220 5 
s15 α3(IV)NC1 201-215 α3(IV)NC1 221-235 5 
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Appendix II – Restriction Maps of plasmid vectors 
 



















TOPO blunt cloning vector, pCR-BLUNT II-TOPO 
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